• Exploring the role of a multidisciplinary hereditary gynecologic oncology clinic in epithelial ovarian cancer risk-reducing surgical decision-making practices: A mixed-methods study.
    • Casalino S, Bruce S, Serfas K, Altman AD, Kean S, Lambert P, McManus KJ, Hartley JN, Nachtigal MW.
    • J Genet Couns. 2023 Feb 20. doi: 10.1002/jgc4.1684. Epub ahead of print.
    • Improving Uptake of Cancer Genetic Risk Assessment in a Remote Tailored Risk Communication and Navigation Intervention: Large Effect Size but Room to Grow.
    • Kinney AY, Walters ST, Lin Y, Lu SE, Kim A, Ani J, Heidt E, Le Compte CJG, O'Malley D, Stroup A, Paddock LE, Grumet S, Boyce TW, Toppmeyer DL, McDougall JA.
    • J Clin Oncol. 2023 Feb 14:JCO2200751. doi: 10.1200/JCO.22.00751. Epub ahead of print.

    Related:

    •• Identifier: NCT03326713: Genetic Risk Assessment for Cancer Education and Empowerment (GRACE) Project (GRACE). (ClinicalTrials.gov . Accessed 2023 Feb 14.)

    • Breast Cancer Screening Utilization and Outcomes in Women with Neurofibromatosis Type 1.
    • Yan K, Gao Y, Heller SL.
    • Clin Breast Cancer. 2023 Feb 12:S1526-8209(23)00035-6. doi: 10.1016/j.clbc.2023.02.005. Epub ahead of print.
    • Measuring high-risk parents' opinions about direct-to-consumer genetic testing for adult-onset inherited cancer syndromes in their adolescent and young adult children.
    • Hasser E, Peshkin BN, Hamilton JG, Brower J, Ovadia H, Friedman Ross L, Sacca R, Tarini B, Domchek SM, Vittone S, Sleiman M Jr, Isaacs C, Knerr S, Wilfond BS, Tercyak KP.
    • J Genet Couns. 2023 Feb 7. doi: 10.1002/jgc4.1685. Epub ahead of print.
    • Video telehealth to manage menopausal symptoms after cancer: a prospective study of clinicians and patient satisfaction.
    • Rachagan N, Szabo RA, Rio I, Rees F, Hiscock HM, Hickey M.
    • Menopause. 2023 Feb 1;30(2):143-148. doi: 10.1097/GME.0000000000002101. Epub 2022 Dec 13.
    • Financial toxicity in BRCA1 and BRCA2 carriers.
    • Proussaloglou EM, Rosenthal AE, Raker CA, Wilbur JS, Stuckey AR, Robison KM.
    • Gynecol Oncol. 2023 Jan 24;170:160-166. doi: 10.1016/j.ygyno.2023.01.007. Epub ahead of print.
    • Genetic Testing for Cancer Risk and Perceived Importance of Genetic Information Among US Population by Race and Ethnicity: a Cross-sectional Study.
    • Hong YR, Yadav S, Wang R, Vadaparampil S, Bian J, George TJ, Braithwaite D.
    • J Racial Ethn Health Disparities. 2023 Jan 23. doi: 10.1007/s40615-023-01526-4. Epub ahead of print.
    • Factors that influence the management recommendations breast surgeons provide to women with pathogenic variants in moderate penetrance breast cancer susceptibility genes.
    • Vanderwal A, Lewis J, Basil J, Atzinger C, Widmeyer K.
    • J Genet Couns. 2023 Jan 15. doi: 10.1002/jgc4.1674. Epub ahead of print.
    • Predictors of Women’s Intentions to Communicate Updated Genetic Test Results to Immediate and Extended Family Members.
    • Winskill C, Goodman MS, Daly BM, Elrick A, Mooney R, Espinel W, Kohlmann W, Kaphingst KA.
    • Public Health Genomics. 2023 Jan 14. doi: 10.1159/000528522. Epub ahead of print.
    • January 2023: Awareness of genetic testing – results and analysis from the 2020 Health Information National Trends Survey.
    • Mechanic L, Helzlsouer K.
    • Genet Med. GenePOD. 2023 Jan 9.

    Related:

    •• Original research:

    Awareness and use of genetic testing: An analysis of the Health Information National Trends Survey 2020.

    • High-dose chemotherapy with stem cell rescue to treat stage III homologous deficient breast cancer: factors influencing clinical implementation.
    • Verbeek JGE, de Jong VMT, Wijnja HM, Jager A, Linn SC, Retèl VP, van Harten WH.
    • BMC Cancer. 2023 Jan 7;23(1):26. doi: 10.1186/s12885-022-10412-x.
    • The Role of Hormonal Replacement Therapy in BRCA Mutated Patients: Lights and Shadows.
    • Loizzi V, Dellino M, Cerbone M, Arezzo F, Cazzato G, Damiani GR, Pinto V, Silvestris E, Kardhashi A, Cicinelli E, Cascardi E, Cormio G.
    • Int J Mol Sci. 2023 Jan 1;24(1):764. doi: 10.3390/ijms24010764.
    • Variations in Practice and Geographic Disparities Between Dedicated Multidisciplinary Clinics for BRCA1/BRCA2 Mutation Carriers in Israel.
    • Hermann N, Mor P, Kaidar-Person O, Bernstein-Molho R, Brodsky M, Madorsky Feldman D, Flugelman AA, Aboody Nevo H, Meshoulam Avital D, Sklair-Levy M, Friedman E, Allweis TM.
    • Isr Med Assoc J. 2023 Jan;25(1):18-22.
    • Effectiveness of Secondary Risk-Reducing Strategies in Patients With Unilateral Breast Cancer With Pathogenic Variants of BRCA1 and BRCA2 Subjected to Breast-Conserving Surgery: Evidence-Based Simulation Study.
    • Maksimenko J, Rodrigues PP, Nakazawa-Miklaševiča M, Pinto D, Miklaševičs E, Trofimovičs G, Gardovskis J, Cardoso F, Cardoso MJ.
    • JMIR Form Res. 2022 Dec 29;6(12):e37144. doi: 10.2196/37144.
    • Genetic Testing in the Latinx community: Impact of acculturation and provider relationships.
    • Ioffe YJ, Hong L, Joachim-Célestin M, Soret C, Montgomery S, Unternaehrer JJ.
    • Gynecol Oncol. 2022 Dec 26;169:125-130. doi: 10.1016/j.ygyno.2022.12.001. Epub ahead of print.
    • Australasian Genetic Counselors’ Perceptions of Their Role in Supporting Clients’ Behavior Change.
    • Jacobs C, Turbitt E, McEwen A, Atkins L.
    • J Pers Med. 2022 Dec 23;13(1):30. doi: 10.3390/jpm13010030.
    • Cancer prevention in cancer predisposition syndromes: A protocol for testing the feasibility of building a hereditary cancer research registry and nurse navigator follow up model.
    • Etchegary H, Pike A, Puddester R, Watkins K, Warren M, Francis V, Woods M, Green J, Savas S, Seal M, Gao Z, Avery S, Curtis F, McGrath J, MacDonald D, Burry TN, Dawson L.
    • PLoS One. 2022 Dec 22;17(12):e0279317. doi: 10.1371/journal.pone.0279317.
    • Fertility Preferences and Practices Among Young Women With Breast Cancer: Germline Genetic Carriers Versus Non-carriers.
    • Lewinsohn R, Zheng Y, Rosenberg SM, Ruddy KJ, Tamimi RM, Schapira L, Peppercorn J, Borges VF, Come S, Snow C, Ginsburg ES, Partridge AH.
    • Clin Breast Cancer. 2022 Dec 21:S1526-8209(22)00290-7. doi: 10.1016/j.clbc.2022.12.012. Epub ahead of print.

    Related:

    •• Identifier: NCT01468246: The Young Women's Breast Cancer Study (HOHO). (ClinicalTrials.gov . Accessed 2022 Dec 21.)

    • Informational needs of individuals from BRCA-harboring families: a systematic review and content analysis.
    • Park SY, Kim Y, Kim S, Katapodi MC.
    • Genet Med. 2022 Dec 18:S1098-3600(22)01068-1. doi: 10.1016/j.gim.2022.100001. Epub ahead of print.
    • A Comparison of Patients’ and Physicians’ Knowledge and Expectations Regarding Precision Oncology Tests.
    • Dehar N, Abedin T, Tang P, Bebb G, Cheung WY.
    • Curr Oncol. 2022 Dec 16;29(12):9916-9927. doi: 10.3390/curroncol29120780.
    • Understanding cancer genetic risk assessment motivations in a remote tailored risk communication and navigation intervention randomized controlled trial.
    • Le Compte CG, Lu SE, Ani J, McDougall J, Walters ST, Toppmeyer D, Boyce TW, Stroup A, Paddock L, Grumet S, Lin Y, Heidt E, Kinney AY.
    • Health Psychol Behav Med. 2022 Dec 9;10(1):1190-1215. doi: 10.1080/21642850.2022.2150623.

    Related:

    •• Identifier: NCT03326713: Genetic Risk Assessment for Cancer Education and Empowerment (GRACE) Project (GRACE). (ClinicalTrials.gov . Accessed 2022 Dec 16.)

    • Awareness and use of genetic testing: An analysis of the Health Information National Trends Survey 2020.
    • Tiner JC, Mechanic LE, Gallicchio L, Gillanders EM, Helzlsouer KJ.
    • Genet Med. 2022 Dec;24(12):2526-2534. doi: 10.1016/j.gim.2022.08.023. Epub 2022 Sep 22.

    Related:

    •• Podcast: January 2023: Awareness of genetic testing – results and analysis from the 2020 Health Information National Trends Survey. (Genetics in Medicine GenePOD)

    • Referral, Genetic Counselling, and BRCA Testing in the Manitoba High-Grade Serous Ovarian Cancer Population, 2004–2019.
    • Winchar K, Lambert P, McManus KJ, Chodirker B, Kean S, Serfas K, Decker K, Nachtigal MW, Altman AD.
    • Curr Oncol. 2022 Nov 30;29(12):9365-9376. doi: 10.3390/curroncol29120735.
    • Clinical and psychological implications of secondary and incidental findings in cancer susceptibility genes after exome sequencing in patients with rare disorders.
    • Carrasco E, López-Fernández A, Codina-Sola M, Valenzuela I, Cueto-González AM, Villacampa G, Navarro V, Torres-Esquius S, Palau D, Cruellas M, Torres M, Perez-Dueñas B, Abulí A, Diez O, Sábado-Álvarez C, García-Arumí E, Tizzano EF, Moreno L, Balmaña J.
    • J Med Genet. 2022 Nov 29:jmg-2022-108929. doi: 10.1136/jmg-2022-108929. Epub ahead of print.
    • Four-in-Five Eligible Breast Cancer Patients Not Informed of Genomic Testing Options.
    • [No author given]
    • Inside Precision Medicine. Topics. Oncology. 2022 Nov 21.
    • Fatalism and metaphor in Confucianism: A qualitative study of barriers to genetic testing among first-degree relatives of hereditary cancer patients from China.
    • Jiang C, Liu L, Wang Y, Wu L, Zhang W, Wu X.
    • Psychooncology. 2022 Nov 15. doi: 10.1002/pon.6068. Epub ahead of print.
    • Testing a deliberative democracy method with citizens of African ancestry to weigh pros and cons of targeted screening for hereditary breast and ovarian cancer risk.
    • Guan Y, Pathak S, Ballard D, Veluswamy JK, McCullough LE, McBride CM, Gornick MC.
    • Front Public Health. 2022 Nov 8;10:984926. doi: 10.3389/fpubh.2022.984926.
    • What happens in the long term: Uptake of cancer surveillance and prevention strategies among at-risk relatives with pathogenic variants detected via cascade testing.
    • Frey MK, Ahsan MD, Badiner N, Lin J, Narayan P, Nitecki R, Rauh-Hain JA, Moss H, Fowlkes RK, Thomas C, Bergeron H, Christos P, Levi SR, Blank SV, Holcomb K, Cantillo E, Sharaf RN, Lipkin S, Offit K, Chapman-Davis E.
    • Cancer. 2022 Oct 27. doi: 10.1002/cncr.34482. Epub ahead of print.
    • Latinx attitudes, barriers, and experiences with genetic counseling and testing: A systematic review.
    • Dron HA, Bucio D, Young JL, Tabor HK, Cho MK.
    • J Genet Couns. 2022 Oct 27. doi: 10.1002/jgc4.1632. Epub ahead of print.
    • Nest Genomics Building EHR-Integrated Clinical Decision Support for Genetics-Informed Care.
    • Cohen JK.
    • GenomeWeb. Disease Areas. Cancer. 2022 Oct 25.
    • From the patient to the population: Use of genomics for population screening.
    • Mighton C, Shickh S, Aguda V, Krishnapillai S, Adi-Wauran E, Bombard Y.
    • Front Genet. 2022 Oct 24;13:893832. doi: 10.3389/fgene.2022.893832.
    • Uptake of BRCA1/BRCA2 predictive genetic testing in an Irish population is low: a missed opportunity.
    • O'Reilly DE, Dooley L, Watson GA, Clarke R, Nolan A, Nolan C, Berkeley E, Farrell M, McDevitt T, Rogers M, Clabby C, Gallagher DJ.
    • Ir J Med Sci. 2022 Oct 19. doi: 10.1007/s11845-022-03176-7. Epub ahead of print.
    • Relatives from Hereditary Breast and Ovarian Cancer and Lynch Syndrome Families Forgoing Genetic Testing: Findings from the Swiss CASCADE Cohort.
    • Sarki M, Ming C, Aceti M, Fink G, Aissaoui S, Bürki N, Graffeo R, Heinimann K, Zufferey MC, Monnerat C, Rabaglio M, Zürrer-Härdi U, Chappuis PO, Katapodi MC.
    • J Pers Med. 2022 Oct 19;12(10):1740. doi: 10.3390/jpm12101740.
    • Interest in genetic testing and risk-reducing behavioral changes: results from a community health assessment in New York City.
    • Lima SM, Nazareth M, Schmitt KM, Reyes A, Fleck E, Schwartz GK, Terry MB, Hillyer GC.
    • J Community Genet. 2022 Oct 13. doi: 10.1007/s12687-022-00610-2. Epub ahead of print.
    • Study: Teens and young adults respond well to learning about familial cancer risk
    • [No author given]
    • FORCE. XRAY. 2022 Oct 11.

    Related:

    Original research:

    Long-Term Adaptation Among Adolescent and Young Adult Children to Familial Cancer Risk.

    Commentary:

    Breaking Down the Barriers of Hereditary Cancer Risk Disclosure in AYA.

    • Barriers to completion of cascade genetic testing: how can we improve the uptake of testing for hereditary breast and ovarian cancer syndrome?
    • Kahn RM, Ahsan MD, Chapman-Davis E, Holcomb K, Nitecki R, Rauh-Hain JA, Fowlkes RK, Tubito F, Pires M, Christos PJ, Tkachuk K, Krinsky H, Sharaf RN, Offit K, Lipkin S, Frey MK.
    • Fam Cancer. 2022 Oct 8. doi: 10.1007/s10689-022-00316-x. Epub ahead of print.
    • Developing theory-driven narrative messages with personal stories: A step-by-step guide.
    • Conley CC, Davidson LG, Scherr CL, Dean M.
    • Psychooncology. 2022 Oct 7. doi: 10.1002/pon.6047. Epub ahead of print.
    • Provider discussion of genetic counseling among high-risk Spanish-preferring Latina breast cancer survivors.
    • Conley CC, Rivera Rivera JN, Castro-Figueroa EM, Moreno L, Dutil J, García JD, Ricker C, Quinn GP, Soliman H, Vadaparampil ST.
    • Transl Behav Med. 2022 Oct 7;12(9):900-908. doi: 10.1093/tbm/ibac031.
    • Use of breast surveillance between women with pathogenic variants and variants of uncertain significance in breast cancer susceptibility genes.
    • Makhnoon S, Chen M, Levin B, Ensinger M, Mattie KD, Grana G, Shete S, Arun BK, Peterson SK.
    • Cancer. 2022 Oct;128(20):3709-3717. doi: 10.1002/cncr.34429. Epub 2022 Aug 23.
    • Effects of diet education on empowerment for individuals who have an increased risk of developing breast or colon cancer: A pilot study.
    • Tlusty K, Jackson M, Riley B, Blase T.
    • J Genet Couns. 2022 Oct;31(5):1138-1147. doi: 10.1002/jgc4.1584. Epub 2022 May 3.
    • Use of a chatbot to increase uptake of cascade genetic testing.
    • Schmidlen T, Jones CL, Campbell-Salome G, McCormick CZ, Vanenkevort E, Sturm AC.
    • J Genet Couns. 2022 Oct;31(5):1219-1230. doi: 10.1002/jgc4.1592. Epub 2022 May 26.
    • Survey: 30 Percent of Women Don’t Know Family Cancer History
    • [No author given]
    • Inside Precision Medicine. Topics. Oncology. 2022 Sep 28.

    Related:

    Press Release: Family Cancer History Still a Mystery to Many Women, Myriad Genetics Survey Finds. (GlobeNewswire)

    Media Deck: Myriad Women’s Health Survey Infographics (Myriad Genetics)

    • Getting Past the Shock of a Previvor Diagnosis and Making a Plan.
    • Swirsky N.
    • FORCE. Blog. 2022 Sep 21.
    • Patient Understanding of Tumor Genomic Testing: A Quality Improvement Effort.
    • Senter L, Veney D, Surplus T, Haynam M, Adams EJ, Hampel H, Toland AE, Presley CJ, Padamsee TJ, Lee CN, Hovick SR, Stover DG.
    • JCO Oncol Pract. 2022 Sep 21:OP2200316. doi: 10.1200/OP.22.00316. Epub ahead of print.
    • Hereditary Breast and Ovarian Cancer Genetic Risk: Screening and Treatment Among Transgender and Gender Diverse Patients.
    • Sakradse M, Zhu S, Ritterman Weintraub M, Jung J, Zaritsky E.
    • Perm J. 2022 Sep 14;26(3):30-38. doi: 10.7812/TPP/21.133. Epub 2022 Jul 28.
    • Who Should Consider BRCA Testing?
    • [No author given]
    • My Gene Counsel. Genetic Journal. 2022 Sep 6.
    • Disparities in germline testing among racial minorities with prostate cancer.
    • Weise N, Shaya J, Javier-Desloges J, Cheng HH, Madlensky L, McKay RR.
    • Prostate Cancer Prostatic Dis. 2022 Sep;25(3):403-410. doi: 10.1038/s41391-021-00469-3. Epub 2021 Nov 13.
    • High Risk Breast Cancer Screening is a Double Edged Sword: A Qualitative Study of Patient Perspectives on the Ontario High Risk Breast Cancer Screening Program.
    • Deng SX, Castelo M, Reel E, Naganathan G, Eisen A, Muradali D, Grunfeld E, Scheer AS.
    • Clin Breast Cancer. 2022 Aug 19:S1526-8209(22)00183-5. doi: 10.1016/j.clbc.2022.08.004. Epub ahead of print.
    • Changing patterns of referral into a family history clinic and detection of ovarian cancer: a retrospective 10-year review.
    • Smallwood KG, Crockett S, Huang V, Cullimore V, Davies J, Satti G, Phillips A.
    • J Obstet Gynaecol. 2022 Aug 18:1-7. doi: 10.1080/01443615.2022.2111253. Epub ahead of print.
    • GeneHome - a Novel Model to Deliver Care to Individuals with Genetic Predisposition to Cancer.
    • Nocera Zachariah N, Lee MC, Chang MD, Moore C, Wang X.
    • Cancer Control. 2022 Jan-Dec [First published 2022 Aug 17];29:10732748221109951. doi: 10.1177/10732748221109951.
    • BI-RADS-0 screening mammography: Risk factors that prevent or delay follow-up time to diagnostic evaluation.
    • Platt S, Montgomery GH, Schnur JH, Margolies L.
    • J Am Coll Radiol. 2022 Aug 16:S1546-1440(22)00576-2. doi: 10.1016/j.jacr.2022.07.006. Epub ahead of print.

    Related:

    Commentary:

    Reducing Disparities in Timely Follow-Up after an Abnormal Screening Mammogram.

    • I know things now: The challenges for genetic counseling of adolescents with a family history of hereditary breast cancer.
    • Wilfond BS.
    • J Pediatr. 2022 Aug 16:S0022-3476(22)00728-4. doi: 10.1016/j.jpeds.2022.08.019. Epub ahead of print.
    • Commentary

    Related:

    Original research:

    Mother and Daughter Perspectives on Genetic Counseling and Testing of Adolescents for Hereditary Breast Cancer Risk.

    • Risk-reducing surgery in unaffected individuals receiving cancer genetic testing in an integrated health care system.
    • Knerr S, Guo B, Mittendorf KF, Feigelson HS, Gilmore MJ, Jarvik GP, Kauffman TL, Keast E, Lynch FL, Muessig KR, Okuyama S, Veenstra DL, Zepp JM, Goddard KAB, Devine B.
    • Cancer. 2022 Aug 15;128(16):3090-3098. doi: 10.1002/cncr.34349. Epub 2022 Jun 9.
    • BRCA mutation carriers' perception about benefits and risks associated with combined hormonal contraceptives use.
    • Grandi G, Monari F, Boggio Sola V, Cortesi L, Toss A, Del Savio MC, Melotti C, Centurioni MG, Gustavino C, Varesco L, Facchinetti F, Barra F.
    • Eur J Contracept Reprod Health Care. 2022 Aug 10:1-6. doi: 10.1080/13625187.2022.2107199. Epub ahead of print.
    • Motivation and family communication in hereditary prostate cancer genetic testing: Survey of patients from a US tertiary medical center.
    • Finn CM, McCormick S, Peterson D, Niendorf KB, Rodgers LH.
    • J Genet Couns. 2022 Aug 8. doi: 10.1002/jgc4.1624. Epub ahead of print.
    • A qualitative reflexive thematic analysis into the experiences of being identified with a BRCA1/2 gene alteration: "So many little, little traumas could have been avoided".
    • Warner NZ, Groarke A.
    • BMC Health Serv Res. 2022 Aug 6;22(1):1007. doi: 10.1186/s12913-022-08372-w.
    • Long-Term Adaptation Among Adolescent and Young Adult Children to Familial Cancer Risk.
    • McDonnell GA, Peshkin BN, DeMarco TA, Peterson SK, Arun BK, Miesfeldt S, O'Neill SC, Schneider K, Garber J, Isaacs C, Luta G, Tercyak KP.
    • Pediatrics. 2022 Aug 1;150(2):e2022056339. doi: 10.1542/peds.2022-056339.

    Related:

    Commentary:

    Breaking Down the Barriers of Hereditary Cancer Risk Disclosure in AYA.

    Related:

    Research news: Study: Teens and young adults respond well to learning about familial cancer risk. (FORCE. XRAYS)

    • A Woman Needs to Know She Is a BRCA Carrier Before She Develops Breast Cancer.
    • Hughes KS, Yin K.
    • Ann Surg Oncol. 2022 Aug;29(8):4667-4669. doi: 10.1245/s10434-022-11860-2. Epub 2022 May 12.

    Related:

    Original research:

    Comparison of Outcomes Between BRCA Pathogenic Variant Carriers Undergoing Breast-Conserving Surgery Versus Mastectomy.

    • Does receiving high or low breast cancer risk estimates produce a reduction in subsequent breast cancer screening attendance? Cohort study.
    • French DP, McWilliams L, Howell A, Evans DG.
    • Breast. 2022 Aug;64:47-49. doi: 10.1016/j.breast.2022.05.001. Epub 2022 May 9.
    • Influence of germline test results on surgical decision making in women with invasive breast cancer.
    • Vargason AB, Turner CE, Shriver CD, Ellsworth RE.
    • Cancer Genet. 2022 Aug;266-267:81-85. doi: 10.1016/j.cancergen.2022.07.003. Epub 2022 Jul 13.
    • Further validation of the Perceptions of Uncertainties in Genome Sequencing scale among patients with cancer undergoing tumor sequencing.
    • Umstead KL, Campbell R, Napier CE, Bartley N, Best MC, Butow PN, Biesecker BB.
    • Clin Genet. 2022 Aug;102(2):110-116. doi: 10.1111/cge.14169. Epub 2022 Jun 10.
    • Decision thresholds with genetic testing.
    • Felder S.
    • Eur J Health Econ. 2022 Aug;23(6):1071-1078. doi: 10.1007/s10198-021-01410-0. Epub 2021 Dec 2.
    • Making BRCA1 genetic test reports easier to understand through user-centered design: A randomized trial.
    • Recchia G, Lawrence ACE, Capacchione L, Freeman ALJ.
    • Genet Med. 2022 Aug;24(8):1684-1696. doi: 10.1016/j.gim.2022.04.016. Epub 2022 May 6.
    • Risk-reducing Salpingo-oophorectomy consults and practices during the COVID-19 pandemic.
    • O'Mara AE, Benedict C, Kurian AW, Wagner SK, Diver E.
    • Gynecol Oncol Rep. 2022 Aug;42:101036. doi: 10.1016/j.gore.2022.101036. Epub 2022 Jun 28.
    • Cancer patients' understandings of genetic variants of uncertain significance in clinical care.
    • Amano Y, Raz A, Timmermans S, Shkedi-Rafid S.
    • J Community Genet. 2022 Aug;13(4):381-388. doi: 10.1007/s12687-022-00594-z. Epub 2022 May 26.
    • Comparing the attitudes of physicians and non-physicians toward communicating a patient's BRCA1 mutation to a first-degree relative against a patient's wishes.
    • Zebrack JE, Yang W, Milone M, Coppes MJ.
    • J Community Genet. 2022 Aug;13(4):403-410. doi: 10.1007/s12687-022-00591-2. Epub 2022 May 21.
    • Toward a better understanding of the experience of patients with moderate penetrance breast cancer gene pathogenic/likely pathogenic variants: A focus on ATM and CHEK2.
    • McCormick S, Hicks S, Wooters M, Grant C.
    • J Genet Couns. 2022 Aug;31(4):956-964. doi: 10.1002/jgc4.1568. Epub 2022 Mar 4.
    • Adapting a Theoretically-Based intervention for underserved clinical populations at increased risk for hereditary Cancer: Lessons learned from the BRCA-Gist experience.
    • Hurtado-de-Mendoza A, Reyna VF, Wolfe CR, Gómez-Trillos S, Sutton AL, Brennan A, Sheppard VB.
    • Prev Med Rep. 2022 Jul 5 [eCollection 2022 Aug];28:101887. doi: 10.1016/j.pmedr.2022.101887.
    • Attitudes towards and sociodemographic determinants of genetic test usage in the USA; data from the Health Information National Trend Survey, 2020.
    • Swoboda CM, Wijayabahu AT, Fareed N.
    • J Genet Couns. 2022 Jul 31. doi: 10.1002/jgc4.1620. Epub ahead of print.
    • Lessons Learned from the Pilot Phase of a Population-Wide Genomic Screening Program: Building the Base to Reach a Diverse Cohort of 100,000 Participants.
    • Allen CG, Lenert L, Hunt K, Jackson A, Levin E, Clinton C, Clark JT, Garrison K, Gallegos S, Wager K, He W, Sterba K, Ramos PS, Melvin C, Ford M, Catchpole K, McMahon L, Judge DP.
    • J Pers Med. 2022 Jul 27;12(8):1228. doi: 10.3390/jpm12081228.
    • Understanding the needs and perspectives of ovarian cancer patients when considering PARP inhibitor maintenance therapy: Findings from two online community events.
    • Monuszko KA, Fish LJ, Sparacio D, Lizaso C, Burn K, Wickenheisser NE, Meyer LA, Reed SD, Davidson BA, Havrilesky LJ.
    • Gynecol Oncol Rep. 2022 Jul 26;43:101050. doi: 10.1016/j.gore.2022.101050.
    • A qualitative study of unaffected ATM and CHEK2 carriers: How participants make meaning of 'moderate risk' genetic results in a population breast cancer screening trial.
    • James JE, Riddle L, Caruncho M, Koenig BA, Joseph G.
    • J Genet Couns. 2022 Jul 25. doi: 10.1002/jgc4.1617. Epub ahead of print.
    • Public Interest in Population Genetic Screening for Cancer Risk.
    • Roberts MC, Foss KS, Henderson GE, Powell SN, Saylor KW, Weck KE, Milko LV.
    • Front Genet. 2022 Jul 22;13:886640. doi: 10.3389/fgene.2022.886640.
    • Patient and Clinician Decision Support to Increase Genetic Counseling for Hereditary Breast and Ovarian Cancer Syndrome in Primary Care: A Cluster Randomized Clinical Trial.
    • Kukafka R, Pan S, Silverman T, Zhang T, Chung WK, Terry MB, Fleck E, Younge RG, Trivedi MS, McGuinness JE, He T, Dimond J, Crew KD.
    • JAMA Netw Open. 2022 Jul 18;5(7):e2222092. doi: 10.1001/jamanetworkopen.2022.22092.

    Related:

    Identifier: NCT03470402: Decision Support for BRCA Testing in Ethnically Diverse Women. (ClinicalTrials.gov)

    • Contraception and Hormone Replacement Therapy in Healthy Carriers of Germline BRCA1/2 Genes Pathogenic Variants: Results from an Italian Survey.
    • Massarotti C, Buonomo B, Dellino M, Campanella M, De Stefano C, Ferrari A, Anserini P, Lambertini M, Peccatori FA.
    • Cancers (Basel). 2022 Jul 15;14(14):3457. doi: 10.3390/cancers14143457.
    • The Clinical and Psychosocial Outcomes for Women Who Received Unexpected Clinically Actionable Germline Information Identified through Research: An Exploratory Sequential Mixed-Methods Comparative Study.
    • Forrest LE, Forbes Shepherd R, Tutty E, Pearce A, Campbell I, Devereux L, Trainer AH, James PA, Young MA.
    • J Pers Med. 2022 Jul 7;12(7):1112. doi: 10.3390/jpm12071112.
    • Women's thoughts on receiving and sharing genetic information: Considerations for genetic counseling.
    • Pfledderer CD, Gren LH, Frost CJ, Andrulis IL, Chung WK, Genkinger J, Glendon G, Hopper JL, John EM, Southey M, Terry MB, Daly MB.
    • J Genet Couns. 2022 Jul 6. doi: 10.1002/jgc4.1599. Epub ahead of print.
    • Randomised trial of population based BRCA testing in Ashkenazi Jews: Long term secondary lifestyle behavioural outcomes.
    • Burnell M, Gaba F, Sobocan M, Desai R, Sanderson S, Loggenberg K, Gessler S, Side L, Brady AF, Dorkins H, Wallis Y, Jacobs C, Legood R, Beller U, Tomlinson I, Wardle J, Menon U, Jacobs I, Manchanda R.
    • BJOG. 2022 Jul 4. doi: 10.1111/1471-0528.17253. Epub ahead of print.
    • Understanding Cancer Genetic Risk Assessment Intentions in a Tailored Risk Communication Intervention Randomized Controlled Trial.
    • LeCompte CG, McDougall J, Walters ST, Toppmeyer D, Boyce TW, Lu S, Stroup A, Paddock L, Grumet S, Lin Y, Ani J, Heidt E, Kinney AY.
    • Cancer Epidemiol Biomarkers Prev. 2022 Jul 1;31(7):1513-1514. doi: 10.1158/1055-9965.EPI-22-0482.
    • Conference abstract
    • Patient ethnicity and cascade genetic testing: a descriptive study of a publicly funded hereditary cancer program.
    • Braley EF, Bedard AC, Nuk J, Hong Q, Bedard JEJ, Sun S, Schrader KA.
    • Fam Cancer. 2022 Jul;21(3):369-374. doi: 10.1007/s10689-021-00270-0. Epub 2021 Jul 7.
    • Hereditary ovarian cancer risk reduction: a retrospective evaluation of patient perspectives and service provision at a regional hereditary gynaecologic cancer clinic 2006-2016.
    • Adolph L, Warias A, Stairs J, Collins-McNeil K, Penney L, Kieser K.
    • BMC Womens Health. 2022 Jun 29;22(1):263. doi: 10.1186/s12905-022-01844-5.
    • High Number of Familial Breast Cancer Cases in the Arabian Gulf Countries: Investigating the Reasons.
    • Mohammed EM.
    • Breast Cancer (Auckl). 2022 Jun 28;16:11782234221107121. doi: 10.1177/11782234221107121.
    • Mother and Daughter Perspectives on Genetic Counseling and Testing of Adolescents for Hereditary Breast Cancer Risk.
    • Jennings C, Wynn J, Miguel C, Levinson E, Florido ME, White M, Sands CB, Schwartz LA, Daly M, O'Toole K, Buys SS, Glendon G, Hanna D, Andrulis IL, Terry MB, Chung WK, Bradbury A.
    • J Pediatr. 2022 Jun 28:S0022-3476(22)00601-1. doi: 10.1016/j.jpeds.2022.06.027. Epub ahead of print.

    Related:

    Commentary:

    I know things now: The challenges for genetic counseling of adolescents with a family history of hereditary breast cancer.

    • TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members.
    • Delahunty R, Nguyen L, Craig S, Creighton B, Ariyaratne D, Garsed DW, Christie E, Fereday S, Andrews L, Lewis A, Limb S, Pandey A, Hendley J, Traficante N, Carvajal N, Spurdle AB, Thompson B, Parsons MT, Beshay V, Volcheck M, Semple T, Lupat R, Doig K, Yu J, Chen XQ, Marsh A, Love C, Bilic S, Beilin M, Nichols CB, Greer C, Lee YC, Gerty S, Gill L, Newton E, Howard J, Williams R, Norris C, Stephens AN, Tutty E, Smyth C, O'Connell S, Jobling T, Stewart CJR, Tan A, Fox SB, Pachter N, Li J, Ellul J, Mir Arnau G, Young MA, Gordon L, Forrest L, Harris M, Livingstone K, Hill J, Chenevix-Trench G, Cohen PA, Webb PM, Friedlander M, James P, Bowtell D, Alsop K; Australian Ovarian Cancer Study, Ovarian Cancer Prognosis and Lifestyle Study and the TRACEBACK Study.
    • J Clin Oncol. 2022 Jun 20;40(18):2036-2047. doi: 10.1200/JCO.21.02108. Epub 2022 Mar 9.
    • Helping Patients Understand and Cope with BRCA Mutations.
    • Makhnoon S, Arun B, Bedrosian I.
    • Curr Oncol Rep. 2022 Jun;24(6):733-740. doi: 10.1007/s11912-022-01254-8. Epub 2022 Mar 18.
    • Laboratory-related outcomes from integrating an accessible delivery model for hereditary cancer risk assessment and genetic testing in populations with barriers to access.
    • Amendola LM, Shuster E, Leo MC, Dorschner MO, Rolf BA, Shirts BH, Gilmore MJ, Okuyama S, Zepp JM, Kauffman TL, Mittendorf KF, Bellcross C, Jenkins CL, Joseph G, Riddle L, Syngal S, Ukaegbu C, Goddard KAB, Wilfond BS, Jarvik GP; CHARM Study.
    • Genet Med. 2022 Jun;24(6):1196-1205. doi: 10.1016/j.gim.2022.02.006. Epub 2022 Mar 16.
    • Perceptions and care Recommendations from Previvors: Qualitative analysis of female BRCA1/2 mutation Carriers' experience with genetic testing and counseling.
    • Dibble KE, Donorfio LKM, Britner PA, Bellizzi KM.
    • Gynecol Oncol Rep. 2022 May 2 [eCollection 2022 Jun];41:100989. doi: 10.1016/j.gore.2022.100989.
    • Sex Differences in Attitudes Toward Marriage and Childbearing Based on the Assumption of Being BRCA1/2 Mutation Carriers Among Young People.
    • Jeong J, Park B, Kim D, Kim J, Lee BY, Yoon J, Kim SW.
    • J Breast Cancer. 2022 Jun;25(3):233-243. doi: 10.4048/jbc.2022.25.e25.
    • Attitudes and interest in incorporating BRCA1/2 cancer susceptibility testing into reproductive carrier screening for Ashkenazi Jewish men and women.
    • Hardy MW, Peshkin BN, Rose E, Ladd MK, Binion S, Tynan M, McBride CM, Grinzaid KA, Schwartz MD.
    • J Community Genet. 2022 Jun;13(3):281-292. doi: 10.1007/s12687-022-00590-3. Epub 2022 Apr 29.
    • Medical knowledge and information needs among women with pathogenic variants in moderate-risk genes for hereditary breast cancer attending genetic counseling at an academic hospital in Germany-A qualitative approach.
    • Stracke C, Lemmen C, Rhiem K, Schmutzler R, Kautz-Freimuth S, Stock S.
    • J Genet Couns. 2022 Jun;31(3):698-712. doi: 10.1002/jgc4.1536. Epub 2021 Nov 26.
    • Transgender patients' perspectives on their cancer genetic counseling experiences.
    • Rolle L, Zayhowski K, Koeller D, Chiluiza D, Carmichael N.
    • J Genet Couns. 2022 Jun;31(3):781-791. doi: 10.1002/jgc4.1544. Epub 2021 Dec 28.
    • Olaparib for ovarian cancer: a single-institution, multi-site qualitative study.
    • Martin NA, Hanna M, Ehret C, Asiedu G, Jatoi A.
    • Support Care Cancer. 2022 Jun;30(6):4807-4812. doi: 10.1007/s00520-022-06879-w. Epub 2022 Feb 11.
    • Personalised Risk Prediction in Hereditary Breast and Ovarian Cancer: A Protocol for a Multi-Centre Randomised Controlled Trial.
    • Archer S, Fennell N, Colvin E, Laquindanum R, Mills M, Dennis R, Stutzin Donoso F, Gold R, Fan A, Downes K, Ford J, Antoniou AC, Kurian AW, Evans DG, Tischkowitz M.
    • Cancers (Basel). 2022 May 31;14(11):2716. doi: 10.3390/cancers14112716.
    • Differences in Willingness to Undergo BRCA1/2 Testing and Risk Reducing Surgery among the General Public, Cancer Patients, and Healthcare Professionals: A Large Population-Based Survey.
    • Chang YJ, Cho S, Joo J, Ryu KH, Lee S, Cho J, Lim MC, Jung SY, Han JH, Lee ES, Kong SY.
    • J Pers Med. 2022 May 18;12(5):818. doi: 10.3390/jpm12050818.
    • Perceived risk and risk reduction behaviours of female first-degree relatives of breast cancer patients attending care at Uganda cancer institute.
    • Ainembabazi P, Abila DB, Manyangwa G, Anguzu G, Musaazi J, Mutyaba I, Osingada CP, Mwaka AD.
    • Psychooncology. 2022 May 18. doi: 10.1002/pon.5963. Epub ahead of print.
    • Jewish cultural and religious factors and uptake of population-based BRCA testing across denominations: a cohort study.
    • Reisel D, Burnell M, Side L, Loggenberg K, Gessler S, Desai R, Sanderson S, Brady AF, Dorkins H, Wallis Y, Jacobs C, Legood R, Beller U, Tomlinson I, Wardle J, Menon U, Jacobs I, Manchanda R.
    • BJOG. 2022 May;129(6):959-968. doi: 10.1111/1471-0528.16994. Epub 2021 Nov 25.
    • Incomplete Penetrance of Population-Based Genetic Screening Results in Electronic Health Record.
    • Elhanan G, Kiser D, Neveux I, Dabe S, Bolze A, Metcalf WJ, Lu JT, Grzymski JJ.
    • Front Genet. 2022 Apr 27;13:866169. doi: 10.3389/fgene.2022.866169.
    • Unselected Population Genetic Testing for Personalised Ovarian Cancer Risk Prediction: A Qualitative Study Using Semi-Structured Interviews.
    • Gaba F, Oxley S, Liu X, Yang X, Chandrasekaran D, Kalsi J, Antoniou A, Side L, Sanderson S, Waller J, Ahmed M, Wallace A, Wallis Y, Menon U, Jacobs I, Legood R, Marks D, Manchanda R.
    • Diagnostics (Basel). 2022 Apr 19;12(5):1028. doi: 10.3390/diagnostics12051028.
    • Preimplantation genetic testing in patients with genetic susceptibility to cancer.
    • Villy MC, Frydman N, Moutou C, Thierry G, Raad J, Colas C, Steffann J, Metras J, Chabbert-Buffet N, Parc Y, Richard S, Benusiglio PR.
    • Fam Cancer. 2022 Apr 12. doi: 10.1007/s10689-022-00293-1. Epub ahead of print.
    • Partner Spotlight: Sharsheret.
    • Montoto R.
    • FORCE. Blog. 2022 Apr 8.
    • A randomized controlled trial comparing self-referred message to family-referred message promoting men's adherence to evidence-based guidelines on BRCA1/2 germline genetic testing: A registered study protocol.
    • Petrocchi S, Ongaro G, Calvello M, Feroce I, Bonanni B, Pravettoni G.
    • PLoS One. 2022 Apr 8;17(4):e0266327. doi: 10.1371/journal.pone.0266327.

    Related:

    Identifier: NCT04683068: Promoting Men's Adherence to BRCA1/2 Germline Genetic Testing (BRCA-MEN). (ClinicalTrials.gov)

    • “You are BRCA2-Positive”: Studies that Have Helped Me.
    • Dreher ME.
    • FORCE. Blog. 2022 Apr 5.
    • Psychological Determinants of Men's Adherence to Cascade Screening for BRCA1/2.
    • Ongaro G, Petrocchi S, Calvello M, Bonanni B, Feroce I, Pravettoni G.
    • Curr Oncol. 2022 Apr 2;29(4):2490-2503. doi: 10.3390/curroncol29040203.
    • Demographic Differences Among US Department of Veterans Affairs Patients Referred for Genetic Consultation to a Centralized VA Telehealth Program, VA Medical Centers, or the Community.
    • Scheuner MT, Huynh AK, Chanfreau-Coffinier C, Lerner B, Gable AR, Lee M, Simon A, Coeshott R, Hamilton AB, Patterson OV, DuVall S, Russell MM.
    • JAMA Netw Open. 2022 Apr 1;5(4):e226687. doi: 10.1001/jamanetworkopen.2022.6687.
    • Information needs of women undergoing gynaecological risk reduction surgery: Applying patient-reported findings to improve service delivery.
    • Jennings B, Ramis MA, Kynoch K, Jagasia N.
    • Aust N Z J Obstet Gynaecol. 2022 Apr;62(2):286-293. doi: 10.1111/ajo.13456. Epub 2021 Nov 9.
    • Recommendation and Acceptance of Counselling for Familial Cancer Risk in Newly Diagnosed Breast Cancer Cases.
    • Kast K, Häfner J, Schröck E, Jahn A, Werner C, Meisel C, Wimberger P.
    • Breast Care (Basel). 2022 Apr;17(2):153-158. doi: 10.1159/000517021. Epub 2021 Jun 17.
    • Risk-Adjusted Cancer Screening and Prevention (RiskAP): Complementing Screening for Early Disease Detection by a Learning Screening Based on Risk Factors.
    • Schmutzler RK, Schmitz-Luhn B, Borisch B, Devilee P, Eccles D, Hall P, Balmaña J, Boccia S, Dabrock P, Emons G, Gaissmaier W, Gronwald J, Houwaart S, Huster S, Kast K, Katalinic A, Linn SC, Moorthie S, Pharoah P, Rhiem K, Spranger T, Stoppa-Lyonnet D, van Delden JJM, van den Bulcke M, Woopen C.
    • Breast Care (Basel). 2022 Apr;17(2):208-223. doi: 10.1159/000517182. Epub 2021 Aug 12.
    • Outcomes of support groups for carriers of BRCA 1/2 pathogenic variants and their relatives: a systematic review.
    • Bertonazzi B, Turchetti D, Godino L.
    • Eur J Hum Genet. 2022 Apr;30(4):398-405. doi: 10.1038/s41431-022-01044-7.
    • "I wish that there was more info": characterizing the uncertainty experienced by carriers of pathogenic ATM and/or CHEK2 variants.
    • Reyes KG, Clark C, Gerhart M, Newson AJ, Ormond KE.
    • Fam Cancer. 2022 Apr;21(2):143-155. doi: 10.1007/s10689-021-00251-3. Epub 2021 Apr 15.
    • The psychological impact and experience of breast cancer screening in young women with an increased risk of breast cancer due to neurofibromatosis type 1.
    • Crook A, Kwa R, Ephraums S, Wilding M, Thiyagarajan L, Fleming J, Moore K, Berman Y.
    • Fam Cancer. 2022 Apr;21(2):241-253. doi: 10.1007/s10689-021-00259-9. Epub 2021 May 8.
    • Association Between Genetic Testing for Hereditary Breast Cancer and Contralateral Prophylactic Mastectomy Among Multiethnic Women Diagnosed With Early-Stage Breast Cancer.
    • Ro V, McGuinness JE, Guo B, Trivedi MS, Jones T, Chung WK, Rao R, Levinson E, Koval C, Russo D, Chilton I, Kukafka R, Crew KD.
    • JCO Oncol Pract. 2022 Apr;18(4):e472-e483. doi: 10.1200/OP.21.00322. Epub 2021 Oct 27.
    • Japanese women's reasons for accompaniment status to hereditary breast and ovarian cancer-focused genetic counseling.
    • Matsukawa M, Torishima M, Satoh C, Honda S, Kosugi S.
    • J Genet Couns. 2022 Apr;31(2):497-509. doi: 10.1002/jgc4.1519. Epub 2021 Oct 18.
    • Assessing the relationship between patient preferences for recontact after BRCA1 or BRCA2 genetic testing and their monitoring coping style in a Norwegian sample.
    • Dahle Ommundsen RM, Strømsvik N, Hamang A.
    • J Genet Couns. 2022 Apr;31(2):554-564. doi: 10.1002/jgc4.1526. Epub 2021 Oct 30.
    • Genetic testing and family entanglements.
    • Dimond R, Doheny S, Ballard L, Clarke A.
    • Soc Sci Med. 2022 Apr;298:114857. doi: 10.1016/j.socscimed.2022.114857. Epub 2022 Feb 24.
    • Attitude towards hereditary cancer risk management among women with cancer in Taiwan.
    • Fang SY, Hsieh LL, Hung CF, Hung FH, Peng HP, Yang AS, Wang YA.
    • Support Care Cancer. 2022 Apr;30(4):3625-3632. doi: 10.1007/s00520-021-06742-4. Epub 2022 Jan 14.
    • Uptake Rates of Risk-Reducing Surgeries for Women at Increased Risk of Hereditary Breast and Ovarian Cancer Applied to Cost-Effectiveness Analyses: A Scoping Systematic Review.
    • Simões Corrêa Galendi J, Kautz-Freimuth S, Stock S, Müller D.
    • Cancers (Basel). 2022 Mar 31;14(7):1786. doi: 10.3390/cancers14071786.
    • The Significant Predictors for Breast, Cervical, Colorectal, or Oral Cancer Screening Intention and Behavior in Taiwan.
    • Huang HC, Chang PC, Li SF, Wang CY, Huang WT, Chen W, Fan SY.
    • Cancer Nurs. 2022 Mar 29. doi: 10.1097/NCC.0000000000001107. Epub ahead of print.
    • Investigating men's motivations to engage in genetic screening for BRCA1 and BRCA2 mutations.
    • Annoni AM, Longhini C.
    • PLoS One. 2022 Mar 18;17(3):e0265387. doi: 10.1371/journal.pone.0265387.
    • Impact of BRCA Status on Reproductive Decision-Making and Self-Concept: A Mixed-Methods Study Informing the Development of Tailored Interventions.
    • Hesse-Biber S, Seven M, Jiang J, Schaik SV, Dwyer AA.
    • Cancers (Basel). 2022 Mar 15;14(6):1494. doi: 10.3390/cancers14061494.
    • Targeted BRCA1/2 population screening among Ashkenazi Jewish individuals using a web-enabled medical model: An observational cohort study.
    • Morgan KM, Hamilton JG, Symecko H, Kamara D, Jenkins C, Lester J, Spielman K, Pace LE, Gabriel C, Levin JD, Tejada PR, Braswell A, Marcell V, Wildman T, Devolder B, Baum RC, Block JN, Fesko Y, Boehler K, Howell V, Heitler J, Robson ME, Nathanson KL, Tung N, Karlan BY, Domchek SM, Garber JE, Offit K.
    • Genet Med. 2022 Mar;24(3):564-575. doi: 10.1016/j.gim.2021.10.016. Epub 2021 Dec 3.
    • Motivations and concerns of patients considering participation in an implementation study of a hereditary cancer risk assessment program in diverse primary care settings.
    • Duenas DM, Shipman KJ, Porter KM, Shuster E, Guerra C, Reyes A, Kauffman TL, Hunter JE, Goddard KAB, Wilfond BS, Kraft SA.
    • Genet Med. 2022 Mar;24(3):610-621. doi: 10.1016/j.gim.2021.11.017. Epub 2021 Nov 23.
    • Women's perceptions of PERSPECTIVE: a breast cancer risk stratification e-platform.
    • Ahmed S, Lévesque E, Garland R, Knoppers B, Dorval M, Simard J, Loiselle CG.
    • Hered Cancer Clin Pract. 2022 Feb 24;20(1):8. doi: 10.1186/s13053-022-00214-4.
    • Predictors of cardiopulmonary fitness in cancer-affected and -unaffected women with a pathogenic germline variant in the genes BRCA1/2 (LIBRE-1).
    • Berling-Ernst A, Yahiaoui-Doktor M, Kiechle M, Engel C, Lammert J, Grill S, Dukatz R, Rhiem K, Baumann FT, Bischoff SC, Erickson N, Schmidt T, Niederberger U, Siniatchkin M, Halle M.
    • Sci Rep. 2022 Feb 21;12(1):2907. doi: 10.1038/s41598-022-06913-1.
    • Evaluation of two evidence-based decision aids for female BRCA1/2 mutation carriers in Germany: study protocol for a randomised controlled parallel-group trial.
    • Kautz-Freimuth S, Redaèlli M, Isselhard A, Shukri A, Vodermaier A, Rhiem K, Schmutzler R, Stock S.
    • Trials. 2022 Feb 16;23(1):157. doi: 10.1186/s13063-022-06081-7.
    • Improving the quality of care for patients with advanced epithelial ovarian cancer: Program components, implementation barriers, and recommendations.
    • Temkin SM, Smeltzer MP, Dawkins MD, Boehmer LM, Senter L, Black DR, Blank SV, Yemelyanova A, Magliocco AM, Finkel MA, Moore TE, Thaker PH.
    • Cancer. 2022 Feb 15;128(4):654-664. doi: 10.1002/cncr.34023. Epub 2021 Nov 17.
    • Psychosocial outcome and health behaviour intent of breast cancer patients with BRCA1/2 and PALB2 pathogenic variants unselected by a priori risk.
    • Padmanabhan H, Hassan NT, Wong SW, Lee YQ, Lim J, Hasan SN, Yip CH, Teo SH, Thong MK, Mohd Taib NA, Yoon SY.
    • PLoS One. 2022 Feb 15;17(2):e0263675. doi: 10.1371/journal.pone.0263675.
    • BRCA2, Early-Stage Prostate Cancer and a Decision at 54.
    • Axler J.
    • FORCE. Blog. 2022 Feb 11.
    • Nurse-led decision coaching by specialized nurses for healthy BRCA1/2 gene mutation carriers - adaptation and pilot testing of a curriculum for nurses: a qualitative study.
    • Berger-Höger B, Vitinius F, Fischer H, Beifus K, Köberlein-Neu J, Isselhard A, Töpper M, Wiedemann R, Rhiem K, Schmutzler R, Stock S, Steckelberg A.
    • BMC Nurs. 2022 Feb 10;21(1):42. doi: 10.1186/s12912-022-00810-8.
    • Retrospective assessment of barriers and access to genetic services for hereditary cancer syndromes in an integrated health care delivery system.
    • Muessig KR, Zepp JM, Keast E, Shuster EE, Reyes AA, Arnold B, Ingphakorn C, Gilmore MJ, Kauffman TL, Hunter JE, Knerr S, Feigelson HS, Goddard KAB.
    • Hered Cancer Clin Pract. 2022 Feb 10;20(1):7. doi: 10.1186/s13053-022-00213-5.
    • An overview of genetic services delivery for hereditary breast cancer.
    • Reid S, Spalluto LB, Lang K, Weidner A, Pal T.
    • Breast Cancer Res Treat. 2022 Feb;191(3):491-500. doi: 10.1007/s10549-021-06478-z. Epub 2022 Jan 26.
    • Optimization of an mHealth lifestyle intervention for families with hereditary cancer syndromes: Study protocol for a multiphase optimization strategy feasibility study.
    • Basen-Engquist K, Raber M, Strong LL, Schembre S, Li L, Arun B, Lu K, You N, Vilar E, Lynch P, Fares S, Peterson SK.
    • Contemp Clin Trials. 2022 Feb;113:106662. doi: 10.1016/j.cct.2021.106662. Epub 2021 Dec 29.
    • Study protocol
    • Patients' and oncologists' preferences for second-line maintenance PARP inhibitor therapy in epithelial ovarian cancer.
    • Stone RL, Cambron-Mellott MJ, Beusterien K, Maculaitis MC, Ritz S, Mulvihill E, Monberg M, Szamreta EA, Amin S, McLaurin K.
    • Future Oncol. 2022 Feb;18(4):491-503. doi: 10.2217/fon-2021-0567. Epub 2021 Dec 8.
    • Characteristics and experiences of patients from a community-based and consumer-directed hereditary cancer population screening initiative.
    • Greve V, Odom K, Pudner S, Lamb NE, Cooper SJ, East K.
    • HGG Adv. 2021 Aug 24 [eCollection 2022 Jan 13];3(1):100055. doi: 10.1016/j.xhgg.2021.100055.
    • Barriers Exist to Cancer Genetic Testing for Black Women, Survey Shows.
    • [No author given]
    • Inside Precision Medicine. Topics. Oncology. 2022 Jan 5.

    Related:

    Original research:

    Genetic Counseling and Testing in African American Patients With Breast Cancer: A Nationwide Survey of US Breast Oncologists.

    • Risk-Reducing Salpingo-Oophorectomy and the Use of Hormone Replacement Therapy Below the Age of Natural Menopause: Scientific Impact Paper No. 66 October 2021: Scientific Impact Paper No. 66.
    • Manchanda R, Gaba F, Talaulikar V, Pundir J, Gessler S, Davies M, Menon U; Royal College of Obstetricians and Gynaecologists.
    • BJOG. 2022 Jan;129(1):e16-e34. doi: 10.1111/1471-0528.16896. Epub 2021 Oct 20.
    • Uptake and timing of bilateral and contralateral risk-reducing mastectomy in women with Li-Fraumeni syndrome.
    • Siegel A, Bremer RC, Klein WMP, Savage SA, Loud JT, Khincha PP.
    • Breast Cancer Res Treat. 2022 Jan;191(1):159-167. doi: 10.1007/s10549-021-06410-5. Epub 2021 Oct 15.
    • Heterogeneity in how women value risk-stratified breast screening.
    • Wheeler JCW, Keogh L, Sierra MA, Devereux L, Jones K, IJzerman MJ, Trainer AH.
    • Genet Med. 2022 Jan;24(1):146-156. doi: 10.1016/j.gim.2021.09.002. Epub 2021 Nov 30.
    • Evaluating the Effect of Health Education Intervention on the Health Beliefs and Behaviors of First-Degree Female Relatives of Breast Cancer Patients.
    • Olgun S, Dizer B.
    • South Asian J Cancer. 2021 Nov 24 [eCollection 2022 Jan];11(1):14-18. doi: 10.1055/s-0041-1733318.
    • Genetic Counseling and Testing in African American Patients With Breast Cancer: A Nationwide Survey of US Breast Oncologists.
    • Ademuyiwa FO, Salyer P, Tao Y, Luo J, Hensing WL, Afolalu A, Peterson LL, Weilbaecher K, Housten AJ, Baumann AA, Desai M, Jones S, Linnenbringer E, Plichta J, Bierut L.
    • J Clin Oncol. 2021 Dec 20;39(36):4020-4028. doi: 10.1200/JCO.21.01426. Epub 2021 Oct 18.

    Related:

    Commentary:

    Acknowledging Disparities in Hereditary Cancer Testing.

    Press: Physician Bias May Contribute to Lower Genetic Testing Rates Among Black Women, Study Suggests. (Precision Oncology News)

    Press: Barriers Exist to Cancer Genetic Testing for Black Women, Survey Shows. (Inside Precision Medicine)

    • Effect of Inquiry-Based Stress Reduction on Well-being and Views on Risk-Reducing Surgery Among Women With BRCA Variants in Israel: A Randomized Clinical Trial.
    • Landau C, Novak AM, Ganz AB, Rolnik B, Friedman E, Lev-Ari S.
    • JAMA Netw Open. 2021 Dec 1;4(12):e2139670. doi: 10.1001/jamanetworkopen.2021.39670.
    • Underutilisation of breast cancer prevention medication in Australia.
    • Macdonald C, Chamberlain JA, Mazza D, Milne RL; kConFab investigators, Phillips KA.
    • Breast. 2021 Dec;60:35-37. doi: 10.1016/. Epub 2021 Aug 23.
    • Breast cancer polygenic risk scores: a 12-month prospective study of patient reported outcomes and risk management behavior.
    • Yanes T, Meiser B, Kaur R, Young MA, Mitchell PB, Scheepers-Joynt M, McInerny S, Taylor S, Barlow-Stewart K, Antill Y, Salmon L, Smyth C, Betz-Stablein B, James PA.
    • Genet Med. 2021 Dec;23(12):2316-2323. doi: 10.1038/s41436-021-01288-6. Epub 2021 Aug 2.

    Related:

    Podcast: GenePod—November: The potential impact of a PRS-based breast cancer risk assessment. (Genetics in Medicine)

    • Unselected Women's Experiences of Receiving Genetic Research Results for Hereditary Breast and Ovarian Cancer: A Qualitative Study.
    • Forbes Shepherd R, Forrest LE, Tutty E, Pearce A, Devereux L, James PA, Campbell IG, Trainer A, Young MA.
    • Genet Test Mol Biomarkers. 2021 Dec;25(12):741-748. doi: 10.1089/gtmb.2021.0115.
    • A systematic review of psycho-social interventions for individuals with a BRCA1/2 pathogenic variant.
    • Warner NZ, Matthews S, Groarke A, McSharry J.
    • J Genet Couns. 2021 Dec;30(6):1695-1706. doi: 10.1002/jgc4.1436. Epub 2021 Jun 1.
    • The role of psychosocial factors in Black women's self-efficacy in receiving genetic counseling and testing.
    • Ding H, Sutton AL, Hurtado-de-Mendoza A, Sheppard VB.
    • J Genet Couns. 2021 Dec;30(6):1719-1726. doi: 10.1002/jgc4.1439. Epub 2021 Jun 4.
    • The DAMA25 Study: Feasibility of a Lifestyle Intervention Programme for Cancer Risk Reduction in Young Italian Women with Breast Cancer Family History.
    • Masala G, Palli D, Ermini I, Occhini D, Facchini L, Sequi L, Castaldo M, Caini S, Bendinelli B, Saieva C, Assedi M, Zanna I.
    • Int J Environ Res Public Health. 2021 Nov 23;18(23):12287. doi: 10.3390/ijerph182312287.
    • Survey Reveals Groups, Strategies to Focus Awareness Efforts for Cancer Germline Testing.
    • Kanski A.
    • Precision Oncology News. Biomarkers. BRCA. 2021 Nov 23.
    • News
    • UK Women's Views of the Concepts of Personalised Breast Cancer Risk Assessment and Risk-Stratified Breast Screening: A Qualitative Interview Study.
    • Kelley-Jones C, Scott S, Waller J.
    • Cancers (Basel). 2021 Nov 19;13(22):5813. doi: 10.3390/cancers13225813.
    • Conference Session Highlight: I'm Not White, Can I Still Have a Mutation?
    • Stallings E, Goldberg D.
    • FORCE. Blog. 2021 Nov 19.
    • Implication and Influence of Multigene Panel Testing with Genetic Counseling in Korean Patients with BRCA1/2 Mutation-Negative Breast Cancer.
    • Park JS, Shin S, Lee YJ, Lee ST, Nam EJ, Han JW, Lee SH, Kim TI, Park HS.
    • Cancer Res Treat. 2021 Nov 17. doi: 10.4143/crt.2021.978. Epub ahead of print.
    • Telephone versus in-person genetic counseling for hereditary cancer risk: Patient predictors of differential outcomes.
    • Binion S, Sorgen LJ, Peshkin BN, Valdimarsdottir H, Isaacs C, Nusbaum R, Graves KD, DeMarco T, Wood M, McKinnon W, Garber J, McCormick S, Ladd MK, Schwartz MD.
    • J Telemed Telecare. 2021 Nov 15:1357633X211052220. doi: 10.1177/1357633X211052220. Epub ahead of print.
    • Systemic Barriers to Risk-Reducing Interventions for Hereditary Cancer Syndromes: Implications for Health Care Inequities.
    • Mittendorf KF, Knerr S, Kauffman TL, Lindberg NM, Anderson KP, Feigelson HS, Gilmore MJ, Hunter JE, Joseph G, Kraft SA, Zepp JM, Syngal S, Wilfond BS, Goddard KAB.
    • JCO Precis Oncol. 2021 Nov 3;5:PO.21.00233. doi: 10.1200/PO.21.00233.
    • Volunteer Spotlight – Karen Ewing.
    • Ewing K.
    • FORCE. Blog. 2021 Nov 2.
    • Uptake and timing of risk-reducing salpingo-oophorectomy among patients with BRCA1/2 mutations.
    • Smith MJ, Gerber D, Olsen A, Khouri OR, Wang Y, Liu M, Smith J, Pothuri B.
    • Am J Obstet Gynecol. 2021 Nov;225(5):508.e1-508.e10. doi: 10.1016/j.ajog.2021.06.070. Epub 2021 Jun 23.
    • Novel Models of Genetic Education and Testing for Pancreatic Cancer Interception: Preliminary Results from the GENERATE Study.
    • Furniss CS, Yurgelun MB, Ukaegbu C, Constantinou PE, Lafferty CC, Talcove-Berko ER, Schwartz AN, Stopfer JE, Underhill-Blazey M, Kenner B, Nelson SH, Okumura S, Law S, Zhou AY, Coffin TB, Rodriguez NJ, Uno H, Ocean AJ, McAllister F, Lowy AM, Lippman SM, Klein AP, Madlensky L, Petersen GM, Garber JE, Goggins MG, Maitra A, Syngal S.
    • Cancer Prev Res (Phila). 2021 Nov;14(11):1021-1032. doi: 10.1158/1940-6207.CAPR-20-0642. Epub 2021 Oct 8.
    • November: The potential impact of a PRS-based breast cancer risk assessment.
    • Yanes T, Graber C.
    • Genetics in Medicine. GenePod. 2021 Nov.

    Related:

    Original research:

    Breast cancer polygenic risk scores: a 12-month prospective study of patient reported outcomes and risk management behavior.

    • Uptake and acceptability of a mainstreaming model of hereditary cancer multigene panel testing among patients with ovarian, pancreatic, and prostate cancer.
    • Hamilton JG, Symecko H, Spielman K, Breen K, Mueller R, Catchings A, Trottier M, Salo-Mullen EE, Shah I, Arutyunova A, Batson M, Gebert R, Pundock S, Schofield E, Offit K, Stadler ZK, Cadoo K, Carlo MI, Narayan V, Reiss KA, Robson ME, Domchek SM.
    • Genet Med. 2021 Nov;23(11):2105-2113. doi: 10.1038/s41436-021-01262-2. Epub 2021 Jul 13.
    • Adherence to PARP inhibitor therapy among women with ovarian cancer.
    • Moss HA, Chen L, Hershman DL, Davidson B, Wright JD.
    • Gynecol Oncol. 2021 Nov;163(2):262-268. doi: 10.1016/j.ygyno.2021.08.025. Epub 2021 Sep 9.
    • Review: The Breast Cancer Book.
    • Steligo K.
    • FORCE. Blog. 2021 Oct 19.
    • Care of men with cancer-predisposing BRCA variants.
    • Horton R, Pharoah P, Hayward J, Lucassen A.
    • BMJ. 2021 Oct 14;375:n2376. doi: 10.1136/bmj.n2376.
    • Review
    • IMProving care After inherited Cancer Testing (IMPACT) study: protocol of a randomized trial evaluating the efficacy of two interventions designed to improve cancer risk management and family communication of genetic test results.
    • Cragun D, Beckstead J, Farmer M, Hooker G, Dean M, Matloff E, Reid S, Tezak A, Weidner A, Whisenant JG, Pal T.
    • BMC Cancer. 2021 Oct 13;21(1):1099. doi: 10.1186/s12885-021-08822-4.
    • Communication processes about predictive genetic testing within high-risk breast cancer families: a two-phase study design.
    • Blomen CL, Pott A, Volk AE, Budäus L, Witzel I.
    • Sci Rep. 2021 Oct 11;11(1):20178. doi: 10.1038/s41598-021-98737-8.
    • Invitae, Outcomes4Me Collaborate to Improve Breast Cancer Genetic Testing Access.
    • [No author given]
    • GenomeWeb. Diagnostics. 2021 Oct 8.
    • Ask Rosa - The making of a digital genetic conversation tool, a chatbot, about hereditary breast and ovarian cancer.
    • Siglen E, Vetti HH, Lunde ABF, Hatlebrekke TA, Strømsvik N, Hamang A, Hovland ST, Rettberg JW, Steen VM, Bjorvatn C.
    • Patient Educ Couns. 2021 Oct 6:S0738-3991(21)00636-4. doi: 10.1016/j.pec.2021.09.027. Epub ahead of print.
    • Fragmented responsibility: views of Israeli HCPs regarding patient recontact following variant reclassification.
    • Fridman AL, Raz A, Timmermans S, Shkedi-Rafid S.
    • J Community Genet. 2021 Oct 5:1–6. doi: 10.1007/s12687-021-00556-x. Epub ahead of print.
    • A culturally targeted video to promote genetic counseling in a community sample of at-risk US Latina women: The role of the concrete mindset.
    • Carrera P, Sheppard VB, Caballero A, Gómez-Trillos S, Hurtado-de-Mendoza A.
    • J Community Psychol. 2021 Oct 4. doi: 10.1002/jcop.22718. Epub ahead of print.
    • Disparities between Uptake of Germline BRCA1/2 Gene Tests and Implementation of Post-test Management Strategies in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients.
    • Hur YM, Mun J, Kim MK, Lee M, Kim YH, Kim SC.
    • J Korean Med Sci. 2021 Oct 4;36(38):e241. doi: 10.3346/jkms.2021.36.e241.
    • Uptake of cancer risk management strategies among women who undergo cascade genetic testing for breast cancer susceptibility genes.
    • Makhnoon S, Tran G, Levin B, Mattie KD, Dreyer B, Volk RJ, Grana G, Arun BK, Peterson SK.
    • Cancer. 2021 Oct 1;127(19):3605-3613. doi: 10.1002/cncr.33668. Epub 2021 Jun 22.
    • BRCA mutation carriers' perceptions on postmenopausal hormone therapy: An Italian study.
    • Grandi G, Boggio Sola V, Cortesi L, Toss A, Giuliani GA, Del Savio MC, Facchinetti F.
    • Psychooncology. 2021 Oct;30(10):1711-1719. doi: 10.1002/pon.5714. Epub 2021 May 28.
    • Exploring Implementation of Personal Breast Cancer Risk Assessments.
    • Sierra MA, Wheeler JCW, Devereux L, Trainer AH, Keogh L.
    • J Pers Med. 2021 Sep 30;11(10):992. doi: 10.3390/jpm11100992.
    • Data on Utility in Cost-Utility Analyses of Genetic Screen-and-Treat Strategies for Breast and Ovarian Cancer.
    • Simões Corrêa Galendi J, Vennedey V, Kentenich H, Stock S, Müller D.
    • Cancers (Basel). 2021 Sep 29;13(19):4879. doi: 10.3390/cancers13194879.
    • Genetic Testing Challenges in Oncology: BRCA1 Variant Downgraded After Risk-Reducing Surgery.
    • Ray T.
    • Precision Oncology News. Biomarkers. BRCA. 2021 Sep 29.
    • Improving our model of cascade testing for hereditary cancer risk by leveraging patient peer support: a concept report.
    • O'Neill SC, Hamilton JG, Conley CC, Peshkin BN, Sacca R, McDonnell GA, Isaacs C, Robson ME, Tercyak KP.
    • Hered Cancer Clin Pract. 2021 Sep 26;19(1):40. doi: 10.1186/s13053-021-00198-7.
    • Building the What Comes Next Cohort for BRCA1 and BRCA2 testing: a descriptive analysis.
    • Dossa F, Metcalfe K, Sutradhar R, Little T, Eisen A, Chun K, Meschino WS, Velsher L, Ellis JL, Baxter NN.
    • CMAJ Open. 2021 Sep 21;9(3):E874-E885. doi: 10.9778/cmajo.20200228.
    • Understanding BRCA1/2 Previvors’ Information and Support Needs: Results from a Community Needs Assessment.
    • Boumis JK, Dean M.
    • FORCE. Blog. 2021 Sep 20.
    • After Three Cancer Diagnoses and a Positive BRCA Test, Endometrial Cancer.
    • Walter P.
    • FORCE. Blog. 2021 Sep 9.
    • Feasibility of genetic testing for cancer risk assessment programme in Nigeria.
    • Adejumo PO, Aniagwu TIG, Awolude OA, Oni AO, Ajayi OO, Fagbenle O, Ogungbade D, Kochheiser M, Ogundiran T, Olopade OI.
    • Ecancermedicalscience. 2021 Sep 7;15:1283. doi: 10.3332/ecancer.2021.1283.
    • A Different Kind of Trial: A Litigation Attorney's Take on Being in a National Institutes of Health Clinical Trial.
    • Hertz B.
    • FORCE. Blog. 2021 Sep 5.
    • Association of Population Screening for Breast Cancer Risk With Use of Mammography Among Women in Medically Underserved Racial and Ethnic Minority Groups.
    • Schwartz C, Chukwudozie IB, Tejeda S, Vijayasiri G, Abraham I, Remo M, Shah HA, Rojas M, Carillo A, Moreno L, Warnecke RB, Hoskins KF.
    • JAMA Netw Open. 2021 Sep 1;4(9):e2123751. doi: 10.1001/jamanetworkopen.2021.23751.

    Related:

    Commentary:

    Practice-Changing Opportunity to Reduce Disparities in Screening Mammography-Implementation of Risk Assessment in Primary Care.

    • Pretest Genetic Education Video Versus Genetic Counseling for Men Considering Prostate Cancer Germline Testing: A Patient-Choice Study to Address Urgent Practice Needs.
    • Russo J, McDougall C, Bowler N, Shimada A, Gross L, Hyatt C, Kelly WK, Calvaresi A, Handley NR, Hirsch IH, Izes JK, Lallas CD, Mann M, Mark JR, Mille PJ, Preate D Jr, Trabulsi EJ, Tsang M, Chandrasekar T, Weiner PR, Gomella LG, Giri VN.
    • JCO Precis Oncol. 2021 Sep 1;5:PO.21.00238. doi: 10.1200/PO.21.00238.

    Related:

    Research news: Men Give Thumbs Up to Video on Genetic Testing in Prostate Cancer. (Medscape Oncology)

    • Volunteer Spotlight – Faith Miller.
    • Miller F.
    • FORCE. Blog. 2021 Aug 30.
    • A Cost Decision Model Supporting Treatment Strategy Selection in BRCA1/2 Mutation Carriers in Breast Cancer.
    • Carbonara N, La Forgia D, Pellegrino R, Ressa C, Tommasi S.
    • J Pers Med. 2021 Aug 27;11(9):847. doi: 10.3390/jpm11090847.
    • Patient-Reported Outcomes following Genetic Testing for Familial Hypercholesterolemia, Breast and Ovarian Cancer Syndrome, and Lynch Syndrome: A Systematic Review.
    • Hendricks-Sturrup RM, Joseph L, Lu CY.
    • J Pers Med. 2021 Aug 27;11(9):850. doi: 10.3390/jpm11090850.
    • Evaluation of a patient decision aid for BRCA1/2 pathogenic variant carriers choosing an ovarian cancer prevention strategy.
    • Steenbeek MP, van Bommel MHD, Harmsen MG, Hoogerbrugge N, van Doorn HC, Keurentjes JHM, van Beurden M, Zweemer RP, Gaarenstroom KN, Penders CGJ, Brood-van Zanten MMA, Vos MC, Piek JM, van Lonkhuijzen LRCW, Apperloo MJA, Coppus SFPJ, IntHout J, de Hullu JA, Hermens RPMG.
    • Gynecol Oncol. 2021 Aug 26:S0090-8258(21)01317-2. doi: 10.1016/j.ygyno.2021.08.019. Epub ahead of print.
    • RE: Endometrial Cancer Risk in Women with Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study.
    • Nahshon C, Lavie O.
    • J Natl Cancer Inst. 2021 Aug 23:djab154. doi: 10.1093/jnci/djab154. Epub ahead of print.

    Related:

    Letter, Reply:

    Response to Nahshon and Lavie.

    Original research:

    Endometrial Cancer Risk in Women with Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study.

    • "Being proactive, not reactive": exploring perceptions of genetic testing among White, Latinx, and Pacific Islander Populations.
    • Chavez-Yenter D, Vagher J, Clayton MF, Rindler M, Shukovich M, Kaphingst KA.
    • J Community Genet. 2021 Aug 20. doi: 10.1007/s12687-021-00542-3. Epub ahead of print.
    • Genetic counselling as a route to enhanced autonomy: using a sequential mixed methods research approach to develop a theory regarding presymptomatic genetic testing for young adults at risk of inherited cancer syndromes.
    • Godino L, Turchetti D, Jackson L, Hennessy C, Skirton H.
    • J Community Genet. 2021 Aug 20. doi: 10.1007/s12687-021-00548-x. Epub ahead of print.
    • Attitudes toward Risk-Reducing Mastectomy and Risk-Reducing Salpingo-oophorectomy among Young, Unmarried, Healthy Women in Korea.
    • Park B, Kim D, Kim J, Lee BY, Yoon J, Kim SW.
    • Cancer Res Treat. 2021 Aug 9. doi: 10.4143/crt.2021.449. Epub ahead of print.
    • Breast cancer worry in higher-risk women offered preventive therapy: a UK multicentre prospective study.
    • Lloyd KE, Hall LH, Ziegler L, Smith SG; ENGAGE investigators.
    • Breast Cancer Res Treat. 2021 Aug;188(3):703-712. doi: 10.1007/s10549-021-06183-x. Epub 2021 Mar 17.
    • Pursuing germline genome sequencing to reduce illness uncertainty may involve additional uncertainties for cancer patients: A mixed-methods study.
    • Bartley N, Best M, Butow P.
    • J Genet Couns. 2021 Aug;30(4):1143-1155. doi: 10.1002/jgc4.1398. Epub 2021 Mar 31.
    • Decision aids for female BRCA mutation carriers: a scoping review protocol.
    • McGarrigle SA, Prizeman G, Spillane C, Byrne N, Drury A, Mockler D, Connolly EM, Brady AM, Hanhauser YP.
    • BMJ Open. 2021 Jul 12;11(7):e045075. doi: 10.1136/bmjopen-2020-045075.
    • Cancer surveillance awareness and practice among families at increased risk for pancreatic adenocarcinoma.
    • Everett JN, Burgos G, Chun J, Baptiste A, Khanna LG, Oberstein PE, Simeone DM.
    • Cancer. 2021 Jul 1;127(13):2271-2278. doi: 10.1002/cncr.33500. Epub 2021 Mar 15.
    • Knowledge and perceptions of BRCA1/2 genetic testing and needs of diverse women with a personal or family history of breast cancer in South Florida.
    • Jones T, Howard H, Freeman-Costin K, Creighton A, Wisdom-Chambers K, Underhill-Blazey M.
    • J Community Genet. 2021 Jul;12(3):415-429. doi: 10.1007/s12687-021-00507-6. Epub 2021 Feb 8.
    • Disclosure of familial implications of pathogenic variants in breast-cancer genes to patients: Opportunity for prompting family communication.
    • Makhnoon S, Smith HS, Bednar EM, Bhatt A, Turner L, Arun B, Volk RJ, Peterson SK.
    • J Community Genet. 2021 Jul;12(3):439-447. doi: 10.1007/s12687-021-00504-9. Epub 2021 Jan 22.
    • Framing Effects on Decision-Making for Diagnostic Genetic Testing: Results from a Randomized Trial.
    • Dwyer AA, Shen H, Zeng Z, Gregas M, Zhao M.
    • Genes (Basel). 2021 Jun 20;12(6):941. doi: 10.3390/genes12060941.
    • Recommendation and Acceptance of Counselling for Familial Cancer Risk in Newly Diagnosed Breast Cancer Cases.
    • Kast K, Häfner J, Schröck E, Jahn A, Werner C, Meisel C, Wimberger P.
    • Breast Care (Basel). 2021 Jun 17. doi: 10.1159/000516376. Epub ahead of print.
    • Development and pilot of an online, personalized risk assessment tool for a breast cancer precision medicine trial.
    • Keane H, Huilgol YS, Shieh Y, Tice JA, Belkora J, Sepucha K, Shibley WP, Wang T, Che M, Goodman D, Ozanne E, Fiscalini AS, Esserman LJ.
    • NPJ Breast Cancer. 2021 Jun 17;7(1):78. doi: 10.1038/s41523-021-00288-8.
    • Development of decision aids for female BRCA1 and BRCA2 mutation carriers in Germany to support preference-sensitive decision-making.
    • Kautz-Freimuth S, Redaèlli M, Rhiem K, Vodermaier A, Krassuski L, Nicolai K, Schnepper M, Kuboth V, Dick J, Vennedey V, Wiedemann R, Schmutzler R, Stock S.
    • BMC Med Inform Decis Mak. 2021 Jun 5;21(1):180. doi: 10.1186/s12911-021-01528-4.
    • Decision Aids for Preventive Treatment Alternatives for BRCA1/2 Mutation Carriers: a Systematic Review.
    • Krassuski LM, Kautz-Freimuth S, Vennedey V, Rhiem K, Schmutzler RK, Stock S.
    • Geburtshilfe Frauenheilkd. 2021 Jun;81(6):679-698. doi: 10.1055/a-1326-1792. Epub 2021 Jun 21.
    • State of recent literature on communication about cancer genetic testing among Latinx populations.
    • Chavez-Yenter D, Chou WS, Kaphingst KA.
    • J Genet Couns. 2021 Jun;30(3):911-918. doi: 10.1002/jgc4.1351. Epub 2020 Nov 3.
    • Motivations and barriers to pursue cancer genomic testing: A systematic review.
    • Smith-Uffen M, Bartley N, Davies G, Best M.
    • Patient Educ Couns. 2021 Jun;104(6):1325-1334. doi: 10.1016/j.pec.2020.12.024. Epub 2020 Dec 25.
    • Review
    • Risk-Reducing Mastectomy and Reconstruction Following Prophylactic Breast Irradiation: Hope Sustained.
    • Ben David MA, Evron E, Rasco AF, Shai A, Corn BW.
    • Cancers (Basel). 2021 May 30;13(11):2694. doi: 10.3390/cancers13112694.
    • Genetic Testing Challenges in Oncology: Immigrant Mislabeled as BRCA-Positive, Regrets Ovary Removal.
    • Ray T.
    • Precision Oncology News. Diagnostics. Molecular Diagnostics. 2021 May 28.
    • Perthera, Side-Out Foundation Partner to Advance Precision Oncology in Breast Cancer.
    • [No author given]
    • Precision Oncology News. Cancer Specialties. Breast Cancer. 2021 May 21.
    • Health system interventions to integrate genetic testing in routine oncology services: A systematic review.
    • O'Shea R, Taylor N, Crook A, Jacobs C, Jung Kang Y, Lewis S, Rankin NM.
    • PLoS One. 2021 May 19;16(5):e0250379. doi: 10.1371/journal.pone.0250379.
    • Uncertainty following an inconclusive result from the BRCA1/2 genetic test: A review about psychological outcomes.
    • Bramanti SM, Trumello C, Lombardi L, Cavallo A, Stuppia L, Antonucci I, Babore A.
    • World J Psychiatry. 2021 May 19;11(5):189-200. doi: 10.5498/wjp.v11.i5.189.
    • Making Sense of a Health Threat: Illness Representations, Coping, and Psychological Distress among BRCA1/2 Mutation Carriers.
    • Brand H, Speiser D, Besch L, Roseman J, Kendel F.
    • Genes (Basel). 2021 May 14;12(5):741. doi: 10.3390/genes12050741.
    • Did Breastfeeding my Daughter Reduce my Ovarian Cancer Risk?
    • Haarlander T.
    • FORCE. Blog. 2021 May 3.

    Related:

    Research news: Study: Breastfeeding may lower risk of ovarian cancer in women with BRCA mutations. (FORCE. XRAY.)

    Original research:

    Hereditary Ovarian Cancer Clinical Study Group. Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation.

    • Evaluation of online Spanish and English health materials for preventive mastectomy. are we providing adequate information?
    • Del Valle DD, Pardo JA, Maselli AM, Valero MG, Fan B, Seyidova N, James TA, Lee BT.
    • Breast Cancer Res Treat. 2021 May;187(1):1-9. doi: 10.1007/s10549-021-06171-1. Epub 2021 Mar 15.
    • Review
    • Testing a best practices risk result format to communicate genetic risks.
    • Davis KW, Roter DL, Schmidlen T, Scheinfeldt LB, Klein WMP.
    • Patient Educ Couns. 2021 May;104(5):936-943. doi: 10.1016/j.pec.2020.10.021. Epub 2020 Oct 19.
    • How patients deal with an ambiguous medical test: Decision-making after genetic testing.
    • Scherr CL, Ramesh S, Getachew-Smith H, Kalke K, Ramsey K, Fischhoff B, Vadaparampil ST.
    • Patient Educ Couns. 2021 May;104(5):953-959. doi: 10.1016/j.pec.2020.10.020. Epub 2020 Oct 18.
    • Baseline knowledge and receptiveness to genetic testing for hereditary breast and ovarian cancer syndromes in Chinese high-risk females.
    • Chu AT, Tse DM, Suen DTK, Kwong A.
    • J Community Genet. 2021 Apr 30. doi: 10.1007/s12687-021-00518-3. Epub ahead of print.
    • CHEK2 Pathogenic Variants in Greek Breast Cancer Patients: Evidence for Strong Associations with Estrogen Receptor Positivity, Overuse of Risk-Reducing Procedures and Population Founder Effects.
    • Apostolou P, Dellatola V, Papadimitriou C, Kalfakakou D, Fountzilas E, Faliakou E, Fountzilas G, Romanidou O, Konstantopoulou I, Fostira F.
    • Cancers (Basel). 2021 Apr 27;13(9):2106. doi: 10.3390/cancers13092106.
    • Family planning in carriers of BRCA1 and BRCA2 pathogenic variants.
    • Haddad JM, Robison K, Beffa L, Laprise J, ScaliaWilbur J, Raker CA, Clark MA, Hofstatter E, Dalela D, Brown A, Bradford L, Toland M, Stuckey A.
    • J Genet Couns. 2021 Apr 27. doi: 10.1002/jgc4.1423. Epub ahead of print.
    • High-risk women are facing barriers to preventive breast cancer care.
    • Branigin A.
    • Washington Post. The Lily. 2021 Apr 27.

    Related:

    Original research:

    Financial constraints on genetic counseling and further risk-management decisions among U.S. women at elevated breast cancer risk.

    • The PREgnancy and FERtility (PREFER) study investigating the need for ovarian function and/or fertility preservation strategies in premenopausal women with early breast cancer.
    • Blondeaux E, Massarotti C, Fontana V, Poggio F, Arecco L, Fregatti P, Bighin C, Giannubilo I, Ruelle T, Razeti MG, Boni L, Anserini P, Del Mastro L, Lambertini M.
    • Front Oncol. 2021 Apr 26;10:690320. doi: 10.3389/fonc.2021.690320.
    • Influencers of the Decision to Undergo Contralateral Prophylactic Mastectomy among Women with Unilateral Breast Cancer.
    • Singareeka Raghavendra A, Alameddine HF, Andersen CR, Selber JC, Brewster AM, Barcenas CH, Caudle AS, Arun BK, Tripathy D, Ibrahim NK.
    • Cancers (Basel). 2021 Apr 23;13(9):2050. doi: 10.3390/cancers13092050.
    • New advancements in cancer screenings bring hope for the future.
    • Meyer Krause C.
    • FORCE. Blog. 2021 Apr 23.

    Related:

    Research news: Update: FDA approves new imaging drug for detecting spread of prostate cancer. (FORCE. XRAY.)

    • Factors Influencing Discussion of Cancer Genetic Testing with Health-Care Providers in a Population-Based Survey.
    • Makhnoon S, Yu R, Cunningham SA, Peterson SK, Shete S.
    • Public Health Genomics. 2021 Apr 22:1-11. doi: 10.1159/000515465. Epub ahead of print.
    • Psychological Distress and Coping Ability of Women at High Risk of Hereditary Breast and Ovarian Cancer before Undergoing Genetic Counseling-An Exploratory Study from Germany.
    • Vajen B, Rosset M, Wallaschek H, Baumann E, Schlegelberger B.
    • Int J Environ Res Public Health. 2021 Apr 19;18(8):4338. doi: 10.3390/ijerph18084338.
    • Universal access to genetic counseling for women with epithelial ovarian cancer in Nova Scotia: Evaluating a new collaborative care model.
    • Warias A, Ferguson M, Chamberlain E, Currie L, Snow N, Matheson K, Penney LS, Kieser K.
    • J Genet Couns. 2021 Apr 19. doi: 10.1002/jgc4.1416. Epub ahead of print.
    • Impact of national guidelines on use of BRCA1/2 germline testing, risk management advice given to women with pathogenic BRCA1/2 variants and uptake of advice.
    • Meiser B, Kaur R, Morrow A, Peate M, Wong WKT, McPike E, Cops E, Nichols C, Austin R, Fine M, Thrupp L, Ward R, Macrae F, Hiller JE, Trainer AH, Mitchell G; ICCon Audit Study Collaborative Group.
    • Hered Cancer Clin Pract. 2021 Apr 9;19(1):24. doi: 10.1186/s13053-021-00180-3.
    • Why So Many of Us Quit Taking Tamoxifen.
    • Horner K.
    • FORCE. Blog. 2021 Apr 6.

    Related:

    Research news: Study: How breast cancer patients experience hormone therapy (FORCE. XRAY.)

    • Contralateral prophylactic mastectomy: A narrative review of the evidence and acceptability.
    • Scheepens JCC, van 't Veer L, Esserman L, Belkora J, Mukhtar RA.
    • Breast. 2021 Apr;56:61-69. doi: 10.1016/j.breast.2021.02.003. Epub 2021 Feb 10.
    • Decision-making for Risk-reducing Salpingo-oophorectomy (RRSO) in Southeast Asian BRCA Mutation Carriers With Breast Cancer: A Qualitative Study.
    • Sa'at H, Lee YK, Yoon SY, Wong SW, Woo YL, Barlow-Stewart K, Mohd Taib NA.
    • Int J Behav Med. 2021 Mar 31. doi: 10.1007/s12529-021-09984-y. Epub ahead of print.
    • Understanding Breast Implant Risks.
    • Spittal K.
    • FORCE. XRAY. 2021 Mar 30.
    • Genetic Testing Challenges in Oncology: BRCA1-Positive Breast Cancer Patient Told She's Negative.
    • Ray T.
    • Precision Oncology News. Biomarkers. BRCA. 2021 Mar 26.

    Related:

    Blog post: Genetic Testing Challenges in Oncology: BRCA1-Positive Breast Cancer Patient Told She’s Negative. (My Gene Counsel)

    • Financial constraints on genetic counseling and further risk-management decisions among U.S. women at elevated breast cancer risk.
    • Meadows RJ, Padamsee TJ.
    • J Genet Couns. 2021 Mar 21. doi: 10.1002/jgc4.1413. Epub ahead of print.

    Related:

    Press: High-risk women are facing barriers to preventive breast cancer care. (Washington Post / The Lily)

    • Correspondence on "Assessing relatives' readiness for hereditary cancer cascade genetic testing" by Bednar et al.
    • Carlson J.
    • Genet Med. 2021 Mar 19. doi: 10.1038/s41436-020-01094-6. Epub ahead of print.
    • Letter

    Related:

    Original research:

    Assessing relatives' readiness for hereditary cancer cascade genetic testing.

    • Variations in breast cancer surgical treatment and timing: determinants and disparities.
    • Dankwa-Mullan I, George J, Roebuck MC, Tkacz J, Willis VC, Reyes F, Arriaga YE.
    • Breast Cancer Res Treat. 2021 Mar 10. doi: 10.1007/s10549-021-06155-1. Epub ahead of print.
    • Knowledge and psychosocial impact of genetic counseling and multigene panel testing among individuals with ovarian cancer.
    • Pozzar RA, Hong F, Xiong N, Stopfer JE, Nayak MM, Underhill-Blazey M.
    • Fam Cancer. 2021 Mar 10. doi: 10.1007/s10689-021-00240-6. Epub ahead of print.
    • The Knowledge and Attitude of Patients Diagnosed with Epithelial Ovarian Cancer towards Genetic Testing.
    • Shin W, Jeong G, Son Y, Seo SS, Kang S, Park SY, Lim MC.
    • Int J Environ Res Public Health. 2021 Feb 26;18(5):2312. doi: 10.3390/ijerph18052312.
    • The needs of Southeast Asian BRCA mutation carriers considering risk-reducing salpingo-oophorectomy: a qualitative study.
    • Sa'at H, Lee YK, Yoon SY, Wong SW, Woo YL, Barlow-Stewart K, Mohd Taib NA.
    • Fam Cancer. 2021 Feb 19. doi: 10.1007/s10689-021-00232-6. Epub ahead of print.
    • (Ex-)breast cancer patients with (pre-existing) symptoms of anxiety and/or depression experience higher barriers to contact health care providers during the COVID-19 pandemic.
    • Mink van der Molen DR, Bargon CA, Batenburg MCT, Gal R, Young-Afat DA, van Stam LE, van Dam IE, van der Leij F, Baas IO, Ernst MF, Maarse W, Vermulst N, Schoenmaeckers EJP, van Dalen T, Bijlsma RM, Doeksen A, Verkooijen HM; UMBRELLA study group.
    • Breast Cancer Res Treat. 2021 Feb 18. doi: 10.1007/s10549-021-06112-y. Epub ahead of print.
    • Surgical decision making in premenopausal BRCA carriers considering risk-reducing early salpingectomy or salpingo-oophorectomy: a qualitative study.
    • Gaba F, Goyal S, Marks D, Chandrasekaran D, Evans O, Robbani S, Tyson C, Legood R, Saridogan E, McCluggage WG, Hanson H, Singh N, Evans DG, Menon U, Manchanda R; PROTECTOR team.
    • J Med Genet. 2021 Feb 10:jmedgenet-2020-107501. doi: 10.1136/jmedgenet-2020-107501. Epub ahead of print.

    Related:

    Research news: Ovarian Cancer Prevention: How Patients Decide on Surgery. (Medscape)

    • Implementing genomic screening in diverse populations.
    • Abul-Husn NS, Soper ER, Braganza GT, Rodriguez JE, Zeid N, Cullina S, Bobo D, Moscati A, Merkelson A, Loos RJF, Cho JH, Belbin GM, Suckiel SA, Kenny EE.
    • Genome Med. 2021 Feb 5;13(1):17. doi: 10.1186/s13073-021-00832-y.
    • The Angelina Jolie effect: Contralateral risk-reducing mastectomy trends in patients at increased risk of breast cancer.
    • Basu NN, Hodson J, Chatterjee S, Gandhi A, Wisely J, Harvey J, Highton L, Murphy J, Barnes N, Johnson R, Barr L, Kirwan CC, Howell S, Baildam AD, Howell A, Evans DG.
    • Sci Rep. 2021 Feb 2;11(1):2847. doi: 10.1038/s41598-021-82654-x.
    • Development and Implementation of an Algorithm to Guide MRI Screening in Patients With a Personal History of Treated Breast Cancer.
    • Strigel RM, Bravo E, Tevaarwerk AJ, Anderson BM, Stella AL, Neuman HB.
    • Clin Breast Cancer. 2021 Feb;21(1):26-30. doi: 10.1016/j.clbc.2020.01.005. Epub 2020 Oct 17.
    • A Retrospective Analysis of the Relationship Between the Result of BRCA1/2 Genetic Testing and Surgical Method Selection in Japan.
    • Inuzuka M, Watanabe C, Yokoyama S, Kuwayama T, Akashi-Tanaka S, Arai M, Nakamura S; Registration Committee of the Japanese HBOC consortium.
    • Clin Breast Cancer. 2021 Feb;21(1):e48-e52. doi: 10.1016/j.clbc.2020.08.004. Epub 2020 Aug 20.
    • Parent-Child Communication and Reproductive Considerations in Families with Genetic Cancer Predisposition Syndromes: A Systematic Review.
    • Dattilo TM, Lipak KG, Clark OE, Gehred A, Sampson A, Quinn G, Zajo K, Sutter ME, Bowman-Curci M, Gardner M, Gerhardt CA, Nahata L.
    • J Adolesc Young Adult Oncol. 2021 Feb;10(1):15-25. doi: 10.1089/jayao.2020.0084. Epub 2020 Sep 8.
    • Utilization, Timing, and Outcomes of BRCA Genetic Testing Among Women With Newly Diagnosed Breast Cancer From a National Commercially Insured Population: The ABOARD Study.
    • Armstrong J, Lynch K, Virgo KS, Schwartz MD, Friedman S, Dean M, Andrews JE, Bourquardez Clark E, Clasen J, Conaty J, Parrillo O, Sutphen R.
    • JCO Oncol Pract. 2021 Feb;17(2):e226-e235. doi: 10.1200/OP.20.00571.
    • Examining information-seeking behavior in genetic testing for cancer predisposition: A qualitative interview study.
    • Zimmermann BM, Fanderl J, Koné I, Rabaglio M, Bürki N, Shaw D, Elger B.
    • Patient Educ Couns. 2021 Feb;104(2):257-264. doi: 10.1016/j.pec.2020.09.019. Epub 2020 Sep 17.
    • The impact of the number of tests presented and a provider recommendation on decisions about genetic testing for cancer risk.
    • Schwartz MLB, Klein WMP, Erby LAH, Smith CH, Roter DL.
    • Patient Educ Couns. 2021 Feb;104(2):265-275. doi: 10.1016/j.pec.2020.09.020. Epub 2020 Sep 18.
    • Experiences, expectations and preferences regarding MRI and mammography as breast cancer screening tools in women at familial risk.
    • Geuzinge HA, Heijnsdijk EAM, Obdeijn IM, de Koning HJ, Tilanus-Linthorst MMA; FaMRIsc study group.
    • Breast. 2021 Jan 18;56:1-6. doi: 10.1016/j.breast.2021.01.002. Epub ahead of print.
    • #TripleNegativeBreastCancer on Instagram.
    • Henderson A, Miller CA, Sutton AL, Guidry JPD.
    • Health Educ Behav. 2021 Jan 10:1090198120985450. doi: 10.1177/1090198120985450. Epub ahead of print.
    • Breast Cancer Chemoprevention: Use and Views of Australian Women and their Clinicians.
    • Macdonald C, Saunders CM, Keogh LA, Hunter M, Mazza D, McLachlan SA, Jones SC, Nesci S, Friedlander ML, Hopper JL, Emery JD, Hickey M, Milne RL, Phillips KA; Kathleen Cuningham Consortium for Research Into Familial Breast Cancer.
    • Cancer Prev Res (Phila). 2021 Jan;14(1):131-144. doi: 10.1158/1940-6207.CAPR-20-0369. Epub 2020 Oct 28.

    Related:

    Commentary:

    Implementation of Risk-reducing Strategies for Breast Cancer is Long Overdue.

    • Differences in cancer patients' and clinicians' preferences for disclosure of uncertain genomic tumor testing results.
    • Fenton AT, Anderson EC, Scharnetzki E, Reed K, Edelman E, Antov A, Rueter J, Han PKJ; MCGI Working Group.
    • Patient Educ Couns. 2021 Jan;104(1):3-11. doi: 10.1016/j.pec.2020.07.010. Epub 2020 Jul 15.
    • The effect of family history on screening procedures and prognosis in breast cancer patients - Results of a large population-based case-control study.
    • Seiffert K, Thoene K, Eulenburg CZ, Behrens S, Schmalfeldt B, Becher H, Chang-Claude J, Witzel I.
    • Breast. 2020 Dec 24;55:98-104. doi: 10.1016/j.breast.2020.12.008. Epub ahead of print.
    • Preimplantation genetic testing for carriers of BRCA1/2 pathogenic variants.
    • Vukovic P, Peccatori FA, Massarotti C, Miralles MS, Beketic-Oreškovic L, Lambertini M.
    • Crit Rev Oncol Hematol. 2020 Dec 14:103201. doi: 10.1016/j.critrevonc.2020.103201. Epub ahead of print.
    • Review
    • The psychosexual effects of risk-reducing bilateral salpingo-oophorectomy in female BRCA1/2 mutation carriers: A systematic review of qualitative studies.
    • Hickey I, Jha S, Wyld L.
    • Gynecol Oncol. 2020 Dec 11:S0090-8258(20)34164-0. doi: 10.1016/j.ygyno.2020.12.001. Epub ahead of print.
    • Review
    • Women's Intentions to Engage in Risk-Reducing Behaviours after Receiving Personal Ovarian Cancer Risk Information: An Experimental Survey Study.
    • Gallagher A, Waller J, Manchanda R, Jacobs I, Sanderson S.
    • Cancers (Basel). 2020 Nov 27;12(12):3543. doi: 10.3390/cancers12123543.
    • Application of the theory of regulatory fit to promote adherence to evidence-based breast cancer screening recommendations: experimental versus longitudinal evidence.
    • Petrocchi S, Ludolph R, Labrie NHM, Schulz P.
    • BMJ Open. 2020 Nov 12;10(11):e037748. doi: 10.1136/bmjopen-2020-037748.
    • Lived experiences of women reporting fatigue during PARP inhibitor maintenance treatment for advanced ovarian cancer: A qualitative study.
    • Poort H, Fenton ATHR, Thompson E, Dinardo MM, Liu JF, Arch JJ, Wright AA.
    • Gynecol Oncol. 2020 Nov 12:S0090-8258(20)34056-7. doi: 10.1016/j.ygyno.2020.10.034. Epub ahead of print.
    • Knowing about an inherited BRCA mutation improves outcomes for women with breast cancer.
    • [No author given]
    • FORCE. XRAY. 2020 Oct 26.

    Related:

    Original research:

    Presymptomatic Awareness of Germline Pathogenic BRCA Variants and Associated Outcomes in Women With Breast Cancer.

    • An in-depth exploration of the post-test informational needs of BRCA1 and BRCA2 pathogenic variant carriers in Asia.
    • Yuen J, Fung SM, Sia CL, Venkatramani M, Shaw T, Courtney E, Li ST, Chiang J, Tan VK, Tan BK, Ngeow J.
    • Hered Cancer Clin Pract. 2020 Oct 23;18:22. doi: 10.1186/s13053-020-00154-x.
    • Doing a Better Job at Reaching LatinX People and Families about Hereditary Cancer.
    • Gómez Trillos S, Hurtado de Mendoza A.
    • FORCE. Blog. 2020 Oct 21.
    • Experiences and attitudes of hereditary cancer screening patients in a consumer directed testing model.
    • Greve V, Garner M, Odom K, Cooper SJ, East KM.
    • Patient Educ Couns. 2020 Oct 11:S0738-3991(20)305498. doi: 10.1016/j.pec.2020.10.014. Epub ahead of print.
    • Astrophysics Meets Breast Cancer Advocacy.
    • Nance S.
    • FORCE. Blog. 2020 Oct 8.
    • Physicians communicating with women at genetic risk of breast and ovarian cancer: Are we in the middle of the ford between contradictory messages and unshared decision making?
    • Fadda M, Chappuis PO, Katapodi MC, Pagani O, Monnerat C, Membrez V, Unger S, Caiata Zufferey M.
    • PLoS One. 2020 Oct 8;15(10):e0240054. doi: 10.1371/journal.pone.0240054.
    • Knowledge and Attitudes About Genetic Testing Among Black and White Women with Breast Cancer.
    • McCall MK, Ibikunle S, Murphy Y, Hunter K, Rosenzweig MQ.
    • J Racial Ethn Health Disparities. 2020 Oct 6. doi: 10.1007/s40615-020-00878-5. Epub ahead of print.
    • BRCA1/2 mutations and risk-reducing bilateral salpingo-oophorectomy among Latinas: The UPTAKE study.
    • Lynce F, Schlam I, Geng X, Peshkin BN, Friedman S, Dutil J, Nahleh Z, Campos C, Ricker C, Rodriguez P, Denduluri N, Ahn J, Isaacs C, Graves KD.
    • J Genet Couns. 2020 Oct 3. doi: 10.1002/jgc4.1322. Epub ahead of print.
    • Establishing a Framework for the Clinical Translation of Germline Findings in Precision Oncology.
    • Dixon K, Young S, Shen Y, Thibodeau ML, Fok A, Pleasance E, Zhao E, Jones M, Aubert G, Armstrong L, Virani A, Regier D, Gelmon K, Renouf D, Chia S, Bosdet I, Rassekh SR, Deyell RJ, Yip S, Fisic A, Titmuss E, Abadi S, Jones SJM, Sun S, Karsan A, Marra M, Laskin J, Lim H, Schrader KA.
    • JNCI Cancer Spectr. 2020 May 29 [eCollection 2020 Oct];4(5):pkaa045. doi: 10.1093/jncics/pkaa045.
    • Bioethics and healthcare policies. The benefit of using genetic tests of BRCA 1 and BRCA 2 in elderly patients.
    • Fonseca V, Caeiro J.
    • Int J Health Plann Manage. 2020 Sep 25. doi: 10.1002/hpm.3072. Epub ahead of print.
    • Commentary
    • Impact of Numeracy Preferences on Information Needs for Genome Sequencing Results.
    • Albrechtsen RD, Goodman MS, Bathar J, Kaphingst KA.
    • Patient Educ Couns. 2020 Sep 25:S0738-3991(20)305309. doi: 10.1016/j.pec.2020.09.032. Epub ahead of print.
    • "I think that a brief conversation from their provider can go a very long way": Patient and provider perspectives on barriers and facilitators of genetic testing after ovarian cancer.
    • Mallen AR, Conley CC, Fuzzell L, Ketcher D, Augusto BM, McIntyre M, Barton LV, Townsend MK, Fridley BL, Tworoger SS, Wenham RM, Vadaparampil ST.
    • Support Care Cancer. 2020 Sep 25. doi: 10.1007/s00520-020-05779-1. Epub ahead of print.
    • Patient reported experiences following laparoscopic prophylactic bilateral salpingo-oophorectomy or salpingectomy in an ambulatory care hospital.
    • Trister R, Jacobson M, Nguyen P, Sobel M, Allen L, Narod SA, Kotsopoulos J.
    • Fam Cancer. 2020 Sep 23. doi: 10.1007/s10689-020-00208-y. Epub ahead of print.
    • Integrative Review of Reproductive Decision Making of Women Who Are BRCA Positive.
    • Skrovanek E, Dunbar-Jacob J, Dunwoody C, Wesmiller S.
    • J Obstet Gynecol Neonatal Nurs. 2020 Sep 11:S0884-2175(20)30117-9. doi: 10.1016/j.jogn.2020.07.006. Epub ahead of print.
    • Review
    • Genetic Testing and Surveillance of Young Breast Cancer Survivors and Blood Relatives: A Cluster Randomized Trial.
    • Katapodi MC, Ming C, Northouse LL, Duffy SA, Duquette D, Mendelsohn-Victor KE, Milliron KJ, Merajver SD, Dinov ID, Janz NK.
    • Cancers (Basel). 2020 Sep 5;12(9):2526. doi: 10.3390/cancers12092526.
    • Reproductive decision-making in the context of hereditary cancer: the effects of an online decision aid on informed decision-making.
    • Reumkens K, Tummers MHE, Severijns Y, Gietel-Habets JJG, van Kuijk SMJ, Aalfs CM, van Asperen CJ, Ausems MGEM, Collée M, Dommering CJ, Kets M, van der Kolk LE, Oosterwijk JC, Tjan-Heijnen VCG, van der Weijden T, de Die-Smulders CEM, van Osch LADM.
    • J Community Genet. 2020 Sep 2. doi: 10.1007/s12687-020-00484-2. Epub ahead of print.
    • Presymptomatic Awareness of Germline Pathogenic BRCA Variants and Associated Outcomes in Women With Breast Cancer.
    • Hadar T, Mor P, Amit G, Lieberman S, Gekhtman D, Rabinovitch R, Levy-Lahad E.
    • JAMA Oncol. 2020 Sep 1;6(9):1460-1463. doi: 10.1001/jamaoncol.2020.2059.

    Related:

    Research news: Study Sees Survival Boost For BRCA1/2 Carriers Tested Before Breast Cancer Diagnosis. (GenomeWeb)

    Research news: 'Knowledge Is Power': Knowing BRCA1/2 Status Tied to Survival. (Medscape)

    Research news: Knowing about an inherited BRCA mutation improves outcomes for women with breast cancer. (FORCE. XRAY.)

    • Using patient perspectives to inform communication training materials for health care professionals discussing BRCA mutation testing.
    • Shilling V, Catt S, Jenkins V, Fallowfield L.
    • Breast Cancer Res Treat. 2020 Aug 18. doi: 10.1007/s10549-020-05871-4. Epub ahead of print.
    • Factors associated with use of hormone therapy after preventive oophorectomy in BRCA mutation carriers.
    • Mejia-Gomez J, Gronwald J, Senter L, Karlan BY, Tung N, Wolfman W, Demsky R, Sun P, Narod SA, Kotsopoulos J; and the Hereditary Breast Cancer Clinical Study Group.
    • Menopause. 2020 Aug 10. doi: 10.1097/GME.0000000000001629. Epub ahead of print.
    • Pinning Pink: Messages About Hereditary Breast Cancer Risk on Pinterest.
    • Miller CA, Henderson AN, Guidry JPD, McGuire KP, Fuemmeler BF.
    • J Cancer Educ. 2020 Aug 8. doi: 10.1007/s13187-020-01842-x. Epub ahead of print.
    • BRCA1/2 genes mutations, ovarian reserve and female reproductive outcomes: a systematic literature review.
    • Merlino L, Chiné A, Galli C, Piccioni MG.
    • Minerva Ginecol. 2020 Aug 3. doi: 10.23736/S0026-4784.20.04624-9. Epub ahead of print.
    • Review
    • Utilization of clinical genetic counseling among childhood and young adult cancer survivors in a registry trial.
    • Anderson N, Delavar A, Friedman DN, Joseph V, Mubdi N, Oeffinger KC, Sklar CA, Offit K, Matasar M, Raghunathan N, Antal Z, Straus D, Walsh M, Latham A, Tonorezos ES.
    • J Community Genet. 2020 Jul 16. doi: 10.1007/s12687-020-00478-0. Epub ahead of print.
    • Mechanisms to increase cascade testing in hereditary breast and ovarian cancer: Impact of introducing standardized communication aids into genetic counseling.
    • Garcia C, Sullivan MW, Lothamer H, Harrison KM, Chatfield L, Thomas MH, Modesitt SC.
    • J Obstet Gynaecol Res. 2020 Jul 12. doi: 10.1111/jog.14366. Epub ahead of print.
    • How to Prepare for a Mastectomy Amid COVID and Other Life Events.
    • Wheaton J.
    • FORCE Blog. 2020 Jul 8.
    • Breast cancer risk (un)awareness among women suffering from neurofibromatosis type 1 in Poland.
    • Karwacki MW.
    • Contemp Oncol (Pozn). 2020;24(2):140-144. doi: 10.5114/wo.2020.97637. Epub 2020 Jul 3.
    • A Modern Dilemma: How Experts Grapple with Ambiguous Genetic Test Results.
    • Scherr CL, Ross Arguedas AA, Getachew-Smith H, Marshall-Fricker C, Shrestha N, Brooks K, Fischhoff B, Vadaparampil ST.
    • Med Decis Making. 2020 Jul;40(5):655-668. doi: 10.1177/0272989X20935864.
    • Breaking Breast Cancer Color Barriers and Building Bridges.
    • Souers J, Thomas M.
    • FORCE. FORCE Blog. 2020 Jun 24.

    Related:

    Web site: For the Breast of Us

    Information Guide: Our Accomplice Guide (For the Breast of Us)

    • A systematic review of communication interventions to help healthcare professionals discuss genetic testing for breast cancer.
    • Starkings R, Shilling V, Jenkins V, Fallowfield L.
    • Breast Cancer Res Treat. 2020 Jun 23. doi: 10.1007/s10549-020-05741-z. Epub ahead of print.
    • Personal Story: A young woman’s story of genetic testing.
    • [No author given.]
    • For the Breast of US. 2020 Jun 23.
    • Genetic testing and results disclosure in diverse populations: what does it take?
    • Horowitz CR.
    • Genet Med. 2020 Jun 22. doi: 10.1038/s41436-020-0874-6. Epub ahead of print.
    • Commentary
    • Web-based return of BRCA2 research results: one-year genetic counselling experience in Iceland.
    • Stefansdottir V, Thorolfsdottir E, Hognason HB, Patch C, van El C, Hentze S, Cordier C, Mendes Á, Jonsson JJ.
    • Eur J Hum Genet. 2020 Jun 10. doi: 10.1038/s41431-020-0665-1. Epub ahead of print.
    • How to improve the identification of patients with cancer eligible for genetic counselling?
    • Bracci R, Gasperini B, Capalbo M, Campanelli T, Caimmi E, Mattioli R, Espinosa E, Prospero E.
    • Eur J Cancer Care (Engl). 2020 Jun 8:e13276. doi: 10.1111/ecc.13276. Epub ahead of print.
    • Implementation and evaluation of a nurse-led decision-coaching program for healthy breast cancer susceptibility gene (BRCA1/2) mutation carriers: a study protocol for the randomized controlled EDCP-BRCA study.
    • Isselhard A, Töpper M, Berger-Höger B, Steckelberg A, Fischer H, Vitinius F, Beifus K, Köberlein-Neu J, Wiedemann R, Rhiem K, Schmutzler R, Stock S.
    • Trials. 2020 Jun 8;21(1):501. doi: 10.1186/s13063-020-04431-x.
    • Health orientation and individual tendencies of a sample of Italian genetic testing consumers.
    • Oliveri S, Durosini I, Cutica I, Cincidda C, Spinella F, Baldi M, Gorini A, Pravettoni G.
    • Mol Genet Genomic Med. 2020 Jun 5:e1291. doi: 10.1002/mgg3.1291. Epub ahead of print.
    • "It wasn't just for me": Motivations and implications of genetic testing for women at a low risk of hereditary breast and ovarian cancer syndrome.
    • Gill G, Beard C, Storey K, Taylor S, Sexton A.
    • Psychooncology. 2020 Jun 4. doi: 10.1002/pon.5436. Epub ahead of print.
    • BFOR Study Uses Digital Tools to Facilitate Population BRCA Screening in Ashkenazi Jewish Community.
    • Anderson A.
    • Precision Oncology News. 2020 Jun 3.
    • Factors Impacting on Decision-Making towards Prophylactic Surgeries in BRCA Mutation Carriers and Women with Familial Predisposition.
    • Segerer R, Peschel C, Kämmerer U, Häussler S, Wöckel A, Segerer S.
    • Breast Care (Basel). 2020 Jun;15(3):253-259. doi: 10.1159/000503370. Epub 2019 Oct 1.
    • Executive Summary of the Early-Onset Breast Cancer Evidence Review Conference.
    • Chelmow D, Pearlman MD, Young A, Bozzuto L, Dayaratna S, Jeudy M, Kremer ME, Scott DM, O'Hara JS.
    • Obstet Gynecol. 2020 Jun;135(6):1457-1478. doi: 10.1097/AOG.0000000000003889.
    • Utilization of Complementary Alternative Medicine, Diet, and Exercise Among Women at High Risk for Developing Breast Cancer.
    • Lee RT, Amico A, Malaka D, Lewin R, Cummings SA, Verp M, Patrick-Miller L, Bradbury AR, Olopade OI.
    • Integr Cancer Ther. 2020 Jan-Dec;19:1534735420922610. doi: 10.1177/1534735420922610. [First Published 2020 May 23.]
    • Women's responses and understanding of polygenic breast cancer risk information.
    • Yanes T, Kaur R, Meiser B, Scheepers-Joynt M, McInerny S, Barlow-Stewart K, Antill Y, Salmon L, Smyth C, James PA, Young MA.
    • Fam Cancer. 2020 May 20. doi: 10.1007/s10689-020-00185-2. Epub ahead of print.
    • Pediatric Reporting of Genomic Results Study (PROGRESS): A Mixed-Methods, Longitudinal, Observational Cohort Study Protocol to Explore Disclosure of Actionable Adult- And Pediatric-Onset Genomic Variants to Minors and Their Parents.
    • Savatt JM, Wagner JK, Joffe S, Rahm AK, Williams MS, Bradbury AR, Davis FD, Hergenrather J, Hu Y, Kelly MA, Kirchner HL, Meyer MN, Mozersky J, O'Dell SM, Pervola J, Seeley A, Sturm AC, Buchanan AH.
    • BMC Pediatr. 2020 May 15;20(1):222. doi: 10.1186/s12887-020-02070-4.
    • Population Study of Ovarian Cancer Risk Prediction for Targeted Screening and Prevention.
    • Gaba F, Blyuss O, Liu X, Goyal S, Lahoti N, Chandrasekaran D, Kurzer M, Kalsi J, Sanderson S, Lanceley A, Ahmed M, Side L, Gentry-Maharaj A, Wallis Y, Wallace A, Waller J, Luccarini C, Yang X, Dennis J, Dunning A, Lee A, Antoniou AC, Legood R, Menon U, Jacobs I, Manchanda R.
    • Cancers (Basel). 2020 May 15;12(5):E1241. doi: 10.3390/cancers12051241.
    • For the Breast of Us celebrates one year online.
    • Souers J, Thomas M.
    • For the Breast of Us. 2020 May 14.
    • Engaging Men With BRCA-Related Cancer Risks: Practical Advice for BRCA Risk Management From Male Stakeholders.
    • Dean M, Campbell-Salome G, Rauscher EA.
    • Am J Mens Health. 2020 May-Jun;14(3):1557988320924932. doi: 10.1177/1557988320924932.
    • Predictors of genetic testing uptake in newly diagnosed breast cancer patients.
    • Ladd MK, Peshkin BN, Isaacs C, Hooker G, Willey S, Valdimarsdottir H, DeMarco T, O'Neill S, Binion S, Schwartz MD; other members of the Surgery After Genetic Evaluation Study Group.
    • J Surg Oncol. 2020 Apr 28. doi: 10.1002/jso.25956. [Epub ahead of print]
    • Hormone Therapy Use After Premature Surgical Menopause Based on Prescription Records: A Population-Based Study.
    • Jang JH, Arora N, Kwon JS, Hanley GE.
    • J Obstet Gynaecol Can. 2020 Apr 27:S1701-2163(20)30336-4. doi: 10.1016/j.jogc.2020.03.022. Epub ahead of print.
    • Patient perspectives on variant reclassification after cancer susceptibility testing.
    • Halverson CME, Connors LM, Wessinger BC, Clayton EW, Wiesner GL.
    • Mol Genet Genomic Med. 2020 Apr 24:e1275. doi: 10.1002/mgg3.1275. [Epub ahead of print]
    • Cancer-related worry and risk perception in Brazilian individuals seeking genetic counseling for hereditary breast cancer.
    • Palmero EI, Campacci N, Schüler-Faccini L, Giugliani R, Rocha JCCD, Vargas FR, Ashton-Prolla P.
    • Genet Mol Biol. 2020 Apr 22;43(2):e20190097. doi: 10.1590/1678-4685-GMB-2019-0097. eCollection 2020.
    • A road map for the future: An exploration of attitudes, perceptions, and beliefs among African Americans to tailor health promotion of cancer-related genetic counseling and testing.
    • Lumpkins CY, Philp A, Nelson KL, Miller LM, Greiner KA.
    • J Genet Couns. 2020 Apr 15. doi: 10.1002/jgc4.1277. [Epub ahead of print]
    • Understanding Patients' Knowledge and Feelings Regarding Their Cryopreserved Ovarian Tissue: A Qualitative Interviewing Study.
    • Cordeiro Mitchell CN, Whiting-Collings LJ, Christianson MS.
    • J Adolesc Young Adult Oncol. 2020 Apr 7. doi: 10.1089/jayao.2020.0014. [Epub ahead of print]
    • Comparison of mammography behaviors, health beliefs, and fear levels of women with and without familial breast cancer history.
    • Erdogan E, Tuzcu A.
    • Women Health. 2020 Apr 6:1-16. doi: 10.1080/03630242.2020.1746949. [Epub ahead of print]
    • Longitudinal outcomes with cancer multigene panel testing in previously tested BRCA1/2 negative patients.
    • Bradbury AR, Egleston BL, Patrick-Miller LJ, Rustgi N, Brandt A, Brower J, DiGiovanni L, Fetzer D, Berkelbach C, Long JM, Powers J, Stopfer JE, Domchek SM.
    • Clin Genet. 2020 Apr;97(4):601-609. doi: 10.1111/cge.13716.
    • Assessing relatives' readiness for hereditary cancer cascade genetic testing.
    • Bednar EM, Sun CC, McCurdy S, Vernon SW.
    • Genet Med. 2020 Apr;22(4):719-726. doi: 10.1038/s41436-019-0735-3. Epub 2019 Dec 20.

    Related:

    Letter:

    Correspondence on "Assessing relatives' readiness for hereditary cancer cascade genetic testing" by Bednar et al.

    • What men want: Qualitative analysis of what men with prostate cancer (PCa) want to learn regarding genetic referral, counseling, and testing.
    • Greenberg S, Slager S, Neil BO, Cooney K, Maughan B, Stopa N, Venne V, Zickmund S, Colonna S.
    • Prostate. 2020 Apr;80(5):441-450. doi: 10.1002/pros.23959. Epub 2020 Feb 6.
    • Uptake of Risk Appropriate Behaviors After Breast Cancer Risk Stratification in the Mammography Screening Population.
    • Conley CC, Niell BL, Augusto BM, McIntyre M, Roetzheim R, Funaro K, Vadaparampil ST.
    • J Am Coll Radiol. 2020 Mar 27. pii: S1546-1440(20)30240-4. doi: 10.1016/j.jacr.2020.02.019. [Epub ahead of print]

    Related:

    Press: Mailed Notices of High Breast Cancer Risk Do Not Often Translate Into Behavior Changes. (Medscape/Reuters)

    • Public perception of predictive cancer genetic testing and research in Oregon.
    • Alvord TW, Marriott LK, Nguyen PT, Shafer A, Brown K, Stoller W, Volpi JL, Vandehey-Guerrero J, Ferrara LK, Blakesley S, Solomon E, Kuehl H, Palma AJ, Farris PE, Hamman KJ, Cotter M, Shannon J.
    • J Genet Couns. 2020 Mar 27. doi: 10.1002/jgc4.1262. [Epub ahead of print]
    • Factors shaping at-risk individuals' decisions to undergo genetic testing for cancer in Asia.
    • Sun S, Li ST, Ngeow J.
    • Health Soc Care Community. 2020 Mar 20. doi: 10.1111/hsc.12981. [Epub ahead of print]
    • Patient-reported burden of intensified surveillance and surgery in high-risk individuals under pancreatic cancer surveillance.
    • Overbeek KA, Cahen DL, Kamps A, Konings ICAW, Harinck F, Kuenen MA, Koerkamp BG, Besselink MG, van Eijck CH, Wagner A, Ausems MGE, van der Vlugt M, Fockens P, Vleggaar FP, Poley JW, van Hooft JE, Bleiker EMA, Bruno MJ; Dutch Familial Pancreatic Cancer Surveillance Study Group.
    • Fam Cancer. 2020 Mar 19. doi: 10.1007/s10689-020-00171-8. [Epub ahead of print]
    • Knowledge and attitude of hereditary breast cancer among Japanese university female students.
    • Terui-Kohbata H, Egawa M, Yura K, Yoshida M.
    • J Hum Genet. 2020 Mar 18. doi: 10.1038/s10038-020-0743-9. [Epub ahead of print]
    • The Ethics of Delivering Precision Medicine-Pretest Counseling and Somatic Genomic Testing.
    • Borno HT, Rider JR, Gunn CM.
    • JAMA Oncol. 2020 Mar 12. doi: 10.1001/jamaoncol.2020.0016. [Epub ahead of print]
    • Commentary
    • Hormone Replacement Therapy Prescription After Premature Surgical Menopause.
    • Garg N, Behbehani S, Kosiorek H, Wasson M.
    • J Minim Invasive Gynecol. 2020 Mar 12. pii: S1553-4650(20)30124-2. doi: 10.1016/j.jmig.2020.03.002. [Epub ahead of print]
    • Involving patients and their families in deciding to use next generation sequencing: Results from a nationally representative survey of U.S. oncologists.
    • Spees LP, Roberts MC, Freedman AN, Butler EN, Klein WMP, Prabhu Das I, de Moor JS.
    • Patient Educ Couns. 2020 Mar 3. pii: S0738-3991(20)30116-6. doi: 10.1016/j.pec.2020.03.001. [Epub ahead of print]
    • When to break the news and whose responsibility is it? A cross-sectional qualitative study of health professionals' views regarding disclosure of BRCA genetic cancer risk.
    • Young AL, Butow PN, Tucker KM, Wakefield CE, Healey E, Williams R.
    • BMJ Open. 2020 Feb 25;10(2):e033127. doi: 10.1136/bmjopen-2019-033127.
    • Perceptions of risk and reward in BRCA1 and BRCA2 mutation carriers choosing salpingectomy for ovarian cancer prevention.
    • Ghezelayagh TS, Stewart LE, Norquist BM, Bowen DJ, Yu V, Agnew KJ, Pennington KP, Swisher EM.
    • Fam Cancer. 2020 Feb 24. doi: 10.1007/s10689-020-00166-5. [Epub ahead of print]
    • Understanding and information needs of cancer patients regarding treatment-focused genomic testing: A systematic review.
    • Wolyniec K, Sharp J, Lazarakis S, Mileshkin L, Schofield P.
    • Psychooncology. 2020 Feb 5. doi: 10.1002/pon.5351. [Epub ahead of print]
    • Review
    • Systematic review of acceptability, cardiovascular, neurological, bone health and HRT outcomes following risk reducing surgery in BRCA carriers.
    • Gaba F, Manchanda R.
    • Best Pract Res Clin Obstet Gynaecol. 2020 Feb 4. pii: S1521-6934(20)30018-3. doi: 10.1016/j.bpobgyn.2020.01.006. [Epub ahead of print]
    • Factors that impact risk management decisions among women with pathogenic variants in moderate penetrance genes associated with hereditary breast cancer.
    • Napoli M, Lewis J, Hopper J, Widmeyer K.
    • J Genet Couns. 2020 Feb 3. doi: 10.1002/jgc4.1220. [Epub ahead of print]
    • Healthcare Utilization and Costs after Receiving a Positive BRCA1/2 Result from a Genomic Screening Program.
    • Hao J, Hassen D, Manickam K, Murray MF, Hartzel DN, Hu Y, Liu K, Rahm AK, Williams MS, Lazzeri A, Buchanan A, Sturm A, Snyder SR.
    • J Pers Med. 2020 Feb 3;10(1). pii: E7. doi: 10.3390/jpm10010007.
    • Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic Predisposition.
    • Vos JR, Fakkert IE, de Hullu JA, van Altena AM, Sie AS, Ouchene H, Willems RW, Nagtegaal ID, Jongmans MCJ, Mensenkamp AR, Woldringh GH, Bulten J, Leter EM, Kets CM, Simons M, Ligtenberg MJL, Hoogerbrugge N; OPA Working Group.
    • J Natl Cancer Inst. 2020 Feb 1;112(2):161-169. doi: 10.1093/jnci/djz080.

    Related:

    Letter:

    RE: Universal tumor DNA BRCA1/2 testing of ovarian cancer: prescreening PARPi treatment and genetic predisposition.

    • Experiences of BRCA1/2 Gene Mutation-Positive Women With Cancer in Communicating Genetic Risk to Their Relatives.
    • Seven M, Shah LL, Daack-Hirsch S, Yazici H.
    • Cancer Nurs. 2020 Jan 30. doi: 10.1097/NCC.0000000000000796. [Epub ahead of print]
    • Patient preferences for maintenance PARP inhibitor therapy in ovarian cancer treatment.
    • Havrilesky LJ, Lim S, Ehrisman JA, Lorenzo A, Alvarez Secord A, Yang JC, Johnson FR, Gonzalez JM, Reed SD.
    • Gynecol Oncol. 2020 Jan 22. pii: S0090-8258(20)30070-6. doi: 10.1016/j.ygyno.2020.01.026. [Epub ahead of print]
    • Predictors of contralateral prophylactic mastectomy in genetically high risk newly diagnosed breast cancer patients.
    • Tynan M, Peshkin BN, Isaacs C, Willey S, Valdimarsdottir HB, Nusbaum R, Hooker G, O'Neill SC, Jandorf L, Kelly SP, Heinzmann J, Kelleher S, Poggi E, Schwartz MD.
    • Breast Cancer Res Treat. 2020 Jan 1. doi: 10.1007/s10549-019-05515-2. [Epub ahead of print]
    • Mental Illness and BRCA1/2 Genetic Testing Intention Among Multiethnic Women Undergoing Screening Mammography.
    • Jones T, Freeman K, Ackerman M, Trivedi MS, Silverman T, Shapiro P, Kukafka R, Crew KD.
    • Oncol Nurs Forum. 2020 Jan 1;47(1):E13-E24. doi: 10.1188/20.ONF.E13-E24.
    • Latinas' knowledge of and experiences with genetic cancer risk assessment: Barriers and facilitators.
    • Gómez-Trillos S, Sheppard VB, Graves KD, Song M, Anderson L, Ostrove N, Lopez K, Campos C, Gonzalez N, Hurtado-de-Mendoza A.
    • J Genet Couns. 2019 Dec 27. doi: 10.1002/jgc4.1201. [Epub ahead of print]
    • Black Women's Confidence in the Genetic Information Nondiscrimination Act.
    • Sutton AL, Henderson A, Hurtado-de-Mendoza A, Tanner E, Khan M, Quillin J, Sheppard VB.
    • Int J Environ Res Public Health. 2019 Dec 14;16(24). pii: E5112. doi: 10.3390/ijerph16245112.
    • Uptake of Polygenic Risk Information among Women at Increased Risk of Breast Cancer.
    • Yanes T, Meiser B, Kaur R, Scheepers-Joynt M, McInerny S, Taylor S, Barlow-Stewart K, Antill Y, Salmon L, Smyth C, Young MA, James PA.
    • Clin Genet. 2019 Dec 12. doi: 10.1111/cge.13687. [Epub ahead of print]
    • Racial and Ethnic Differences in BRCA1/2 and Multigene Panel Testing Among Young Breast Cancer Patients.
    • Jones T, Trivedi MS, Jiang X, Silverman T, Underhill M, Chung WK, Kukafka R, Crew KD.
    • J Cancer Educ. 2019 Dec 4. doi: 10.1007/s13187-019-01646-8. [Epub ahead of print]

    Related:

    Research news: Study: Racial and ethnic differences in genetic testing among young breast cancer survivors. (FORCE. XRAYS.)

    • Study on the differences of opinions and choices of high-risk breast cancer populations in China before and after genetic testing.
    • Cheng X, Gu Z, Sun X, Zhuang Z.
    • Transl Cancer Res. 2019 Dec;8(8):2893-2905. doi: 10.21037/tcr.2019.11.43.
    • Mainstreamed genetic testing in ovarian cancer: patient experience of the testing process.
    • McLeavy L, Rahman B, Kristeleit R, Ledermann J, Lockley M, McCormack M, Mould T, Side L, Lanceley A.
    • Int J Gynecol Cancer. 2019 Nov 19. pii: ijgc-2019-000630. doi: 10.1136/ijgc-2019-000630. [Epub ahead of print]
    • Prophylactic nipple-sparing mastectomy in young previvors: Examining decision-making, reconstructive outcomes, and patient satisfaction in BRCA+ patients under 30.
    • Salibian AA, Bekisz JM, Frey JD, Miller B, Choi M, Karp NS.
    • Breast J. 2019 Nov 17. doi: 10.1111/tbj.13692. [Epub ahead of print]
    • Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations.
    • Vysotskaia V, Kaseniit KE, Bucheit L, Ready K, Price K, Johansen Taber K.
    • Cancer. 2019 Nov 4. doi: 10.1002/cncr.32572. [Epub ahead of print]
    • Impact of Genetic Testing on Risk-Management Behavior of Black Breast Cancer Survivors: A Longitudinal, Observational Study.
    • Conley CC, Kasting ML, Augusto BM, Garcia JD, Cragun D, Gonzalez BD, Kim J, Ashing KT, Knott CL, Hughes-Halbert C, Pal T, Vadaparampil ST.
    • Ann Surg Oncol. 2019 Nov 1. doi: 10.1245/s10434-019-07982-9. [Epub ahead of print]
    • Who should access Germline Genome Sequencing? A mixed methods study of patient views.
    • Best MC, Butow P, Jacobs C, Savard J, Biesecker B, Ballinger ML, Bartley N, Davies G, Napier CE, Smit AK, Thomas DM, Newson AJ; And members of the PiGeOn Project.
    • Clin Genet. 2019 Nov 1. doi: 10.1111/cge.13664. [Epub ahead of print]
    • How Do We Respond to Men with BRCA Mutations when They Ask About Prostate Cancer?
    • Karzai F, Madan RA, Dahut WL.
    • Eur Urol. 2019 Oct 29. pii: S0302-2838(19)30767-5. doi: 10.1016/j.eururo.2019.10.001. [Epub ahead of print]
    • Editorial
    • Parent of origin differences in psychosocial burden and approach to BRCA risk management.
    • Hesse-Biber S, Dwyer AA, Yi S.
    • Breast J. 2019 Oct 28. doi: 10.1111/tbj.13633. [Epub ahead of print]
    • Genetic counselling and personalised risk assessment in the Australian pancreatic cancer screening program.
    • Dwarte T, McKay S, Johns A, Tucker K, Spigelman AD, Williams D, Stoita A.
    • Hered Cancer Clin Pract. 2019 Oct 23;17:30. doi: 10.1186/s13053-019-0129-1.
    • Decision Making About Genetic Testing Among Women With a Personal and Family History of Breast Cancer.
    • Scott D, Friedman S, Telli ML, Kurian AW.
    • J Oncol Pract. 2019 Oct 15:JOP1900221. doi: 10.1200/JOP.19.00221. [Epub ahead of print]
    • Exploring factors that impact uptake of risk-reducing bilateral salpingo-oophorectomy (RRBSO) in high-risk women.
    • Hickey M, Rio I, Trainer A, Marino JL, Wrede CD, Peate M.
    • Menopause. 2019 Oct 14. doi: 10.1097/GME.0000000000001422. [Epub ahead of print]
    • "How do we rally around the one who was positive?" Familial uncertainty management in the context of men managing BRCA-related cancer risks.
    • Rauscher EA, Dean M, Campbell-Salome G, Barbour JB.
    • Soc Sci Med. 2019 Oct 11;242:112592. doi: 10.1016/j.socscimed.2019.112592. [Epub ahead of print]
    • All For BRCA, BRCA For All?
    • Resta R.
    • The DNA Exchange. 2019 Oct 7.
    • Beyoncé's Dad Just Revealed His Breast Cancer Diagnosis—Here's What You Need to Know About Male Breast Cancer.
    • Brenza A.
    • Health. 2019 Oct 3.
    • How to inform relatives at risk of hereditary diseases? A mixed-methods systematic review on patient attitudes.
    • van den Heuvel LM, Smets EMA, van Tintelen JP, Christiaans I.
    • J Genet Couns. 2019 Oct;28(5):1042-1058. doi: 10.1002/jgc4.1143. Epub 2019 Jun 19.
    • Review
    • Recontacting patients for multigene panel testing in hereditary cancer: Efficacy and insights.
    • Sawyer L, Creswick H, Lewandowski R, Quillin J.
    • J Genet Couns. 2019 Sep 25. doi: 10.1002/jgc4.1173. [Epub ahead of print]
    • Patients' willingness to reconsider cancer genetic testing after initially declining: Mention it again.
    • Halverson CME, Wessinger BC, Clayton EW, Wiesner GL.
    • J Genet Couns. 2019 Sep 25. doi: 10.1002/jgc4.1174. [Epub ahead of print]
    • Health professional and at-risk BRCA young adult perspectives about information needs: What does Gen Y need to know?
    • Young AL, Butow PN, Tucker KM, Williams R, Healey E, Wakefield CE.
    • J Genet Couns. 2019 Sep 19. doi: 10.1002/jgc4.1167. [Epub ahead of print]
    • Understanding Medical Mistrust in Black Women at Risk of BRCA 1/2 Mutations.
    • Sutton AL, He J, Tanner E, Edmonds MC, Henderson A, Hurtado de Mendoza A, Sheppard VB.
    • J Health Dispar Res Pract. 2019 Fall;12(3):35-47.
    • Trends in contralateral prophylactic mastectomy rate according to clinicopathologic and socioeconomic status.
    • Jeon HJ, Park HS, Park JS, Nam EJ, Lee ST, Han J.
    • Ann Surg Treat Res. 2019 Sep;97(3):113-118. doi: 10.4174/astr.2019.97.3.113. Epub 2019 Aug 29.
    • Risk Estimation, Anxiety and Breast Cancer Worry in Women at Risk for Breast Cancer: A Single-Arm Trial of Personalized Risk Communication.
    • Xie Z, Wenger N, Stanton A, Sepucha K, Kaplan C, Madlensky L, Elashoff D, Trent J, Petruse A, Johansen L, Layton T, Naeim A.
    • Psychooncology. 2019 Aug 28. doi: 10.1002/pon.5211. [Epub ahead of print]
    • The Genetic Education for Men (GEM) Trial: Development of Web-Based Education for Untested Men in BRCA1/2-Positive Families.
    • Peshkin BN, Ladd MK, Isaacs C, Segal H, Jacobs A, Taylor KL, Graves KD, O'Neill SC, Schwartz MD.
    • J Cancer Educ. 2019 Aug 11. doi: 10.1007/s13187-019-01599-y. [Epub ahead of print]
    • Impact of genetic counseling on the uptake of contralateral prophylactic mastectomy among younger women with breast cancer.
    • Terkelsen T, Rønning H, Skytte AB.
    • Acta Oncol. 2019 Aug 5:1-6. doi: 10.1080/0284186X.2019.1648860. [Epub ahead of print]
    • Effectiveness of decision aids for female BRCA1 and BRCA2 mutation carriers: a systematic review.
    • Krassuski L, Vennedey V, Stock S, Kautz-Freimuth S.
    • BMC Med Inform Decis Mak. 2019 Aug 1;19(1):154. doi: 10.1186/s12911-019-0872-2.
    • A Microsimulation Model for Evaluating the Effectiveness of Cancer Risk Management for BRCA Pathogenic Variant Carriers: miBRovaCAre.
    • Petelin L, Hossack L, Mitchell G, Liew D, Trainer AH, James PA.
    • Value Health. 2019 Aug;22(8):854-862. doi: 10.1016/j.jval.2019.03.008. Epub 2019 May 17.
    • From Targeting Somatic Mutations to Finding Inherited Cancer Predispositions: The Other Side of the Coin.
    • Pujol P, De La Motte Rouge T, Penault-Llorca F.
    • Diagnostics (Basel). 2019 Jul 26;9(3). pii: E83. doi: 10.3390/diagnostics9030083.
    • Uptake of genetic counseling among adult children of BRCA1/2 mutation carriers in France.
    • Gauna Cristaldo FB, Touzani R, Apostolidis T, Mouret-Fourme E, Stoppa-Lyonnet D, Lasset C, Fricker JP, Berthet P, Julian-Reynier C, Mancini J, Noguès C, Bouhnik AD.
    • Psychooncology. 2019 Jul 5. doi: 10.1002/pon.5169. [Epub ahead of print]
    • Willingness to decrease mammogram frequency among women at low risk for hereditary breast cancer.
    • Guan Y, Nehl E, Pencea I, Condit CM, Escoffery C, Bellcross CA, McBride CM.
    • Sci Rep. 2019 Jul 3;9(1):9599. doi: 10.1038/s41598-019-45967-6.
    • Awareness and acceptability of population-based screening for pathogenic BRCA variants: Do race and ethnicity matter?
    • Rubinsak LA, Kleinman A, Quillin J, Gordon SW, Sullivan SA, Sutton AL, Sheppard VB, Temkin SM.
    • Gynecol Oncol. 2019 Jun 22. pii: S0090-8258(19)31320-4. doi: 10.1016/j.ygyno.2019.06.009. [Epub ahead of print]
    • A Simple Way to Make Genetic Counseling More Efficient and Accessible.
    • Markman M.
    • Medscape Oncology. 2019 Jun 14.

    Related:

    Original research:

    Modified panel-based genetic counseling for ovarian cancer susceptibility: A randomized non-inferiority study.

    • How Safe Is Hormone Replacement Therapy After Risk-Reducing Salpingo-oophorectomy in Women With BRCA Mutations?
    • Markman M.
    • Medscape Oncology. 2019 Jun 14.

    Related:

    Review:

    Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits.

    • Barriers to the utilization of genetic testing and genetic counseling in patients with suspected hereditary breast and ovarian cancers.
    • Swink A, Nair A, Hoof P, Matthews A, Burden C, Johnson K, Blum JL.
    • Proc (Bayl Univ Med Cent). 2019 Jun 11;32(3):340-344. doi: 10.1080/08998280.2019.1612702. eCollection 2019 Jul.
    • A young woman's story of genetic testing and risk-reducing mastectomy.
    • [No author given]
    • FORCE. XRAYS. 2019 Jun 6.

    Related:

    Narrative: I Had a Preventive Mastectomy—Then Found Out I Already Had Breast Cancer. (Health)

    • Genetic counseling of patients with ovarian carcinoma: acceptance, timing, and psychological wellbeing.
    • Van de Beek I, Smets EMA, Legdeur MA, de Hullu JA, Lok CAR, Buist MR, Mourits MJE, Kets CM, van der Kolk LE, Oosterwijk JC, Aalfs CM.
    • J Community Genet. 2019 Jun 5. doi: 10.1007/s12687-019-00427-6. [Epub ahead of print]
    • Previving: How Unaffected Women with a BRCA1/2 Mutation Navigate Previvor Identity.
    • Getachew-Smith H, Ross AA, Scherr CL, Dean M, Clements ML.
    • Health Commun. 2019 Jun 4:1-10. doi: 10.1080/10410236.2019.1625002. [Epub ahead of print]
    • Disparities in genetic services utilization in a random sample of young breast cancer survivors.
    • Nikolaidis C, Duquette D, Mendelsohn-Victor KE, Anderson B, Copeland G, Milliron KJ, Merajver SD, Janz NK, Northouse LL, Duffy SA, Katapodi MC.
    • Genet Med. 2019 Jun;21(6):1363-1370. doi: 10.1038/s41436-018-0349-1. Epub 2018 Nov 2.
    • Online decision support for persons having a genetic predisposition to cancer and their partners during reproductive decision-making.
    • Reumkens K, Tummers MHE, Gietel-Habets JJG, van Kuijk SMJ, Aalfs CM, van Asperen CJ, Ausems MGEM, Collée M, Dommering CJ, Kets CM, van der Kolk LE, Oosterwijk JC, Tjan-Heijnen VCG, van der Weijden T1, de Die-Smulders CEM, van Osch LADM.
    • J Genet Couns. 2019 Jun;28(3):533-542. doi: 10.1002/jgc4.1056. Epub 2018 Dec 21.
    • Factors affecting breast cancer patients' need for genetic risk information: From information insufficiency to information need.
    • Hong SJ, Biesecker B, Ivanovich J, Goodman M, Kaphingst KA.
    • J Genet Couns. 2019 Jun;28(3):543-557. doi: 10.1002/jgc4.1087. Epub 2019 Jan 24.
    • Genetic counseling, genetic testing, and risk perceptions for breast and colorectal cancer: Results from the 2015 National Health Interview Survey.
    • Turbitt E, Roberts MC, Taber JM, Waters EA, McNeel TS, Biesecker BB, Klein WMP.
    • Prev Med. 2019 Jun;123:12-19. doi: 10.1016/j.ypmed.2019.02.027. Epub 2019 Feb 25.
    • NF1 Patients Receiving Breast Cancer Screening: Insights from The Ontario High Risk Breast Screening Program.
    • Maani N, Westergard S, Yang J, Scaranelo AM, Telesca S, Thain E, Schachter NF, McCuaig JM, Kim RH.
    • Cancers (Basel). 2019 May 22;11(5). pii: E707. doi: 10.3390/cancers11050707.
    • Developing a culturally targeted video to enhance the use of genetic counseling in Latina women at increased risk for hereditary breast and ovarian cancer.
    • Hurtado-de-Mendoza A, Graves KD, Gómez-Trillos S, Song M, Anderson L, Campos C, Carrera P, Ostrove N, Peshkin BN, Schwartz MD, Ficca N, Cupertino AP, Gonzalez N, Otero A, Huerta E, Sheppard VB.
    • J Community Genet. 2019 May 18. doi: 10.1007/s12687-019-00423-w. [Epub ahead of print]
    • I Had a Preventive Mastectomy—Then Found Out I Already Had Breast Cancer.
    • Campoverdi A, Brody B.
    • Health. 2019 May 16.

    Related:

    Blog post: Personal Story: A young woman’s story of genetic testing. (For the Breast of US)

    • Universal tumor DNA BRCA1/2 testing of ovarian cancer: prescreening PARPi treatment and genetic predisposition.
    • Vos JR, Fakkert IE, de Hullu JA, van Altena AM, Sie AS, Ouchene H, Willems RW, Nagtegaal ID, Jongmans MCJ, Mensenkamp AR, Woldringh GH, Bulten J, Leter EM, Kets CM, Simons M, Ligtenberg MJL, Hoogerbrugge N.
    • J Natl Cancer Inst. 2019 May 11. pii: djz080. doi: 10.1093/jnci/djz080. [Epub ahead of print]

    Related:

    Letter, Comment:

    RE: Universal tumor DNA BRCA1/2 testing of ovarian cancer: prescreening PARPi treatment and genetic predisposition.

    • Exploring Predictors of Genetic Counseling and Testing for Hereditary Breast and Ovarian Cancer: Findings from the 2015 U.S. National Health Interview Survey.
    • Allen CG, Roberts M, Guan Y.
    • J Pers Med. 2019 May 10;9(2). pii: E26. doi: 10.3390/jpm9020026.
    • Effectiveness of interventions to identify and manage patients with familial cancer risk in primary care: a systematic review.
    • Lee SI, Patel M, Dutton B, Weng S, Luveta J, Qureshi N.
    • J Community Genet. 2019 May 6. doi: 10.1007/s12687-019-00419-6. [Epub ahead of print]
    • Review
    • Understanding BRCA Mutation Carriers' Preferences for Communication of Genetic Modifiers of Breast Cancer Risk.
    • Hovick SR, Tan N, Morr L, Senter L, Kinnamon DD, Pyatt RE, Toland AE.
    • J Health Commun. 2019 May 6:1-8. doi: 10.1080/10810730.2019.1604912. [Epub ahead of print]
    • A qualitative study on decision-making about BRCA1/2 testing in Italian women.
    • Battistuzzi L, Franiuk M, Kasparian N, Rania N, Migliorini L, Varesco L.
    • Eur J Cancer Care (Engl). 2019 May 5:e13083. doi: 10.1111/ecc.13083. [Epub ahead of print]
    • Accuracy in risk understanding among BRCA1/2-mutation carriers.
    • Speiser D, Rebitschek FG, Feufel MA, Brand H, Besch L, Kendel F.
    • Patient Educ Couns. 2019 May 5. pii: S0738-3991(18)30887-5. doi: 10.1016/j.pec.2019.05.007. [Epub ahead of print]
    • Evaluation of Cancer-Based Criteria for Use in Mainstream BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer.
    • Kemp Z, Turnbull A, Yost S, Seal S, Mahamdallie S, Poyastro-Pearson E, Warren-Perry M, Eccleston A, Tan MM, Teo SH, Turner N, Strydom A, George A, Rahman N.
    • JAMA Netw Open. 2019 May 3;2(5):e194428. doi: 10.1001/jamanetworkopen.2019.4428.
    • Attitude towards and factors affecting uptake of population-based BRCA testing in the Ashkenazi Jewish population: a cohort study.
    • Manchanda R, Burnell M, Gaba F, Sanderson S, Loggenberg K, Gessler S, Wardle J, Side L, Desai R, Brady AF, Dorkins H, Wallis Y, Chapman C, Jacobs C, Tomlinson I, Beller U, Menon U, Jacobs I.
    • BJOG. 2019 May;126(6):784-794. doi: 10.1111/1471-0528.15654. Epub 2019 Mar 18.
    • A narrative overview of the patients' outcomes after multigene cancer panel testing, and a thorough evaluation of its implications for genetic counselling.
    • Esteban I, Lopez-Fernandez A, Balmaña J.
    • Eur J Med Genet. 2019 May;62(5):342-349. doi: 10.1016/j.ejmg.2018.11.027. Epub 2018 Nov 23.
    • Review
    • Decisional conflict among breast cancer patients considering contralateral prophylactic mastectomy.
    • Manne S, Smith B, Mitarotondo A, Frederick S, Toppmeyer D, Kirstein L.
    • Patient Educ Couns. 2019 May;102(5):902-908. doi: 10.1016/j.pec.2018.12.008. Epub 2018 Dec 10.
    • A randomized controlled intervention to promote readiness to genetic counseling for breast cancer survivors.
    • Kasting ML, Conley CC, Hoogland AI, Scherr CL, Kim J, Thapa R, Reblin M, Meade CD, Lee MC, Pal T, Quinn GP, Vadaparampil ST.
    • Psychooncology. 2019 May;28(5):980-988. doi: 10.1002/pon.5059. Epub 2019 Apr 11.
    • Women's perceptions of personalized risk-based breast cancer screening and prevention: An international focus group study.
    • Rainey L, Jervaeus A, Donnelly LS, Evans DG, Hammarström M, Hall P, Wengström Y, Broeders MJM, van der Waal D.
    • Psychooncology. 2019 May;28(5):1056-1062. doi: 10.1002/pon.5051. Epub 2019 Mar 25.
    • Factors associated with intentions for breast cancer risk management: Does risk group matter?
    • Conley CC, Agnese DM, Vadaparampil ST, Andersen BL.
    • Psychooncology. 2019 May;28(5):1119-1126. doi: 10.1002/pon.5066. Epub 2019 Apr 10.
    • Shared-patient physician networks and their impact on the uptake of genomic testing in breast cancer.
    • Rotter J, Wilson L, Greiner MA, Pollack CE, Dinan M.
    • Breast Cancer Res Treat. 2019 Apr 26. doi: 10.1007/s10549-019-05248-2. [Epub ahead of print]
    • Uptake of genetic testing for germline BRCA1/2 pathogenic variants in a predominantly Hispanic population.
    • McGuinness JE, Trivedi MS, Silverman T, Marte A, Mata J, Kukafka R, Crew KD.
    • Cancer Genet. 2019 Apr 24. pii: S2210-7762(19)30059-6. doi: 10.1016/j.cancergen.2019.04.063. [Epub ahead of print]
    • Improving access to cancer genetic services: perspectives of high-risk clients in a community-based setting.
    • Miller I, Greenberg S, Yashar BM, Marvin ML.
    • J Community Genet. 2019 Apr 24. doi: 10.1007/s12687-019-00420-z. [Epub ahead of print]
    • "A natural progression" - Australian women's attitudes about an individualised breast screening model.
    • Lippey J, Keogh LA, Mann GB, Campbell IG, Forrest LE.
    • Cancer Prev Res (Phila). 2019 Apr 19. pii: canprevres.0443.2018. doi: 10.1158/1940-6207.CAPR-18-0443. [Epub ahead of print]
    • Development and testing of the KnowGene scale to assess general cancer genetic knowledge related to multigene panel testing.
    • Underhill-Blazey M, Stopfer J, Chittenden A, Nayak MM, Lansang K, Lederman R, Garber J, Gundersen DA.
    • Patient Educ Couns. 2019 Apr 13. pii: S0738-3991(19)30138-7. doi: 10.1016/j.pec.2019.04.014. [Epub ahead of print]
    • Hereditary Breast Cancer Risk Analysis in Uninsured Mexican-Origin Women Living in the U.S.-Mexico Border Region.
    • Salinas JJ, Roy R, Dwivedi AK, Shokar NK.
    • Hisp Health Care Int. 2019 Apr 12:1540415319837850. doi: 10.1177/1540415319837850. [Epub ahead of print]
    • International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation.
    • Metcalfe K, Eisen A, Senter L, Armel S, Bordeleau L, Meschino WS, Pal T, Lynch HT, Tung NM, Kwong A, Ainsworth P, Karlan B, Moller P, Eng C, Weitzel JN, Sun P, Lubinski J, Narod SA; Hereditary Breast Cancer Clinical Study Group.
    • Br J Cancer. 2019 Apr 11. doi: 10.1038/s41416-019-0446-1. [Epub ahead of print]

    Related:

    Editorial:

    Cancer screening and prevention in BRCA mutation carriers: a missed opportunity?

    • Factors Influencing Not Perceiving Family Health History Assessments as Important: Opportunities to Improve Dissemination of Evidence-Based Population Screening for Cancer.
    • Allen CG, Escoffery C, Haardörfer R, McBride CM.
    • Public Health Genomics. 2019 Apr 9:1-10. doi: 10.1159/000499125. [Epub ahead of print]
    • "It felt like unfinished business, it feels like that's finished now": Women's experiences of decision making around Contralateral Prophylactic Mastectomy (CPM).
    • Tollow P, Williams VS, Harcourt D, Paraskeva N.
    • Psychooncology. 2019 Apr 8. doi: 10.1002/pon.5086. [Epub ahead of print]
    • Predictive Power of PEN-3 Model Constructs in Breast Cancer Screening Behaviors among Teachers: A Cross- Sectional Study in Central Iran.
    • Moghaddam ES, Shahnazi H, Hassanzadeh A.
    • Eur J Breast Health. 2019 Apr 1;15(2):105-110. doi: 10.5152/ejbh.2019.4417. eCollection 2019 Apr.
    • A clinically structured and partnered approach to genetic testing in Trinidadian women with breast cancer and their families.
    • Donenberg T, George S, Ali J, Bravo G, Hernandez K, Sookar N, Ashing KT, Narod SA, Akbari MR, Hurley J.
    • Breast Cancer Res Treat. 2019 Apr;174(2):469-477. doi: 10.1007/s10549-018-5045-y. Epub 2018 Dec 4.
    • Communication about genetic testing with breast and ovarian cancer patients: a scoping review.
    • Jacobs C, Patch C, Michie S.
    • Eur J Hum Genet. 2019 Apr;27(4):511-524. doi: 10.1038/s41431-018-0310-4. Epub 2018 Dec 20.
    • Referral frequency, attrition rate, and outcomes of germline testing in patients with pancreatic adenocarcinoma.
    • Walker EJ, Carnevale J, Pedley C, Blanco A, Chan S, Collisson EA, Tempero MA, Ko AH.
    • Fam Cancer. 2019 Apr;18(2):241-251. doi: 10.1007/s10689-018-0106-2.
    • Exploring the preferences of involved health professionals regarding the implementation of an online decision aid to support couples during reproductive decision-making in hereditary cancer: a mixed methods approach.
    • Reumkens K, de Die-Smulders CEM, van Osch LADM.
    • Fam Cancer. 2019 Apr;18(2):285-291. doi: 10.1007/s10689-019-00119-7.
    • Population-based genetic testing of asymptomatic women for breast and ovarian cancer susceptibility.
    • Rowley SM, Mascarenhas L, Devereux L, Li N, Amarasinghe KC, Zethoven M, Lee JEA, Lewis A, Morgan JA, Limb S, Young MA, James PA, Trainer AH, Campbell IG.
    • Genet Med. 2019 Apr;21(4):913-922. doi: 10.1038/s41436-018-0277-0. Epub 2018 Sep 26.
    • A patient-centered mobile health application to motivate use of genetic counseling among women with ovarian cancer: A pilot randomized controlled trial.
    • Vogel RI, Niendorf K, Petzel S, Lee H, Teoh D, Blaes AH, Argenta P, Rivard C, Winterhoff B, Lee HY, Geller MA.
    • Gynecol Oncol. 2019 Apr;153(1):100-107. doi: 10.1016/j.ygyno.2019.01.019. Epub 2019 Feb 1.
    • Modified panel-based genetic counseling for ovarian cancer susceptibility: A randomized non-inferiority study.
    • McCuaig JM, Tone AA, Maganti M, Romagnuolo T, Ricker N, Shuldiner J, Rodin G, Stockley T, Kim RH, Bernardini MQ.
    • Gynecol Oncol. 2019 Apr;153(1):108-115. doi: 10.1016/j.ygyno.2018.12.027. Epub 2019 Jan 10.

    Related:

    Commentary: A Simple Way to Make Genetic Counseling More Efficient and Accessible. (Medscape Oncology)

    • Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2
    • Gordhandas S, Norquist BM, Pennington KP, Yung RL, Laya MB, Swisher EM.
    • Gynecol Oncol. 2019 Apr;153(1):192-200. doi: 10.1016/j.ygyno.2018.12.014. Epub 2019 Jan 17.
    • Review

    Related:

    Commentary: How Safe Is Hormone Replacement Therapy After Risk-Reducing Salpingo-oophorectomy in Women With BRCA Mutations? (Medscape Oncology)

    • Risk perception and screening behavior of Filipino women at risk for breast cancer: implications for cancer genetic counseling.
    • Lagarde JBB, Laurino MY, San Juan MD, Cauyan JML, Tumulak MJR, Ventura ER.
    • J Community Genet. 2019 Apr;10(2):281-289. doi: 10.1007/s12687-018-0391-3. Epub 2018 Sep 27.
    • Current knowledge of risk reducing mastectomy: Indications, techniques, results, benefits, harms.
    • Baildam AD.
    • Breast. 2019 Mar 29;46:48-51. doi: 10.1016/j.breast.2019.03.011. [Epub ahead of print]
    • Review
    • Experiences and interpretations of BRCA1/2 testing among women affected by breast or ovarian cancer who received a negative result.
    • Stafford L, Flehr A, Judd F, Lindeman GJ, Gibson P, Komiti A, Mann GB, Kentwell M.
    • J Community Genet. 2019 Mar 27. doi: 10.1007/s12687-019-00415-w. [Epub ahead of print]
    • Gaps in information about breast cancer risk and prevention impact African American women.
    • [No author given]
    • FORCE. XRAYS. 2019 Mar 14.

    Related:

    Original research:

    Layers of information: interacting constraints on breast cancer risk-management by high-risk African American women.

    • Impact of Implementing B-RSTTM to Screen for Hereditary Breast and Ovarian Cancer on Risk Perception and Genetic Counseling Uptake Among Women in an Academic Safety Net Hospital.
    • Wernke K, Bellcross C, Gabram S, Ali N, Stanislaw C.
    • Clin Breast Cancer. 2019 Mar 11. pii: S1526-8209(18)30730-4. doi: 10.1016/j.clbc.2019.02.014. [Epub ahead of print]
    • Concerns and Expectations of Risk-Reducing Surgery in Women with Hereditary Breast and Ovarian Cancer Syndrome.
    • Modaffari P, Ponzone R, Ferrari A, Cipullo I, Liberale V, D'Alonzo M, Maggiorotto F, Biglia N.
    • J Clin Med. 2019 Mar 5;8(3). pii: E313. doi: 10.3390/jcm8030313.
    • Chemoprevention acceptance and adherence in women with high-risk breast lesions.
    • Roche CA, Tang R, Coopey SB, Hughes KS.
    • Breast J. 2019 Mar;25(2):190-195. doi: 10.1111/tbj.13064. Epub 2018 May 21

    Related:

    Editorial:

    Applying the Hippocratic Oath in breast cancer-The case for promoting prevention.

    Press: Chemoprevention of Breast Cancer: Personal Touch Helps Uptake. (Medscape Oncology)

    • Painting a portrait: Analysis of national health survey data for cancer genetic counseling.
    • Stamp MH, Gordon OK, Childers CP, Childers KK.
    • Cancer Med. 2019 Mar;8(3):1306-1314. doi: 10.1002/cam4.1864. Epub 2019 Feb 7.
    • Author response to "a response to 'personalised medicine and population health: breast and ovarian cancer'".
    • Narod SA.
    • Hum Genet. 2019 Mar;138(3):291-292. doi: 10.1007/s00439-019-01981-2. Epub 2019 Feb 21.
    • Letter, Reply

    Related:

    Letter, Commentary:

    A response to "Personalised medicine and population health: breast and ovarian cancer".

    Review:

    Personalised medicine and population health: breast and ovarian cancer.

    • The influence of BRCA variants of unknown significance on cancer risk management decision-making.
    • Chern JY, Lee SS, Frey MK, Lee J, Blank SV.
    • J Gynecol Oncol. 2019 Feb 27. doi: 10.3802/jgo.2019.30.e60. [Epub ahead of print]

    Related:

    Editorial:

    Clinical significance of variants of unknown significances in BRCA genes.

    • BRACAVENIR: an observational study of expectations and coping in young women with high hereditary risk of breast and ovarian cancer.
    • Kwiatkowski F, Gay-Bellile M, Dessenne P, Laquet C, Boussion V, Béguinot M, Petit MF, Grémeau AS, Verlet C, Chaptal C, Broult M, Jouvency S, Duclos M, Bignon YJ.
    • Hered Cancer Clin Pract. 2019 Feb 27;17:7. doi: 10.1186/s13053-019-0107-7. eCollection 2019.
    • Psychosocial, attitudinal, and demographic correlates of cancer-related germline genetic testing in the 2017 Health Information National Trends Survey.
    • Roberts MC, Turbitt E, Klein WMP.
    • J Community Genet. 2019 Feb 20. doi: 10.1007/s12687-018-00405-4. [Epub ahead of print]
    • The cost of cancer care and impact of financial hardship on treatment.
    • [No author given]
    • FORCE. XRAYS. 2019 Feb 8.

    Related:

    Original research:

    BRCA1 and BRCA2 Testing in Medically Underserved Medicare Beneficiaries With Breast or Ovarian Cancer.

    News: Labs, Advocacy Groups Push Back on Medicare Policy Shift on NGS Testing for Hereditary Cancer Risk. (GenomeWeb)

    News: Pricey Precision Medicine Often Financially Toxic For Cancer Patients. (Kaiser Health News)

    • Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations.
    • Bancroft EK, Saya S, Page EC, Myhill K, Thomas S, Pope J, Chamberlain A, Hart R, Glover W, Cook J, Rosario DJ, Helfand BT, Hutten Selkirk C, Davidson R, Longmuir M, Eccles DM, Gadea N, Brewer C, Barwell J, Salinas M, Greenhalgh L, Tischkowitz M, Henderson A, Evans DG, Buys SS; IMPACT Study Steering Committee; IMPACT Collaborators, Eeles RA, Aaronson NK.
    • BJU Int. 2019 Feb;123(2):284-292. doi: 10.1111/bju.14412. Epub 2018 Jun 22.
    • Consumer and clinician perspectives on personalising breast cancer prevention information.
    • Keogh LA, Steel E, Weideman P, Butow P, Collins IM, Emery JD, Mann GB, Bickerstaffe A, Trainer AH, Hopper LJ, Phillips KA.
    • Breast. 2019 Feb;43:39-47. doi: 10.1016/j.breast.2018.11.002. Epub 2018 Nov 7.
    • Genetic Testing Across Young Hispanic and Non-Hispanic White Breast Cancer Survivors: Facilitators, Barriers, and Awareness of the Genetic Information Nondiscrimination Act.
    • Cragun D, Weidner A, Kechik J, Pal T.
    • Genet Test Mol Biomarkers. 2019 Feb;23(2):75-83. doi: 10.1089/gtmb.2018.0253. Epub 2019 Jan 24.
    • Legacies and Relationships: Diverse Social Networks and BRCA1/2 Risk Management Decisions and Actions.
    • Ersig AL, Werner-Lin A, Hoskins L, Young J, Loud JT, Peters J, Greene MH.
    • J Fam Nurs. 2019 Feb;25(1):28-53. doi: 10.1177/1074840718815844. Epub 2018 Dec 12.
    • Determinants of hormone therapy uptake and decision-making after bilateral oophorectomy (BO): A narrative review.
    • Siyam T, Carbon J, Ross S, Yuksel N.
    • Maturitas. 2019 Feb;120:68-76. doi: 10.1016/j.maturitas.2018.11.005. Epub 2018 Nov 12.
    • Risk factors for sexual dysfunction in BRCA mutation carriers after risk-reducing salpingo-oophorectomy.
    • Chan JL, Senapati S, Johnson LNC, DiGiovanni L, Voong C, Butts SF, Domchek SM.
    • Menopause. 2019 Feb;26(2):132-139. doi: 10.1097/GME.0000000000001176.
    • Development and Testing of a Decision Aid for Unaffected Women with a BRCA1 or BRCA2 Mutation.
    • Jabaley T, Underhill-Blazey ML, Berry DL.
    • J Cancer Educ. 2019 Jan 19. doi: 10.1007/s13187-019-1470-9. [Epub ahead of print]
    • The Impact of a Risk-Based Breast Cancer Screening Decision Aid on Initiation of Mammography Among Younger Women: Report of a Randomized Trial.
    • Schapira MM, Hubbard RA, Seitz HH, Conant EF, Schnall M, Cappella JN, Harrington T, Inge C, Armstrong K.
    • MDM Policy Pract. 2019 Jan 17;4(1):2381468318812889. doi: 10.1177/2381468318812889. eCollection 2019 Jan-Jun.
    • Knowledge, attitudes and practice of physicians towards fertility and pregnancy-related issues in youngBRCA-mutated breast cancer patients.
    • Lambertini M, Di Maio M, Poggio F, Pagani O, Curigliano G, Mastro LD, Paluch-Shimon S, Loibl S, Partridge AH, Azim HA Jr, Peccatori FA, Demeestere I.
    • Reprod Biomed Online. 2019 Jan 10. pii: S1472-6483(19)30011-2. doi: 10.1016/j.rbmo.2018.11.031. [Epub ahead of print]
    • Improving outcomes for young women with breast cancer: fertility and childbearing issues.
    • [No author given]
    • FORCE. XRAYS. 2019 Jan 7.

    Related:

    ClinicalTrials.gov: Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer (POSITIVE) (NIH. ClinicalTrials.gov.)

    • Risk-Reducing Mastectomy in BRCA1 and BRCA2 Mutation Carriers: A Complex Discussion.
    • Domchek SM.
    • JAMA. 2019 Jan 1;321(1):27. doi: 10.1001/jama.2018.18942.
    • Review, Commentary
    • High patient satisfaction with a simplified BRCA1/2 testing procedure: long-term results of a prospective study.
    • Nilsson MP, Nilsson ED, Borg Å, Brandberg Y, Silfverberg B, Loman N.
    • Breast Cancer Res Treat. 2019 Jan;173(2):313-318. doi: 10.1007/s10549-018-5000-y. Epub 2018 Oct 11.
    • Different Patterns of Risk Reducing Decisions in Affected or Unaffected BRCA Pathogenic Variant Carriers.
    • Lee EG, Kang HJ, Lim MC, Park B, Park SJ, Jung SY, Lee S, Kang HS, Park SY, Park B, Joo J, Han JH, Kong SY, Lee ES.
    • Cancer Res Treat. 2019 Jan;51(1):280-288. doi: 10.4143/crt.2018.079. Epub 2018 May 4.
    • Psychosocial and behavioral outcomes of genomic testing in cancer: a systematic review.
    • Yanes T, Willis AM, Meiser B, Tucker KM, Best M.
    • Eur J Hum Genet. 2019 Jan;27(1):28-35. doi: 10.1038/s41431-018-0257-5. Epub 2018 Sep 11.
    • Review
    • The development of an online decision aid to support persons having a genetic predisposition to cancer and their partners during reproductive decision-making: a usability and pilot study.
    • Reumkens K, Tummers MHE, Gietel-Habets JJG, van Kuijk SMJ, Aalfs CM, van Asperen CJ, Ausems MGEM, Collée M, Dommering CJ, Kets CM, van der Kolk LE, Oosterwijk JC, Tjan-Heijnen VCG, van der Weijden T, de Die-Smulders CEM, van Osch LADM.
    • Fam Cancer. 2019 Jan;18(1):137-146. doi: 10.1007/s10689-018-0092-4.
    • Written pretest information and germline BRCA1/2 pathogenic variant testing in unselected breast cancer patients: predictors of testing uptake.
    • Nilsson MP, Nilsson ED, Silfverberg B, Borg Å, Loman N.
    • Genet Med. 2019 Jan;21(1):89-96. doi: 10.1038/s41436-018-0021-9. Epub 2018 Jun 6.
    • Preventative Health and Risk Behaviors Among Adolescent Girls With and Without Family Histories of Breast Cancer.
    • Schwartz LA, Henry-Moss D, Egleston B, Patrick-Miller L, Markman E, Daly M, Tuchman L, Moore C, Rauch PK, Karpink K, Sands CB, Domchek SM, Bradbury AR.
    • J Adolesc Health. 2019 Jan;64(1):116-123. doi: 10.1016/j.jadohealth.2018.07.011. Epub 2018 Oct 6.
    • BRCA Testing Dichotomy in Saudi Arabia.
    • Abusanad A.
    • J Glob Oncol. 2019 Jan;(5):1-2. doi: 10.1200/JGO.18.00188.
    • Development of Breast Cancer Choices: a decision support tool for young women with breast cancer deciding whether to have genetic testing for BRCA1/2 mutations.
    • Grimmett C, Brooks C, Recio-Saucedo A, Armstrong A, Cutress RI, Gareth Evans D, Copson E, Turner L, Meiser B, Wakefield CE, Eccles D, Foster C.
    • Support Care Cancer. 2019 Jan;27(1):297-309. doi: 10.1007/s00520-018-4307-x. Epub 2018 Jun 28.
    • Identification and Confirmation of Potentially Actionable Germline Mutations in Tumor-Only Genomic Sequencing.
    • Clark DF, Maxwell KN, Powers J, Lieberman DB, Ebrahimzadeh J, Long JM, McKenna D, Shah P, Bradbury A, Morrissette JJD, Nathanson KL, Domchek SM.
    • JCO Precis Oncol. 2019;3. doi: 10.1200/PO.19.00076. Epub 2019 Aug 19.
    • Patients' Medical and Psychosocial Experiences After Detection of a CDH1 Variant With Multigene Panel Testing.
    • Hamilton JG, Long JM, Brandt AC, Brower J, Symecko H, Salo-Mullen EE, Christian SN, Harstad T, Couch FJ, Garber JE, Offit K, Robson ME, Domchek SM.
    • JCO Precis Oncol. 2019;3. doi: 10.1200/PO.18.00300. Epub 2019 Mar 28.
    • Layers of information: interacting constraints on breast cancer risk-management by high-risk African American women.
    • Padamsee TJ, Meadows R, Hils M.
    • Ethn Health. 2018 Dec 27:1-24. doi: 10.1080/13557858.2018.1562053. [Epub ahead of print]

    Related:

    Research news: Gaps in information about breast cancer risk and prevention impact African American women (FORCE. XRAYS.)

    • Black and Minority Ethnic women's decision-making for risk reduction strategies after BRCA testing: Use of context and knowledge.
    • Machirori M, Patch C, Metcalfe A.
    • Eur J Med Genet. 2018 Dec 12. pii: S1769-7212(18)30405-1. doi: 10.1016/j.ejmg.2018.12.006. [Epub ahead of print]
    • A Systematic Review of the Psychological Implications of Genetic Testing: A Comparative Analysis Among Cardiovascular, Neurodegenerative and Cancer Diseases.
    • Oliveri S, Ferrari F, Manfrinati A, Pravettoni G.
    • Front Genet. 2018 Dec 10;9:624. doi: 10.3389/fgene.2018.00624.
    • Cancer Risk Estimates for Study of Multiple-Gene Testing After Diagnosis of Breast Cancer.
    • Narod SA.
    • JAMA Oncol. 2018 Dec 1;4(12):1787-1788. doi: 10.1001/jamaoncol.2018.4931.
    • Letter, Comment

    Related:

    Original Research:

    Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer.

    Letter, reply:

    Cancer Risk Estimates for Study of Multiple-Gene Testing After Diagnosis of Breast Cancer—Reply

    • Satisfaction and Impact on Quality of Life of Clinical and Instrumental Surveillance and Prophylactic Surgery in BRCA-mutation Carriers.
    • D'Alonzo M, Piva E, Pecchio S, Liberale V, Modaffari P, Ponzone R, Biglia N.
    • Clin Breast Cancer. 2018 Dec;18(6):e1361-e1366. doi: 10.1016/j.clbc.2018.07.015. Epub 2018 Jul 26.
    • "I Am Uncertain About What My Uncertainty Even Is": Men's Uncertainty and Information Management of Their BRCA-Related Cancer Risks.
    • Rauscher EA, Dean M, Campbell-Salome GM.
    • J Genet Couns. 2018 Dec;27(6):1417-1427. doi: 10.1007/s10897-018-0276-y. Epub 2018 Jul 3.
    • Impact of Appointment Waiting Time on Attendance Rates at a Clinical Cancer Genetics Service.
    • Shaw T, Metras J, Ting ZAL, Courtney E, Li ST, Ngeow J.
    • J Genet Couns. 2018 Dec;27(6):1473-1481. doi: 10.1007/s10897-018-0259-z. Epub 2018 May 24.
    • Creation and Implementation of an Environmental Scan to Assess Cancer Genetics Services at Three Oncology Care Settings.
    • Bednar EM, Walsh MT Jr, Baker E, Muse KI, Oakley HD, Krukenberg RC, Dresbold CS, Jenkinson SB, Eppolito AL, Teed KB, Klein MH, Morman NA, Bowdish EC, Russ P, Wise EE, Cooper JN, Method MW, Henson JW, Grainger AV, Arun BK, Lu KH.
    • J Genet Couns. 2018 Dec;27(6):1482-1496. doi: 10.1007/s10897-018-0262-4. Epub 2018 May 24.
    • The influence of Malay cultural beliefs on breast cancer screening and genetic testing: A focus group study.
    • Shaw T, Ishak D, Lie D, Menon S, Courtney E, Li ST, Ngeow J.
    • Psychooncology. 2018 Dec;27(12):2855-2861. doi: 10.1002/pon.4902. Epub 2018 Oct 16.
    • Men's and Women's Approaches to Disclosure About BRCA-Related Cancer Risks and Family Planning Decision-Making.
    • Dean M, Rauscher EA.
    • Qual Health Res. 2018 Dec;28(14):2155-2168. doi: 10.1177/1049732318788377. Epub 2018 Jul 27.
    • Predictors of risk-reducing surgery intentions following genetic counseling for hereditary breast and ovarian cancer.
    • Ladd MK, Peshkin BN, Senter L, Baldinger S, Isaacs C, Segal H, Philip S, Phillips C, Shane K, Martin A, Weinstein V, Pilarski R, Jeter J, Sweet K, Hatten B, Wurtmann EJ, Phippen S, Bro D, Schwartz MD.
    • Transl Behav Med. 2018 Nov 10. doi: 10.1093/tbm/iby101. [Epub ahead of print]
    • Pathogenic Variants in Less Familiar Cancer Susceptibility Genes: What Happens After Genetic Testing?
    • Hall ET, Parikh D, Caswell-Jin JL, Gupta T, Mills MA, Kingham KE, Koff R, Ford JM, Kurian AW.
    • JCO Precis Oncol. [2018 Nov 8];2:1-10. doi: 10.1200/PO.18.00167.
    • Role of the general practitioner in the care of BRCA1 and BRCA2 mutation carriers: General practitioner and patient perspectives.
    • Vande Perre P, Toledano D, Corsini C, Escriba E, Laporte M, Bertet H, Yauy K, Toledano A, Galibert V, Baudry K, Clotet L, Million E, Picot MC, Geneviève D, Pujol P.
    • Mol Genet Genomic Med. 2018 Nov;6(6):957-965. doi: 10.1002/mgg3.464. Epub 2018 Oct 11.
    • A randomized controlled trial of a supportive expressive group intervention for women with a family history of breast cancer.
    • Esplen MJ, Leszcz M, Hunter J, Wong J, Leung YW, Toner B, Messner S, Glendon G, Stuckless N, Butler C.
    • Psychooncology. 2018 Nov;27(11):2645-2653. doi: 10.1002/pon.4822. Epub 2018 Jul 17.
    • Knowledge regarding and patterns of genetic testing in patients newly diagnosed with breast cancer participating in the iCanDecide trial.
    • Gornick MC, Kurian AW, An LC, Fagerlin A, Jagsi R, Katz SJ, Hawley ST.
    • Cancer. 2018 Oct 15;124(20):4000-4009. doi: 10.1002/cncr.31731. Epub 2018 Oct 5.
    • Comparison of gynecologic cancer risk factors, incidence and mortality trends between South Korea and Israel, 1999-2013.
    • Michaan N, Park SY, Won YJ, Lim MC.
    • Jpn J Clin Oncol. 2018 Oct 1;48(10):884-891. doi: 10.1093/jjco/hyy111.
    • Risk management adherence following genetic testing for hereditary cancer syndromes: a Singaporean experience.
    • Courtney E, Chin XW, Yuen J, Li ST, Chen Y, Allen JC Jr, Tan V, Lim GH, Ngeow J.
    • Fam Cancer. 2018 Oct;17(4):621-626. doi: 10.1007/s10689-018-0071-9.
    • Personalised medicine and population health: breast and ovarian cancer.
    • Narod SA.
    • Hum Genet. 2018 Oct;137(10):769-778. doi: 10.1007/s00439-018-1944-6. Epub 2018 Oct 17.
    • Review

    Related:

    Letter, Commentary:

    A response to "Personalised medicine and population health: breast and ovarian cancer".

    Letter, Reply:

    Author response to “a response to ‘personalised medicine and population health: breast and ovarian cancer’”.

    • The development of a template for psychological assessment of women considering risk-reducing or contralateral prophylactic mastectomy: A national Delphi consensus study.
    • Braude L, Kirsten L, Gilchrist J, Juraskova I.
    • Psychooncology. 2018 Oct;27(10):2349-2356. doi: 10.1002/pon.4830. Epub 2018 Sep 4.
    • Cancer experience in families affects decision making.
    • [No author given]
    • FORCE. XRAYS. 2018 Sep 25.

    Related:

    Press: How a Loved One’s Experience With Cancer Guides Breast Cancer Decisions. (U.S. News & World Report)

    • Provider's Perceptions of Barriers and Facilitators for Latinas to Participate in Genetic Cancer Risk Assessment for Hereditary Breast and Ovarian Cancer.
    • Hurtado-de-Mendoza A, Graves K, Gómez-Trillos S, Anderson L, Campos C, Evans C, Stearns S, Zhu Q, Gonzalez N, Sheppard VB.
    • Healthcare (Basel). 2018 Sep 17;6(3). pii: E116. doi: 10.3390/healthcare6030116.
    • A Dietary Intervention to Lower Serum Levels of IGF-I in BRCA Mutation Carriers.
    • Pasanisi P, Bruno E, Venturelli E, Morelli D, Oliverio A, Baldassari I, Rovera F, Iula G, Taborelli M, Peissel B, Azzolini J, Manoukian S.
    • Cancers (Basel). 2018 Sep 4;10(9). pii: E309. doi: 10.3390/cancers10090309.
    • Do All BRCA 1 and 2 Carriers with a Known and Unknown Breast Cancer Choose Bilateral Mastectomies?
    • Gaffley M, Villa A, Vu T, Steelman S, Howard-McNatt M.
    • Am Surg. 2018 Sep 1;84(9):1544-1545.
    • Catalysts towards cancer risk management action: A longitudinal study of reproductive-aged women with BRCA1/2 mutations.
    • Werner-Lin A, Ersig AL, Mueller R, Young JL, Hoskins LM, Desai R, Greene MH.
    • J Psychosoc Oncol. 2018 Sep-Oct;36(5):529-544. doi: 10.1080/07347332.2018.1469565. Epub 2018 Jun 4.
    • Factors associated with breast MRI use among women with a family history of breast cancer.
    • White MC, Soman A, Weinberg CR, Rodriguez JL, Sabatino SA, Peipins LA, DeRoo L, Nichols HB, Hodgson ME, Sandler DP.
    • Breast J. 2018 Sep;24(5):764-771. doi: 10.1111/tbj.13063. Epub 2018 May 20.
    • Factors Influencing Clinical Follow-Up for Individuals with a Personal History of Breast and/or Ovarian Cancer and Previous Uninformative BRCA1 and BRCA2 Testing.
    • Chadwell SE, He H, Knapke S, Lewis J, Sisson R, Hopper J.
    • J Genet Couns. 2018 Sep;27(5):1210-1219. doi: 10.1007/s10897-018-0241-9. Epub 2018 Mar 17.
    • Involvement and Influence of Healthcare Providers, Family Members, and Other Mutation Carriers in the Cancer Risk Management Decision-Making Process of BRCA1 and BRCA2 Mutation Carriers.
    • Puski A, Hovick S, Senter L, Toland AE4.
    • J Genet Couns. 2018 Sep;27(5):1291-1301. doi: 10.1007/s10897-018-0254-4. Epub 2018 Mar 29.
    • Response to "A Psychological Perspective on Factors Predicting Prophylactic Salpingo-Oophorectomy in a Sample of Italian Women from the General Population. Results from a Hypothetical Study in the Context of BRCA Mutations".
    • Cox DM.
    • J Genet Couns. 2018 Sep;27(5):1312-1313. doi: 10.1007/s10897-018-0280-2. Epub 2018 Jul 21.
    • Letter

    Related:

    A Psychological Perspective on Factors Predicting Prophylactic Salpingo-Oophorectomy in a Sample of Italian Women from the General Population. Results from a Hypothetical Study in the Context of BRCA Mutations.

    Letter, Reply:

    Letter to the Editor: Response to Cox (2018).

    • [The Population Need in Genetic Tests for Predisposition to Breast Cancer].
    • Ishkineeva FF, Ozerova KA, Kaveeva AD, Husnullina ES.
    • Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med. 2018 Sep;26(5):276-281. doi: 10.32687/0869-866X-2018-26-5-276-281.
    • Review, [Article in Russian]
    • Study protocol: a cluster randomized controlled trial of web-based decision support tools for increasing BRCA1/2 genetic counseling referral in primary care.
    • Silverman TB, Vanegas A, Marte A, Mata J, Sin M, Ramirez JCR, Tsai WY, Crew KD, Kukafka R.
    • BMC Health Serv Res. 2018 Aug 13;18(1):633. doi: 10.1186/s12913-018-3442-x.
    • Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer.
    • Kurian AW, Ward KC, Hamilton AS, Deapen DM, Abrahamse P, Bondarenko I, Li Y, Hawley ST, Morrow M, Jagsi R, Katz SJ.
    • JAMA Oncol. 2018 Aug 1;4(8):1066-1072. doi: 10.1001/jamaoncol.2018.0644.

    Related:

    Press: Multigene Sequencing Rapidly Replacing BRCA Tests. (Medscape Oncology)

    Letter, Comment:

    Cancer Risk Estimates for Study of Multiple-Gene Testing After Diagnosis of Breast Cancer.

    Letter, Reply:

    Cancer Risk Estimates for Study of Multiple-Gene Testing After Diagnosis of Breast Cancer-Reply.

    • Patients' perspectives and experiences concerning barriers to accessing information about bilateral prophylactic mastectomy.
    • Glassey R, O'Connor M, Ives A, Saunders C, kConFab Investigators, O'Sullivan S, Hardcastle SJ.
    • Breast. 2018 Aug;40:116-122. doi: 10.1016/j.breast.2018.05.003. Epub 2018 May 11.
    • Randomized trial of proactive rapid genetic counseling versus usual care for newly diagnosed breast cancer patients.
    • Schwartz MD, Peshkin BN, Isaacs C, Willey S, Valdimarsdottir HB, Nusbaum R, Hooker G, O'Neill S, Jandorf L, Kelly SP, Heinzmann J, Zidell A, Khoury K.
    • Breast Cancer Res Treat. 2018 Aug;170(3):517-524. doi: 10.1007/s10549-018-4773-3. Epub 2018 Apr 2.
    • Inadequate Rates of BRCA Testing with its Negative Consequences for Women with Epithelial Ovarian Cancer and their Families: an Overview of the Literature.
    • Hoskins PJ.
    • Clin Oncol (R Coll Radiol). 2018 Aug;30(8):472-483. doi: 10.1016/j.clon.2018.04.004. Epub 2018 May 5.
    • Review
    • Breast Cancer Genetics Knowledge and Testing Intentions among Nigerian Professional Women.
    • Ngene SO, Adedokun B, Adejumo P, Olopade O.
    • J Genet Couns. 2018 Aug;27(4):863-873. doi: 10.1007/s10897-017-0194-4. Epub 2017 Dec 19.
    • Identification as a Mutation Carrier and Effects on Life According to Experiences of Finnish Male BRCA1/2 Mutation Carriers.
    • Kajula O, Kuismin O, Kyngäs H.
    • J Genet Couns. 2018 Aug;27(4):874-884. doi: 10.1007/s10897-017-0209-1. Epub 2018 Jan 13.
    • Reproductive Decision Support: Preferences and Needs of Couples at Risk for Hereditary Cancer and Clinical Geneticists.
    • Reumkens K, van Oudheusden AJG, Gietel-Habets JJG, Tummers MHE, de Die-Smulders CEM, van Osch LADM.
    • J Genet Couns. 2018 Aug;27(4):920-926. doi: 10.1007/s10897-017-0204-6. Epub 2018 Jan 25.
    • Long-term outcomes of bilateral direct-to-implant breast reconstruction in women at high breast cancer risk.
    • van Verschuer VMT, Mureau MAM, Heemskerk-Gerritsen BAM, Gadjradj PS, Rogier C, Verhoef C, Gopie JP, Seynaeve C, Koppert LB.
    • J Plast Surg Hand Surg. 2018 Aug;52(4):245-252. doi: 10.1080/2000656X.2018.1476364. Epub 2018 May 28.
    • The Cancer Worry Scale Revised for Breast Cancer Genetic Counseling.
    • Caruso A, Vigna C, Gremigni P.
    • Cancer Nurs. 2018 Jul/Aug;41(4):311-319. doi: 10.1097/NCC.0000000000000511.
    • "Guys Don't Have Breasts": The Lived Experience of Men Who Have BRCA Gene Mutations and Are at Risk for Male Breast Cancer.
    • Skop M, Lorentz J, Jassi M, Vesprini D, Einstein G.
    • Am J Mens Health. 2018 Jul;12(4):961-972. doi: 10.1177/1557988317753241. Epub 2018 Feb 5.
    • Psychological outcomes and surgical decisions after genetic testing in women newly diagnosed with breast cancer with and without a family history.
    • Meiser B, Quinn VF, Mitchell G, Tucker K, Watts KJ, Rahman B, Peate M, Saunders C, Geelhoed E, Gleeson M, Barlow-Stewart K, Field M, Harris M, Antill YC, Susman R, Bowen MT, Mills L, Kirk J; TFGT Collaborative Group.
    • Eur J Hum Genet. 2018 Jul;26(7):972-983. doi: 10.1038/s41431-017-0057-3. Epub 2018 Mar 30.
    • Bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction: A pilot study in women with BRCA1/2 mutations.
    • Nebgen DR, Hurteau J, Holman LL, Bradford A, Munsell MF, Soletsky BR, Sun CC, Chisholm GB, Lu KH.
    • Gynecol Oncol. 2018 Jul;150(1):79-84. doi: 10.1016/j.ygyno.2018.04.564. Epub 2018 May 4.
    • Geographic Variation in Postoperative Imaging for Low-Risk Breast Cancer.
    • Franc BL, Copeland TP, Thombley R, Park M, Marafino B, Dean ML, Boscardin WJ, Rugo HS, Seidenwurm D, Sharma B, Johnston SR, Dudley RA.
    • J Natl Compr Canc Netw. 2018 Jul;16(7):829-837. doi: 10.6004/jnccn.2018.7024.
    • Health education models application by peer group for improving breast cancer screening among Iranian women with a family history of breast cancer: A randomized control trial.
    • Fathollahi-Dehkordi F, Farajzadegan Z.
    • Med J Islam Repub Iran. 2018 Jun 21;32:51. doi: 10.14196/mjiri.32.51. eCollection 2018.
    • Nipple-sparing bilateral prophylactic mastectomy and immediate reconstruction with TiLoop® Bra mesh in BRCA1/2 mutation carriers: A prospective study of long-term and patient reported outcomes using the BREAST-Q.
    • Casella D, Di Taranto G, Marcasciano M, Sordi S, Kothari A, Kovacs T, Lo Torto F, Cigna E, Ribuffo D, Calabrese C.
    • Breast. 2018 Jun;39:8-13. doi: 10.1016/j.breast.2018.02.001. Epub 2018 Feb 18.
    • Nipple-sparing mastectomy in women at high risk of developing breast cancer.
    • Lewis RS, George A, Rusby JE.
    • Gland Surg. 2018 Jun;7(3):325-336. doi: 10.21037/gs.2018.04.01.
    • Implementation of a quality improvement project for universal genetic testing in women with ovarian cancer.
    • Uyar D, Neary J, Monroe A, Nugent M, Simpson P, Geurts JL.
    • Gynecol Oncol. 2018 Jun;149(3):565-569. doi: 10.1016/j.ygyno.2018.03.059. Epub 2018 Apr 10.
    • A patient decision aid for risk-reducing surgery in premenopausal BRCA1/2 mutation carriers: Development process and pilot testing.
    • Harmsen MG, Steenbeek MP, Hoogerbrugge N, van Doorn HC, Gaarenstroom KN, Vos MC, Massuger LFAG, de Hullu JA, Hermens RPMG.
    • Health Expect. 2018 Jun;21(3):659-667. doi: 10.1111/hex.12661. Epub 2017 Dec 27.
    • The development of an online decision aid to support persons having a genetic predisposition to cancer and their partners during reproductive decision-making: a usability and pilot study.
    • Reumkens K, Tummers MHE, Gietel-Habets JJG, van Kuijk SMJ, Aalfs CM, van Asperen CJ, Ausems MGEM, Collée M, Dommering CJ, Kets CM, van der Kolk LE, Oosterwijk JC, Tjan-Heijnen VCG, Weijden T, de Die-Smulders CEM, van Osch LADM.
    • Fam Cancer. 2018 May 30. doi: 10.1007/s10689-018-0092-4. [Epub ahead of print]
    • Long-term outcomes of bilateral direct-to-implant breast reconstruction in women at high breast cancer risk.
    • van Verschuer VMT, Mureau MAM, Heemskerk-Gerritsen BAM, Gadjradj PS, Rogier C, Verhoef C, Gopie JP, Seynaeve C, Koppert LB.
    • J Plast Surg Hand Surg. 2018 May 28:1-8. doi: 10.1080/2000656X.2018.1476364. [Epub ahead of print]
    • Patients' Views of Treatment-Focused Genetic Testing (TFGT): Some Lessons for the Mainstreaming of BRCA1 and BRCA2 Testing.
    • Wright S, Porteous M, Stirling D, Lawton J, Young O, Gourley C, Hallowell N.
    • J Genet Couns. 2018 May 11. doi: 10.1007/s10897-018-0261-5. [Epub ahead of print]
    • Timing and Mode of Breast Care Nurse Consultation From the Patient's Perspective.
    • Brown J, Refeld G, Cooper A.
    • Oncol Nurs Forum. 2018 May 1;45(3):389-398. doi: 10.1188/18.ONF.389-398.
    • A Trans-Feminine Youth with a BRCA1 Mutation: Case Study.
    • Wolf-Gould CS, Riley MR, Carswell JM.
    • LGBT Health. 2018 May/Jun;5(4):270-272. doi: 10.1089/lgbt.2017.0148. Epub 2018 May 11.
    • Letter, Case report
    • Early cancer diagnoses through BRCA1/2 screening of unselected adult biobank participants.
    • Buchanan AH, Manickam K, Meyer MN, Wagner JK, Hallquist MLG, Williams JL, Rahm AK, Williams MS, Chen ZE, Shah CK, Garg TK, Lazzeri AL, Schwartz MLB, Lindbuchler DM, Fan AL, Leeming R, Servano PO 3rd, Smith AL, Vogel VG, Abul-Husn NS, Dewey FE, Lebo MS, Mason-Suares HM, Ritchie MD, Davis FD, Carey DJ, Feinberg DT, Faucett WA, Ledbetter DH, Murray MF.
    • Genet Med. [2018 May;]20(5):554-558. doi: 10.1038/gim.2017.145. Epub 2017 Oct 26.
    • Systematic review of the empirical investigation of resources to support decision-making regarding BRCA1 and BRCA2 genetic testing in women with breast cancer.
    • Grimmett C, Pickett K, Shepherd J, Welch K, Recio-Saucedo A, Streit E, Seers H, Armstrong A, Cutress RI, Evans DG, Copson E, Meiser B, Eccles D, Foster C.
    • Patient Educ Couns. 2018 May;101(5):779-788. doi: 10.1016/j.pec.2017.11.016. Epub 2017 Nov 26.
    • Review
    • Investigating barriers to genetic counseling and germline mutation testing in women with suspected hereditary breast and ovarian cancer syndrome and Lynch syndrome.
    • Shaw J, Bulsara C, Cohen PA, Gryta M, Nichols CB, Schofield L, O'Sullivan S, Pachter N, Hardcastle SJ.
    • Patient Educ Couns. 2018 May;101(5):938-944. doi: 10.1016/j.pec.2017.12.011. Epub 2017 Dec 12.
    • Genetic Diagnosis before Surgery has an Impact on Surgical Decision in BRCA Mutation Carriers with Breast Cancer.
    • Park S, Lee JE, Ryu JM, Kim I, Bae SY, Lee SK, Yu J, Kim SW, Nam SJ.
    • World J Surg. 2018 May;42(5):1384-1390. doi: 10.1007/s00268-017-4342-7.
    • Challenges in recruiting African-American women for a breast cancer genetics study.
    • Compadre AJ, Simonson ME, Gray K, Runnells G, Kadlubar S, Zorn KK.
    • Hered Cancer Clin Pract. 2018 Apr 24;16:8. doi: 10.1186/s13053-018-0091-3. eCollection 2018.
    • Gaps in Receipt of Clinically Indicated Genetic Counseling After Diagnosis of Breast Cancer.
    • Katz SJ, Ward KC, Hamilton AS, Mcleod MC, Wallner LP, Morrow M, Jagsi R, Hawley ST, Kurian AW.
    • J Clin Oncol. 2018 Apr 20;36(12):1218-1224. doi: 10.1200/JCO.2017.76.2369. Epub 2018 Mar 12.

    Related:

    Press: Many Breast Cancer Patients Not Receiving Genetic Evaluation. (Medscape)

    • Returning Individual Genetic Research Results to Research Participants: Uptake and Outcomes Among Patients With Breast Cancer.
    • Bradbury AR, Patrick-Miller L, Egleston BL, Maxwell KN, DiGiovanni L, Brower J, Fetzer D, Bennett Gaieski J, Brandt A, McKenna D, Long J, Powers J, Stopfer JE, Nathanson KL, Domchek SM.
    • JCO Precis Oncol. 2018;2. doi: 10.1200/po.17.00250. Epub 2018 Apr 16.
    • Patient experience and utility of genetic information: a cross-sectional study among patients tested for cancer susceptibility and thrombophilia.
    • D'Andrea E, Lagerberg T, De Vito C, Pitini E, Marzuillo C, Massimi A, Vacchio MR, Grammatico P, Villari P.
    • Eur J Hum Genet. 2018 Apr;26(4):518-526. doi: 10.1038/s41431-017-0083-1. Epub 2018 Jan 26.
    • Trends in utilization and costs of BRCA testing among women aged 18-64 years in the United States, 2003-2014.
    • Chen Z, Kolor K, Grosse SD, Rodriguez JL, Lynch JA, Green RF, Dotson WD, Bowen MS, Khoury MJ.
    • Genet Med. 2018 Apr;20(4):428-434. doi: 10.1038/gim.2017.118. Epub 2017 Sep 21.
    • Disparities in genetics assessment for women with ovarian cancer: Can we do better?
    • Manrriquez E, Chapman JS, Mak J, Blanco AM, Chen LM.
    • Gynecol Oncol. 2018 Apr;149(1):84-88. doi: 10.1016/j.ygyno.2017.10.034.
    • Impact of Multigene Panel Testing on Surgical Decision Making in Breast Cancer Patients.
    • Pederson HJ, Gopalakrishnan D, Noss R, Yanda C, Eng C, Grobmyer SR.
    • J Am Coll Surg. 2018 Apr;226(4):560-565. doi: 10.1016/j.jamcollsurg.2017.12.037. Epub 2018 Jan 31.
    • A Two-Phase Approach to Developing SNAP: an iPhone Application to Support Appointment Scheduling and Management for Women with a BRCA Mutation.
    • Scherr CL, Feuston JL, Nixon DM, Cohen SA.
    • J Genet Couns. 2018 Apr;27(2):439-445. doi: 10.1007/s10897-018-0222-z. Epub 2018 Feb 8.
    • An iPhone Application Intervention to Promote Surveillance Among Women with a BRCA Mutation: Pre-intervention Data.
    • Cohen SA, Scherr CL, Nixon DM.
    • J Genet Couns. 2018 Apr;27(2):446-456. doi: 10.1007/s10897-018-0224-x. Epub 2018 Feb 10.
    • Take your time, follow your heart: strategies for communication about family planning.
    • [No author given]
    • FORCE. XRAYS. 2018 Mar 28.

    Related:

    "Take your time, then follow your heart:" Previvors' advice for communicating about family planning after testing positive for a BRCA genetic variant.

    • The Right Not to Know: When Ignorance Is Bliss but Deadly.
    • Clausen AM.
    • Global Health NOW. 2018 Mar 20.

    Related:

    Commentary: The right not to know when not knowing is dangerous. (FORCE. XRAYS.)

    • Factors Influencing Clinical Follow-Up for Individuals with a Personal History of Breast and/or Ovarian Cancer and Previous Uninformative BRCA1 and BRCA2 Testing.
    • Chadwell SE, He H, Knapke S, Lewis J, Sisson R, Hopper J.
    • J Genet Couns. 2018 Mar 17. doi: 10.1007/s10897-018-0241-9. [Epub ahead of print]
    • Impact of a genetic counseling requirement prior to genetic testing.
    • Stenehjem DD, Au T, Sainski AM, Bauer H, Brown K, Lancaster J, Stevens V, Brixner DI.
    • BMC Health Serv Res. 2018 Mar 7;18(1):165. doi: 10.1186/s12913-018-2957-5.
    • NSGC Responds to U.S. Food and Drug Administration Approval of Direct-to-Consumer Cancer Test that Reports Three BRCA Mutations.
    • [No author given]
    • NSGC blog, 2018 Mar 6.

    Related:

    FDA News Release: FDA authorizes, with special controls, direct-to-consumer test that reports three mutations in the BRCA breast cancer genes (U.S. Food & Drug Administration)

    • A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention.
    • Hanley GE, McAlpine JN, Miller D, Huntsman D, Schrader KA, Blake Gilks C, Mitchell G.
    • BMC Cancer. 2018 Mar 5;18(1):254. doi: 10.1186/s12885-018-4153-8.
    • Commercially Available Lifestyle Modification Program Decreases Inflammatory Biomarkers in BRCA1/2+ Breast Cancer Survivors.
    • Sturgeon KM, Foo W, Schmitz KH/
    • Cancer Epidemiol Biomarkers Prev. 2018 Mar;27(3):357-357. doi: 10.1158/1055-9965.EPI-18-0063.
    • Conference abstract
    • Adaptation of Genetic Counseling According to an Individual's Literacy Regarding Genomics.
    • Nakamura S, Narimatsu H.
    • J Clin Oncol. 2018 Feb 10;36(5):516-517. doi: 10.1200/JCO.2017.76.3300. Epub 2018 Jan 2.
    • Letter, Comment

    Related:

    National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer.

    Letter, Reply:

    Reply to S. Nakamura et al and S. Narod et al.

    • Provider Discussions of Genetic Tests With U.S. Women at Risk for a BRCA Mutation.
    • Hull LE, Haas JS, Simon SR.
    • Am J Prev Med. 2018 Feb;54(2):221-228. doi: 10.1016/j.amepre.2017.10.015. Epub 2017 Dec 11.
    • Previvors' Uncertainty Management Strategies for Hereditary Breast and Ovarian Cancer.
    • Dean M, Davidson LG.
    • Health Commun. 2018 Feb;33(2):122-130. doi: 10.1080/10410236.2016.1250187. Epub 2016 Dec 15.
    • Self-compassion, physical fitness and climacteric symptoms in oophorectomized BRCA1/2 mutation carriers.
    • Arts-de Jong M, van Westerop LL, Hoogerbrugge N, Massuger LF, Maas AH, van Beek MH, de Hullu JA.
    • Maturitas. 2018 Feb;108:13-17. doi: 10.1016/j.maturitas.2017.11.002. Epub 2017 Nov 3.
    • "I've just never gotten around to doing it": Men's approaches to managing BRCA-related cancer risks.
    • Rauscher EA, Dean M.
    • Patient Educ Couns. 2018 Feb;101(2):340-345. doi: 10.1016/j.pec.2017.07.015. Epub 2017 Jul 23.
    • Men's information-seeking behavior regarding cancer risk and screening: A meta-narrative systematic review.
    • Saab MM, Reidy M, Hegarty J, O'Mahony M, Murphy M, Von Wagner C, Drummond FJ.
    • Psychooncology. 2018 Feb;27(2):410-419. doi: 10.1002/pon.4506. Epub 2017 Aug 18.
    • Review
    • Communication of cancer-related genetic and genomic information: A landscape analysis of reviews.
    • Peterson EB, Chou WS, Gaysynsky A, Krakow M, Elrick A, Khoury MJ, Kaphingst KA.
    • Transl Behav Med. 2018 Jan 29;8(1):59-70. doi: 10.1093/tbm/ibx063.
    • Genetic Testing for Hereditary Breast Cancer: The Decision to Decline.
    • White VB, Walsh KK, Foss KS, Amacker-North L, Lenarcic S, McNeely L, White RL Jr..
    • Am Surg. 2018 Jan 1;84(1):154-160.
    • Breast Cancer Screening Behaviors of First Degree Relatives of Women Receiving Breast Cancer Treatment and the Affecting Factors.
    • Kırca N, Tuzcu A, Gözüm S.
    • Eur J Breast Health. 2018 Jan 1;14(1):23-28. doi: 10.5152/ejbh.2017.3272. eCollection 2018 Jan.
    • Surgeon Influence on Variation in Receipt of Contralateral Prophylactic Mastectomy For Women With Breast Cancer.
    • Katz SJ, Hawley ST, Hamilton AS, Ward KC, Morrow M, Jagsi R, Hofer TP.
    • JAMA Surg. 2018 Jan 1;153(1):29-36. doi: 10.1001/jamasurg.2017.3415.
    • Quality-of-life implications of risk-reducing cancer surgery.
    • Altman AM, Hui JYC, Tuttle TM.
    • Br J Surg. 2018 Jan;105(2):e121-e130. doi: 10.1002/bjs.10725.
    • Heightened perception of breast cancer risk in young women at risk of familial breast cancer.
    • Glassey R, O'Connor M, Ives A, Saunders C; kConFab Investigators, O'Sullivan S, Hardcastle SJ.
    • Fam Cancer. 2018 Jan;17(1):15-22. doi: 10.1007/s10689-017-0001-2.
    • Breadth of Genetic Testing Selected by Patients at Risk of Hereditary Breast and Ovarian Cancer.
    • Szender JB, Kaur J, Clayback K, Hutton ML, Mikkelson J, Odunsi K, Dresbold C.
    • Int J Gynecol Cancer. 2018 Jan;28(1):26-33. doi: 10.1097/IGC.0000000000001122.
    • Preferences for multigene panel testing for hereditary breast cancer risk among ethnically diverse BRCA-uninformative families.
    • Vicuña B, Delaney HD, Flores KG, Ballinger L, Royce M, Dayao Z, Pal T, Kinney AY.
    • J Community Genet. 2018 Jan;9(1):81-92. doi: 10.1007/s12687-017-0322-8. Epub 2017 Oct 2.
    • From the small screen to breast cancer screening: examining the effects of a television storyline on awareness of genetic risk factors.
    • Rosenthal EL, de Castro Buffington S, Cole G.
    • J Commun Healthc. 2018;11(2):140-150. doi: 10.1080/17538068.2018.1438766. Epub 2018 Feb 15.
    • Influences on anticipated time to ovarian cancer symptom presentation in women at increased risk compared to population risk of ovarian cancer.
    • Smits S, Boivin J, Menon U, Brain K.
    • BMC Cancer. 2017 Dec 4;17(1):814. doi: 10.1186/s12885-017-3835-y.
    • Experiencing the cancer of a loved one influences decision-making for breast cancer prevention.
    • Padamsee TJ, Muraveva A, Yee LD, Wills CE, Paskett ED.
    • J Health Psychol. 2017 Dec 1:1359105317746480. doi: 10.1177/1359105317746480. [Epub ahead of print]
    • Facilitating decision-making in women undergoing genetic testing for hereditary breast cancer: BRECONDA randomized controlled trial results.
    • Sherman KA, Kilby CJ, Shaw LK, Winch C, Kirk J, Tucker K, Elder E.
    • Breast. 2017 Dec;36:79-85. doi: 10.1016/j.breast.2017.10.001. Epub 2017 Oct 12.
    • Prophylactic Surgery: For Whom, When and How?
    • Mau C, Untch M.
    • Breast Care (Basel). 2017 Dec;12(6):379-384. doi: 10.1159/000485830. Epub 2017 Dec 13.
    • Genetic Testing in a Population-Based Sample of Breast and Ovarian Cancer Survivors from the REACH Randomized Trial: Cost Barriers and Moderators of Counseling Mode.
    • Steffen LE, Du R, Gammon A, Mandelblatt JS, Kohlmann WK, Lee JH, Buys SS, Stroup AM, Campo RA, Flores KG, Vicuña B, Schwartz MD, Kinney AY.
    • Cancer Epidemiol Biomarkers Prev. 2017 Dec;26(12):1772-1780. doi: 10.1158/1055-9965.EPI-17-0389. Epub 2017 Sep 29.
    • Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutated patients: An evidence-based approach on what women should know.
    • De Felice F, Marchetti C, Boccia SM, Romito A, Sassu CM, Porpora MG, Muzii L, Tombolini V, Benedetti Panici P.
    • Cancer Treat Rev. 2017 Dec;61:1-5. doi: 10.1016/j.ctrv.2017.09.005. Epub 2017 Sep 28.
    • Review
    • No evidence of excessive cancer screening in female noncarriers from BRCA1/2 mutation-positive families.
    • Guedaoura S, Pelletier S, Foulkes WD, Hamet P, Simard J, Wong N, El Haffaf Z, Chiquette J, Dorval M.
    • Curr Oncol. 2017 Dec;24(6):352-359. doi: 10.3747/co.24.3759. Epub 2017 Dec 20.
    • "Take your time, then follow your heart:" Previvors' advice for communicating about family planning after testing positive for a BRCA genetic variant.
    • Rauscher EA, Dean M.
    • Fam Syst Health. 2017 Dec;35(4):486-497. doi: 10.1037/fsh0000312.

    Related:

    Research news: Take your time, follow your heart: strategies for communication about family planning. (FORCE. XRAYS.)

    • When to Consider Risk-Reducing Mastectomy in BRCA1/BRCA2 Mutation Carriers with Advanced Stage Ovarian Cancer: a Case Study Illustrating the Genetic Counseling Challenges.
    • Speight B, Tischkowitz M.
    • J Genet Couns. 2017 Dec;26(6):1173-1178. doi: 10.1007/s10897-017-0136-1. Epub 2017 Aug 5.
    • Universal BRCA1/BRCA2 Testing for Ovarian Cancer Patients is Welcomed, but with Care: How Women and Staff Contextualize Experiences of Expanded Access.
    • Shipman H, Flynn S, MacDonald-Smith CF, Brenton J, Crawford R, Tischkowitz M; GTEOC Study Group, Hulbert-Williams NJ.
    • J Genet Couns. 2017 Dec;26(6):1280-1291. doi: 10.1007/s10897-017-0108-5. Epub 2017 May 24.
    • Rapid genetic counseling and testing in newly diagnosed breast cancer: Patients' and health professionals' attitudes, experiences, and evaluation of effects on treatment decision making.
    • Wevers MR, Aaronson NK, Bleiker EMA, Hahn DEE, Brouwer T, van Dalen T, Theunissen EB, van Ooijen B, de Roos MA, Borgstein PJ, Vrouenraets BC, Vriens E, Bouma WH, Rijna H, Vente JP, Kuenen MA, van der Sanden-Melis J, Witkamp AJ, Rutgers EJT, Verhoef S, Ausems MGEM.
    • J Surg Oncol. 2017 Dec;116(8):1029-1039. doi: 10.1002/jso.24763. Epub 2017 Jul 13.
    • VUS Reclassified to "Suspected Deleterious": When Genetic Counseling Updates Become Life-Saving.
    • [No author given]
    • My Gene Counsel. 2017 Nov 30.
    • A qualitative study on Singaporean women's views towards breast cancer screening and Single Nucleotide Polymorphisms (SNPs) gene testing to guide personalised screening strategies.
    • Wong XY, Chong KJ, van Til JA, Wee HL.
    • BMC Cancer. 2017 Nov 21;17(1):776. doi: 10.1186/s12885-017-3781-8.
    • [A survey of willingness about genetic counseling and tests in patients of epithelial ovarian cancer].
    • Li L, Qiu L, Wu M.
    • Zhonghua Yi Xue Za Zhi. 2017 Nov 21;97(43):3412-3415. doi: 10.3760/cma.j.issn.0376-2491.2017.43.011.
    • English Abstract, [Article in Chinese]
    • Feasibility of structured endurance training and Mediterranean diet in BRCA1 and BRCA2 mutation carriers - an interventional randomized controlled multicenter trial (LIBRE-1).
    • Kiechle M, Dukatz R, Yahiaoui-Doktor M, Berling A, Basrai M, Staiger V, Niederberger U, Marter N, Lammert J, Grill S, Pfeifer K, Rhiem K, Schmutzler RK, Laudes M, Siniatchkin M, Halle M, Bischoff SC, Engel C.
    • BMC Cancer. 2017 Nov 10;17(1):752. doi: 10.1186/s12885-017-3732-4.
    • Sexual Health Is Paramount in the Counseling of Women at Risk for Breast or Ovarian Cancer Undergoing Risk-Reducing Surgery.
    • Rullo JE, Pruthi S.
    • J Natl Compr Canc Netw. 2017 Nov 1;15(11):1297. doi: 10.6004/jnccn.2017.7016.
    • Commentary
    • Validity of self-reported breast cancer characteristics in a nationwide cohort of women with a family history of breast cancer.
    • D'Aloisio AA, Nichols HB, Hodgson ME, Deming-Halverson SL, Sandler DP.
    • BMC Cancer. 2017 Oct 23;17(1):692. doi: 10.1186/s12885-017-3686-6.
    • To Have Or Not To Have Genetic Testing?
    • [No author given]
    • My Gene Counsel. 2017 Oct 17.
    • Patient experience with breast reconstruction process following bilateral mastectomy in BRCA mutation carriers.
    • Nurudeen S, Guo H, Chun Y, Coopey S, Barry W, Garber J, Dominici LS.
    • Am J Surg. 2017 Oct;214(4):687-694. doi: 10.1016/j.amjsurg.2017.06.017. Epub 2017 Jun 28.
    • A Psychological Perspective on Factors Predicting Prophylactic Salpingo-Oophorectomy in a Sample of Italian Women from the General Population. Results from a Hypothetical Study in the Context of BRCA Mutations.
    • Gavaruzzi T, Tasso A, Franiuk M, Varesco L, Lotto L.
    • J Genet Couns. 2017 Oct;26(5):1144-1152. doi: 10.1007/s10897-017-0093-8. Epub 2017 Mar 23.

    Related:

    Letter:

    Response to "A Psychological Perspective on Factors Predicting Prophylactic Salpingo-Oophorectomy in a Sample of Italian Women from the General Population. Results from a Hypothetical Study in the Context of BRCA Mutations".

    Letter, Reply:

    Letter to the Editor: Response to Cox (2018).

    • Cancer Predisposition Cascade Screening for Hereditary Breast/Ovarian Cancer and Lynch Syndromes in Switzerland: Study Protocol.
    • Katapodi MC, Viassolo V, Caiata-Zufferey M, Nikolaidis C, Bührer-Landolt R5, Buerki N, Graffeo R, Horváth HC, Kurzeder C, Rabaglio M, Scharfe M, Urech C, Erlanger TE, Probst-Hensch N, Heinimann K, Heinzelmann-Schwarz V, Pagani O, Chappuis PO.
    • JMIR Res Protoc. 2017 Sep 20;6(9):e184. doi: 10.2196/resprot.8138.
    • [Satisfaction and overall quality of life in BRCA positive women after prophylactic surgeries].
    • Šašková P, Pavlišta D, Dostálek L.
    • Rozhl Chir. 2017 Fall;96(8):328-333.
    • Review, [Article in Czech]
    • Within-Gender Differences in Medical Decision Making Among Male Carriers of the BRCA Genetic Mutation for Hereditary Breast Cancer.
    • Hesse-Biber S, An C.
    • Am J Mens Health. 2017 Sep;11(5):1444-1459. doi: 10.1177/1557988315610806. Epub 2015 Oct 14.
    • Randomized Noninferiority Trial of Telephone vs In-Person Genetic Counseling for Hereditary Breast and Ovarian Cancer: A 12-Month Follow-Up.
    • Interrante MK, Segal H, Peshkin BN, Valdimarsdottir HB, Nusbaum R, Similuk M, DeMarco T, Hooker G, Graves K, Isaacs C, Wood M, McKinnon W, Garber J, McCormick S, Heinzmann J, Kinney AY, Schwartz MD.
    • JNCI Cancer Spectr. 2017 Sep;1(1):pkx002. doi: 10.1093/jncics/pkx002. Epub 2017 Sep 22.
    • "When information is not enough": A model for understanding BRCA-positive previvors' information needs regarding hereditary breast and ovarian cancer risk.
    • Dean M, Scherr CL, Clements M, Koruo R, Martinez J, Ross A.
    • Patient Educ Couns. 2017 Sep;100(9):1738-1743. doi: 10.1016/j.pec.2017.03.013. Epub 2017 Mar 10.
    • How do women at increased breast cancer risk perceive and decide between risks of cancer and risk-reducing treatments? A synthesis of qualitative research.
    • Fielden HG, Brown SL, Saini P, Beesley H, Salmon P.
    • Psychooncology. 2017 Sep;26(9):1254-1262. doi: 10.1002/pon.4349. Epub 2017 Jan 26.
    • Quality of Patient Decisions About Breast Reconstruction After Mastectomy.
    • Lee CN, Deal AM, Huh R, Ubel PA, Liu YJ, Blizard L, Hunt C, Pignone MP.
    • JAMA Surg. 2017 Aug 1;152(8):741-748. doi: 10.1001/jamasurg.2017.0977.
    • Breast Cancer Risk Assessment at the Time of Screening Mammography: Perceptions and Clinical Management Outcomes for Women at High Risk.
    • Morman NA, Byrne L, Collins C, Reynolds K, Bell JG.
    • J Genet Couns. 2017 Aug;26(4):776-784. doi: 10.1007/s10897-016-0050-y. Epub 2017 Jan 26.
    • Gaps in Incorporating Germline Genetic Testing Into Treatment Decision-Making for Early-Stage Breast Cancer.
    • Kurian AW, Li Y, Hamilton AS, Ward KC, Hawley ST, Morrow M, McLeod MC, Jagsi R, Katz SJ.
    • J Clin Oncol. 2017 Jul 10;35(20):2232-2239. doi: 10.1200/JCO.2016.71.6480. Epub 2017 Apr 12.

    Related:

    Press: Lack of Understanding of Genetic Breast Cancer Testing. (Medscape)

    • Longitudinal cancer risk management trajectories of BRCA1/2 mutation-positive reproductive-age women.
    • Young JL, Werner-Lin A, Mueller R, Hoskins L, Epstein N, Greene MH.
    • J Psychosoc Oncol. 2017 Jul-Aug;35(4):393-408. doi: 10.1080/07347332.2017.1292574. Epub 2017 Feb 14.
    • Predictors of BRCA1/2 genetic testing among Black women with breast cancer: a population-based study.
    • Jones T, McCarthy AM, Kim Y, Armstrong K.
    • Cancer Med. 2017 Jul;6(7):1787-1798. doi: 10.1002/cam4.1120. Epub 2017 Jun 19.
    • High-risk patients with breast cancer may not receive genetic testing.
    • Printz C
    • Cancer. 2017 Jun 1;123(11):1887. doi: 10.1002/cncr.30774.

    Related:

    Letter, Comment:

    Genetic Testing and Counseling Among Patients With Newly Diagnosed Breast Cancer.

    • Influence of the Angelina Jolie Announcement and Insurance Reimbursement on Practice Patterns for Hereditary Breast Cancer.
    • Lee J, Kim S, Kang E, Park S, Kim Z, Lee MH; Korean Breast Cancer Society.
    • J Breast Cancer. 2017 Jun;20(2):203-207. doi: 10.4048/jbc.2017.20.2.203. Epub 2017 Jun 26.
    • Factors Associated with Interest in Gene-Panel Testing and Risk Communication Preferences in Women from BRCA1/2 Negative Families.
    • Flores KG, Steffen LE, McLouth CJ, Vicuña BE, Gammon A, Kohlmann W, Vigil L, Dayao ZR, Royce ME, Kinney AY.
    • J Genet Couns. 2017 Jun;26(3):480-490. doi: 10.1007/s10897-016-0001-7. Epub 2016 Aug 6.
    • Reproductive Decision-Making in Women with BRCA1/2 Mutations.
    • Chan JL, Johnson LN, Sammel MD, DiGiovanni L, Voong C, Domchek SM, Gracia CR.
    • J Genet Couns. 2017 Jun;26(3):594-603. doi: 10.1007/s10897-016-0035-x. Epub 2016 Oct 28.
    • Familial breast cancer: Genetic counseling over time, including patients´ expectations and initiators considering the Angelina Jolie effect.
    • Evers C, Fischer C, Dikow N, Schott S.
    • PLoS One. 2017 May 25;12(5):e0177893. doi: 10.1371/journal.pone.0177893. eCollection 2017.
    • Validation of the German version of the Mediterranean Diet Adherence Screener (MEDAS) questionnaire.
    • Hebestreit K, Yahiaoui-Doktor M, Engel C, Vetter W, Siniatchkin M, Erickson N, Halle M, Kiechle M, Bischoff SC.
    • BMC Cancer. 2017 May 18;17(1):341. doi: 10.1186/s12885-017-3337-y.
    • Deficit of Risk-Reducing Salpingo-Oophorectomies in BRCA1/2 Mutation Carriers After Telephone Genetic Counseling.
    • Benusiglio PR, Caron O.
    • J Clin Oncol. 2017 Apr 10;35(11):1255. doi: 10.1200/JCO.2016.70.5780. Epub 2017 Jan 23.

    Related:

    Randomized Noninferiority Trial of Telephone Delivery of BRCA1/2 Genetic Counseling Compared With In-Person Counseling: 1-Year Follow-Up.

    • Patient and medical barriers preclude uptake of tamoxifen preventative therapy in women with a strong family history.
    • Skandarajah AR, Thomas S, Shackleton K, Chin-Lenn L, Lindeman GJ, Mann GB.
    • Breast. 2017 Apr;32:93-97. doi: 10.1016/j.breast.2017.01.002. Epub 2017 Jan 18.
    • Commercially available lifestyle modification program: randomized controlled trial addressing heart and bone health in BRCA1/2+ breast cancer survivors after risk-reducing salpingo-oophorectomy.
    • Sturgeon KM, Dean LT, Heroux M, Kane J, Bauer T, Palmer E, Long J, Lynch S, Jacobs L, Sarwer DB, Leonard MB, Schmitz K.
    • J Cancer Surviv. 2017 Apr;11(2):246-255. doi: 10.1007/s11764-016-0582-z. Epub 2016 Nov 21.
    • Decision making for breast cancer prevention among women at elevated risk.
    • Padamsee TJ, Wills CE, Yee LD, Paskett ED.
    • Breast Cancer Res. 2017 Mar 24;19(1):34. doi: 10.1186/s13058-017-0826-5.
    • Effect of decision aid for breast cancer prevention on decisional conflict in women with a BRCA1 or BRCA2 mutation: a multisite, randomized, controlled trial.
    • Metcalfe KA, Dennis CL, Poll A, Armel S, Demsky R, Carlsson L, Nanda S, Kiss A, Narod SA.
    • Genet Med. 2017 Mar;19(3):330-336. doi: 10.1038/gim.2016.108. Epub 2016 Sep 1.
    • An exploratory study of patients' views about being at high-risk for breast cancer and risk management beliefs and intentions, before and after risk counselling: Preliminary evidence of the influence of beliefs on post-counselling prevention intentions.
    • Paquet L, Simmonds L, Yang C, Verma S.
    • Patient Educ Couns. 2017 Mar;100(3):575-582. doi: 10.1016/j.pec.2016.10.005. Epub 2016 Oct 11.
    • Genetic Testing and Counseling Among Patients With Newly Diagnosed Breast Cancer .
    • Kurian AW, Griffith KA, Hamilton AS, Ward KC, Morrow M, Katz SJ, Jagsi R.
    • JAMA. 2017 Feb 7;317(5):531-534. doi: 10.1001/jama.2016.16918.
    • Letter, Comment

    Related:

    Viewpoint:

    Multigene Panel Testing in Oncology Practice: How Should We Respond?

    Research news: High-risk patients with breast cancer may not receive genetic testing. (Cancer)

    Press: Shortage of Genetic Counselors in Face of Growing Need. (Medscape Conference News)

    • Health Behaviors and their Relationship with Disease Control in People Attending Genetic Clinics with a Family History of Breast or Colorectal Cancer.
    • Anderson AS, Caswell S, Macleod M, Steele RJ, Berg J, Dunlop J, Stead M, Eadie D, O'Carroll RE.
    • J Genet Couns. 2017 Feb;26(1):40-51. doi: 10.1007/s10897-016-9977-2. Epub 2016 Jun 17.
    • Adherence to Recommended Risk Management among Unaffected Women with a BRCA Mutation.
    • Buchanan AH, Voils CI, Schildkraut JM, Fine C, Horick NK, Marcom PK, Wiggins K, Skinner CS.
    • J Genet Couns. 2017 Feb;26(1):79-92. doi: 10.1007/s10897-016-9981-6. Epub 2016 Jun 6.
    • Engagement with Genetic Information and Uptake of Genetic Testing: the Role of Trust and Personal Cancer History.
    • Roberts MC, Taber JM, Klein WM.
    • J Cancer Educ. 2017 Jan 20. doi: 10.1007/s13187-016-1160-9. [Epub ahead of print]
    • Anxiety and depression symptoms among women attending group-based patient education courses for hereditary breast and ovarian cancer.
    • Listøl W, Høberg-Vetti H, Eide GE, Bjorvatn C.
    • Hered Cancer Clin Pract. 2017 Jan 11;15:2. doi: 10.1186/s13053-016-0062-5. eCollection 2017.
    • Do women change their breast cancer mammogram screening behaviour after BRCA1/2 testing?
    • Larouche G, Chiquette J, Pelletier S, Simard J, Dorval M.
    • Fam Cancer. 2017 Jan;16(1):35-40. doi: 10.1007/s10689-016-9920-6.
    • Psychological factors associated with the intention to choose for risk-reducing mastectomy in family cancer clinic attendees.
    • van Driel CM, Oosterwijk JC, Meijers-Heijboer EJ, van Asperen CJ, Zeijlmans van Emmichoven IA, de Vries J, Mourits MJ, Henneman L, Timmermans DR, de Bock GH.
    • Breast. 2016 Dec;30:66-72. doi: 10.1016/j.breast.2016.08.016. Epub 2016 Sep 14.
    • Preparing young people for future decision-making about cancer risk in families affected or at risk from hereditary breast cancer: A qualitative interview study.
    • Rowland E, Plumridge G, Considine AM, Metcalfe A.
    • Eur J Oncol Nurs. 2016 Dec;25:9-15. doi: 10.1016/j.ejon.2016.08.006. Epub 2016 Sep 20.
    • Experience of Norwegian Female BRCA1 and BRCA2 Mutation-Carrying Participants in Educational Support Groups: a Qualitative Study.
    • Myklebust M, Gjengedal E, Strømsvik N.
    • J Genet Couns. 2016 Dec;25(6):1198-1206. Epub 2016 Apr 19.
    • When knowledge of a heritable gene mutation comes out of the blue: treatment-focused genetic testing in women newly diagnosed with breast cancer.
    • Meiser B, Quinn VF, Gleeson M, Kirk J, Tucker KM, Rahman B, Saunders C, Watts KJ, Peate M, Geelhoed E, Barlow-Stewart K, Field M, Harris M, Antill YC, Mitchell G.
    • Eur J Hum Genet. 2016 Nov;24(11):1517-1523. doi: 10.1038/ejhg.2016.69. Epub 2016 Jun 22.
    • Impact that Timing of Genetic Mutation Diagnosis has on Surgical Decision Making and Outcome for BRCA1/BRCA2 Mutation Carriers with Breast Cancer.
    • Chiba A, Hoskin TL, Hallberg EJ, Cogswell JA, Heins CN, Couch FJ, Boughey JC.
    • Ann Surg Oncol. 2016 Oct;23(10):3232-8. doi: 10.1245/s10434-016-5328-7. Epub 2016 Jun 23.

    Related:

    Comments on NSGC Discussion Forum Cancer SIG

    Subject: Impact of Timing of BRCA Testing

    • Surgeons' Perspectives of Contralateral Prophylactic Mastectomy.
    • Bellavance E, Peppercorn J, Kronsberg S, Greenup R, Keune J, Lynch J, Collyar D, Magder L, Tilburt J, Hlubocky F, Yao K.
    • Ann Surg Oncol. 2016 Sep;23(9):2779-87. doi: 10.1245/s10434-016-5253-9. Epub 2016 May 11.
    • Randomized Noninferiority Trial of Telephone Delivery of BRCA1/2 Genetic Counseling Compared With In-Person Counseling: 1-Year Follow-Up.
    • Kinney AY, Steffen LE, Brumbach BH, Kohlmann W, Du R, Lee JH, Gammon A, Butler K, Buys SS, Stroup AM, Campo RA, Flores KG, Mandelblatt JS, Schwartz MD.
    • J Clin Oncol. 2016 Aug 20;34(24):2914-24. doi: 10.1200/JCO.2015.65.9557. Epub 2016 Jun 20.

    Related:

    Letter:

    Deficit of Risk-Reducing Salpingo-Oophorectomies in BRCA1/2 Mutation Carriers After Telephone Genetic Counseling.

    Press: Telephone counseling can help make cancer genetic services more accessible to rural women (News Medical)

    • Multigene Panel Tests Yield Clues to Breast and Ovarian Cancer Risk.
    • Greg Kennelty.
    • Oncology Nursing News. 2016 Aug 3.
    • Women Need More Information to Cope With Aftermath of BRCA-Prompted Preventive Surgery.
    • Ellie Leick.
    • Oncology Nursing News. 2016 Aug 1
    • "It's not if I get cancer, it's when I get cancer": BRCA-positive patients' (un)certain health experiences regarding hereditary breast and ovarian cancer risk.
    • Dean M.
    • Soc Sci Med. 2016 Aug;163:21-7. doi: 10.1016/j.socscimed.2016.06.039. Epub 2016 Jun 23.
    • Genetic testing and personalized ovarian cancer screening: a survey of public attitudes.
    • Meisel SF, Rahman B, Side L, Fraser L, Gessler S, Lanceley A, Wardle J; PROMISE-2016 study team.
    • BMC Womens Health. 2016 Jul 26;16(1):46. doi: 10.1186/s12905-016-0325-3.
    • Quality of Life and Psychological State in Chinese Breast Cancer Patients Who Received BRCA1/2 Genetic Testing.
    • Qiu J, Guan J, Yang X, Wu J, Liu G, Di G, Chen C, Hou Y, Han Q, Shen Z, Shao Z, Hu Z.
    • PLoS One. 2016 Jul 18;11(7):e0158531. doi: 10.1371/journal.pone.0158531. eCollection 2016.
    • Understanding Genetic Breast Cancer Risk: Processing Loci of the BRCA Gist Intelligent Tutoring System.
    • Wolfe CR, Reyna VF, Widmer CL, Cedillos-Whynott EM, Brust-Renck PG, Weil AM, Hu X.
    • Learn Individ Differ. 2016 Jul;49:178-189. doi: 10.1016/j.lindif.2016.06.009. Epub 2016 Jul 1.
    • The double-edged sword of ovarian cancer information for women at increased risk who have previously taken part in screening.
    • Smits S, Boivin J, Menon U, Brain K.
    • Ecancermedicalscience. 2016 Jun 30;10:650. doi: 10.3332/ecancer.2016.650. eCollection 2016.
    • Trends in Breast Reconstruction by Ethnicity: An Institutional Review Centered on the Treatment of an Urban Population.
    • Rodby KA, Danielson KK, Shay E, Robinson E, Benjamin M, Antony AK.
    • Am Surg. 2016 Jun;82(6):497-504.
    • Clinical follow-up and breast and ovarian cancer screening of true BRCA1/2 noncarriers: a qualitative investigation.
    • Pelletier S, Wong N, El Haffaf Z, Foulkes WD, Chiquette J, Hamet P, Simard J, Dorval M.
    • Genet Med. 2016 Jun;18(6):627-34. doi: 10.1038/gim.2015.135. Epub 2015 Nov 5.
    • The Quality of Genetic Counseling and Connected Factors as Evaluated by Male BRCA1/2 Mutation Carriers in Finland.
    • Kajula O, Kääriäinen M, Moilanen JS, Kyngäs H.
    • J Genet Couns. 2016 Jun;25(3):413-21. doi: 10.1007/s10897-015-9885-x. Epub 2015 Sep 29.
    • Counselees' Expressed Level of Understanding of the Risk Estimate and Surveillance Recommendation are Not Associated with Breast Cancer Surveillance Adherence.
    • Albada A, van Dulmen S, Dijkstra H, Wieffer I, Witkamp A, Ausems MG.
    • J Genet Couns. 2016 Apr;25(2):279-89. doi: 10.1007/s10897-015-9869-x. Epub 2015 Sep 1.
    • Impact of Genetic Counseling in Women with a Family History of Breast Cancer in Italy.
    • Godino L, Razzaboni E, Bianconi M, Turchetti D.
    • J Genet Couns. 2016 Apr;25(2):405-11. doi: 10.1007/s10897-015-9884-y. Epub 2015 Sep 10.
    • Influence of Personal Exposure to the Cancer of a Loved One on the Breast Cancer Prevention Decisions of High Risk Women.
    • Padamsee TJ, Muraveva A, Wills C, Yee L, Paskett E.
    • Cancer Epidemiol Biomarkers Prev. 2016 Mar;25(3):561. 40th Annual (2016) ASPO meeting. doi: 10.1158/1055-9965.EPI-16-0090.
    • Conference abstract
    • Evaluation of the Relationship Between Family History of Breast Cancer and Risk Perception and Impacts on Repetition of Mammography.
    • Khoshravesh S, Taymoori P, Roshani D.
    • Asian Pac J Cancer Prev. 2016;17 Spec No.:135-41.
    • Acceptance of, inclination for, and barriers in genetic testing for gene mutations that increase the risk of breast and ovarian cancers among female residents of Warsaw.
    • Olejniczak D, Dera P, Religioni U, Duda-Zalewska A, Deptała A.
    • Contemp Oncol (Pozn). 2016;20(1):80-5. doi: 10.5114/wo.2016.58504. Epub 2016 Mar 16.
    • UC Launches Framingham-Like Study to Inform Personalized Breast Cancer Screening Guidelines.
    • Ray T.
    • GenomeWeb. 2015 Oct 26.
    • News
    • Genetic counseling and testing for hereditary cancer risk in young adult women: Facilitating autonomy and informed decision making is key.
    • Peshkin BN, Vadaparampil ST, Hoskins LM, O'Neill SM, Barter JF.
    • Gynecol Oncol Rep. 2015 Oct 20;14:44-5. doi: 10.1016/j.gore.2015.10.001. eCollection 2015.

    Related:

    Letter

    In response to Peshkin et al. "Genetic counseling and testing for hereditary cancer risk in young adult women: Facilitating autonomy and informed decision making is key".

    • BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance.
    • Eccles DM, Mitchell G, Monteiro AN, Schmutzler R, Couch FJ, Spurdle AB, Gómez-García EB; ENIGMA Clinical Working Group.
    • Ann Oncol. 2015 Oct;26(10):2057-65. doi: 10.1093/annonc/mdv278. Epub 2015 Jul 7.
    • Why do women not return family history forms when referred to breast cancer genetics services? A mixed-method study.
    • Hanning KA, Steel M, Goudie D, McLeish L, Dunlop J, Myring J, Sullivan F, Berg J, Humphris G, Ozakinci G.
    • Health Expect. 2015 Oct;18(5):1735-43. doi: 10.1111/hex.12166. Epub 2014 Jan 5.
    • Personalized Medicine Through SNP Testing for Breast Cancer Risk: Clinical Implementation.
    • Howe R, Miron-Shatz T, Hanoch Y, Omer ZB, O'Donoghue C, Ozanne EM.
    • J Genet Couns. 2015 Oct;24(5):744-51. doi: 10.1007/s10897-014-9803-7. Epub 2014 Dec 18.
    • Opportunistic salpingectomy for ovarian cancer prevention.
    • Hanley GE, McAlpine JN, Kwon JS, Mitchell G.
    • Gynecol Oncol Res Pract. 2015 Sep 17;2:5. doi: 10.1186/s40661-015-0014-1. eCollection 2015.
    • Genetic Testing Can Lead to Insights — Or Uncertainty.
    • Lauren M. Green.
    • Cure. 2015 Aug 13.
    • Familial risk for lifestyle-related chronic diseases: can family health history be used as a motivational tool to promote health behaviour in young adults?
    • Prichard I, Lee A, Hutchinson AD, Wilson C.
    • Health Promot J Austr. 2015 Aug;26(2):122-8.
    • The sooner the better: Genetic testing following ovarian cancer diagnosis.
    • Fox E, McCuaig J, Demsky R, Shuman C, Chitayat D, Maganti M, Murphy J, Rosen B, Ferguson S, Randall Armel S.
    • Gynecol Oncol. 2015 Jun;137(3):423-9. doi: 10.1016/j.ygyno.2015.03.057. Epub 2015 Apr 11.
    • The relationship between the belief in a genetic cause for breast cancer and bilateral mastectomy.
    • Petrie KJ, Myrtveit SM, Partridge AH, Stephens M, Stanton AL.
    • Health Psychol. 2015 May;34(5):473-6. doi: 10.1037/hea0000118. Epub 2014 Aug 18.
    • A Pilot Study of BRCA Mutation Carriers' Knowledge About the Clinical Impact of Prophylactic-oophorectomy and Views on Fertility Consultation: A Single-Center Pilot Study.
    • Kim J, Skrzynia C, Mersereau JE.
    • J Genet Couns. 2015 Feb;24(1):149-57. doi: 10.1007/s10897-014-9747-y. Epub 2014 Aug 15.
    • Attitudes toward molecular testing for personalized cancer therapy.
    • Yusuf RA, Rogith D, Hovick SR, Peterson SK, Burton-Chase AM, Fellman BM, Li Y, McKinney C, Bernstam EV, Meric-Bernstam F.
    • Cancer. 2015 Jan 15;121(2):243-250. doi: 10.1002/cncr.28966. Epub 2014 Sep 10.
    • Addressing sexual dysfunction after risk-reducing salpingo-oophorectomy: effects of a brief, psychosexual intervention.
    • Bober SL, Recklitis CJ, Bakan J, Garber JE, Patenaude AF.
    • J Sex Med. 2015 Jan;12(1):189-97. doi: 10.1111/jsm.12713. Epub 2014 Oct 14.

    Related:

    Review:

    Interventions to improve psychosocial well-being in female BRCA-mutation carriers following risk-reducing surgery.

    • Intentions for risk-reducing surgery among high-risk women referred for BRCA1/BRCA2 genetic counseling.
    • Tong A, Kelly S, Nusbaum R, Graves K, Peshkin BN, Valdimarsdottir HB, Wood M, McKinnon W, Garber J, McCormick SR, Jandorf L, Schwartz MD.
    • Psychooncology. 2015 Jan;24(1):33-9. doi: 10.1002/pon.3560. Epub 2014 May 17.
    • Cancer risk management decision making for BRCA+ women.
    • Leonarczyk TJ, Mawn BE.
    • West J Nurs Res. 2015 Jan;37(1):66-84. doi: 10.1177/0193945913519870. Epub 2014 Jan 26.
    • Comparison of risk management strategies between women testing positive for a BRCA variant of unknown significance and women with known BRCA deleterious mutations.
    • Garcia C, Lyon L, Littell RD, Powell CB.
    • Genet Med. 2014 Dec;16(12):896-902. doi: 10.1038/gim.2014.48. Epub 2014 May 22.
    • Adapting the coping in deliberation (CODE) framework: A multi-method approach in the context of familial ovarian cancer risk management.
    • Witt J, Elwyn G, Wood F, Rogers MT, Menon U, Brain K.
    • Patient Educ Couns. 2014 Nov;97(2):200-10. doi: 10.1016/j.pec.2014.07.004. Epub 2014 Jul 14.
    • Attitudes and compliance of clinical management after genetic testing for hereditary breast and ovarian cancer among high-risk Southern Chinese females with breast cancer history.
    • Kwong A, Chu AT, Wu CT, Tse DM.
    • Fam Cancer. 2014 Sep;13(3):423-30. doi: 10.1007/s10689-014-9706-7.
    • Characterizing biased cancer-related cognitive processing: Relationships with BRCA1/2 genetic mutation status, personal cancer history, age, and prophylactic surgery.
    • Carpenter KM, Eisenberg S, Weltfreid S, Low CA, Beran T, Stanton AL.
    • Health Psychol. 2014 Sep;33(9):1003-11. doi: 10.1037/a0032737. Epub 2013 Jun 17.
    • Does perceived risk predict breast cancer screening use? Findings from a prospective cohort study of female relatives from the Ontario site of the breast cancer family registry.
    • Walker MJ, Mirea L, Glendon G, Ritvo P, Andrulis IL, Knight JA, Chiarelli AM.
    • Breast. 2014 Aug;23(4):482-8. doi: 10.1016/j.breast.2014.04.001. Epub 2014 May 10.
    • Maximising survival: the main concern of women with hereditary breast and ovarian cancer who undergo genetic testing for BRCA1/2.
    • Jeffers L, Morrison PJ, McCaughan E, Fitzsimons D.
    • Eur J Oncol Nurs. 2014 Aug;18(4):411-8. doi: 10.1016/j.ejon.2014.03.007. Epub 2014 Apr 13.
    • Women's preferences for selective estrogen reuptake modulators: An investigation using protection motivation theory.
    • Ralph AF, Ager B, Bell ML, Collins IM, Andrews L, Tucker K, Phillips KA, Butow P.
    • Patient Educ Couns. 2014 Jul;96(1):106-12. doi: 10.1016/j.pec.2014.04.011. Epub 2014 Apr 28.
    • Decision Making After BRCA Genetic Testing.
    • Connors LM, Voian N, Shi Y, Lally RM, Edge S.
    • Clin J Oncol Nurs. 2014 Jun 1;18(3):E58-63. doi: 10.1188/14.CJON.E58-E63.
    • Informed decision-making is the key in women at high risk of breast cancer.
    • Taylor A, Tischkowitz M.
    • Eur J Surg Oncol. 2014 Jun;40(6):667-9. doi: 10.1016/j.ejso.2014.02.219. Epub 2014 Feb 17.
    • Seeking Balance: Decision Support Needs of Women Without Cancer and a Deleterious BRCA1 or BRCA2 Mutation.
    • Underhill ML, Crotser CB.
    • J Genet Couns. 2014 Jun;23(3):350-62. doi: 10.1007/s10897-013-9667-2. Epub 2013 Nov 22.
    • The Genetic Testing Experience of BRCA-Positive Women: Deciding Between Surveillance and Surgery.
    • Hesse-Biber S.
    • Qual Health Res. 2014 Jun;24(6):773-789. Epub 2014 Apr 18.
    • Ovarian Cancer 101 for the Newly Diagnosed.
    • Ilana Cass.
    • FORCE. Be Empowered Webinars. 2014 Apr 11.
    • Disclosure Pattern and Follow-Up After the Molecular Diagnosis of BRCA/CHEK2 Mutations.
    • Kegelaers D, Merckx W, Odeurs P, van den Ende J, Blaumeiser B.
    • J Genet Couns. 2014 Apr;23(2):254-61. doi: 10.1007/s10897-013-9656-5. Epub 2013 Oct 11.
    • Newly Diagnosed with Breast Cancer: What You Need to Know.
    • Melinda Telli.
    • FORCE. Be Empowered Webinars. 2014 Mar 26.
    • In their own words: treating very young BRCA1/2 mutation-positive women with care and caution.
    • Hoskins LM, Werner-Lin A, Greene MH.
    • PLoS One. 2014 Feb 28;9(2):e87696. doi: 10.1371/journal.pone.0087696. eCollection 2014.
    • Patients' understanding of how genotype variation affects benefits of tamoxifen therapy for breast cancer.
    • Brewer NT, Defrank JT, Chiu WK, Ibrahim JG, Walko CM, Rubin P, Olajide OA, Moore SG, Raab RE, Carrizosa DR, Corso SW, Schwartz G, Peppercorn JM, McLeod HL, Carey LA, Irvin WJ Jr.
    • Public Health Genomics. [2014 Feb;]17(1):43-7. doi: 10.1159/000356565. Epub 2014 Jan 22.
    • Patient compliance based on genetic medicine: a literature review.
    • Schneider KI, Schmidtke J.
    • J Community Genet. 2014 Jan;5(1):31-48. doi: 10.1007/s12687-013-0160-2. Epub 2013 Aug 10.
    • Systematic review of educational tools used during the BRCA1/2 genetic testing process.
    • Dorval M, Bouchard K, Chiquette J.
    • Per Med. 2014 Jan;11(1):113-124. doi: 10.2217/pme.13.94.
    • Review
    • Understanding how breast cancer patients use risk information from genomic tests.
    • DeFrank JT, Carey LA, Brewer NT.
    • J Behav Med. 2013 Dec;36(6):567-73. doi: 10.1007/s10865-012-9449-6. Epub 2012 Aug 10.
    • Acceptability of chemoprevention trials in high-risk subjects.
    • Bonanni B, Lazzeroni M.
    • Ann Oncol. 2013 Nov;24 Suppl 8:viii42-viii46. doi: 10.1093/annonc/mdt328.
    • Variants of unknown significance in BRCA testing: impact on risk perception, worry, prevention and counseling.
    • Richter S, Haroun I, Graham TC, Eisen A, Kiss A, Warner E.
    • Ann Oncol. 2013 Nov;24 Suppl 8:viii69-viii74. doi: 10.1093/annonc/mdt312.
    • Young breast cancer patients' involvement in treatment decisions: the major role played by decision-making about surgery.
    • Seror V, Cortaredona S, Bouhnik AD, Meresse M, Cluze C, Viens P, Rey D, Peretti-Watel P.
    • Psychooncology. 2013 Nov;22(11):2546-56. doi: 10.1002/pon.3316. Epub 2013 Jun 7.
    • A qualitative study of women's experiences of familial ovarian cancer screening.
    • Lifford KJ, Clements A, Fraser L, Lancastle D, Brain K; PsyFOCS Management Group.
    • Psychooncology. 2013 Nov;22(11):2576-84. doi: 10.1002/pon.3324. Epub 2013 Jun 26.
    • Young breast cancer patients often opt for mastectomy.
    • Printz C.
    • Cancer. 2013 Oct 1;119(19):3425. doi: 10.1002/cncr.28362.
    • What do women do when they test positive for a BRCA mutation?
    • Garcia C, Wendt J, Lyon L, Jones J, Raine-Bennett T, Littell R, Powell CB.
    • Gynecologic Oncology. 2013 Oct;131(1):256. doi: 10.1016/j.ygyno.2013.07.024.
    • Conference abstract
    • Who Gets Genomic Testing for Breast Cancer Recurrence Risk?
    • Defrank JT, Salz T, Reeder-Hayes K, Brewer NT.
    • Public Health Genomics. [2013 Oct;]16(5):215-222. Epub 2013 Jul 30.
    • Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: a cross-sectional survey.
    • Rosenberg SM, Tracy MS, Meyer ME, Sepucha K, Gelber S, Hirshfield-Bartek J, Troyan S, Morrow M, Schapira L, Come SE, Winer EP, Partridge AH.
    • Ann Intern Med. 2013 Sep 17;159(6):373-81. doi: 10.7326/0003-4819-159-6-201309170-00003.

    Related:

    Editorial, Comment:

    Contralateral prophylactic mastectomy: perceptions versus reality.

    Summary for Patients:

    Do women with breast cancer overestimate their risk for cancer in the unaffected breast?

    News:

    Women With Breast Cancer Who Opt for Contralateral Prophylactic Mastectomy May Overestimate Future Risk.

    News:

    Young women fearing recurrence opt for prophylactic mastectomy.

    • Contralateral prophylactic mastectomy: perceptions versus reality.
    • Portschy PR, Tuttle TM.
    • Ann Intern Med. 2013 Sep 17;159(6):428-9. doi: 10.7326/0003-4819-159-6-201309170-00011.
    • Editorial, Comment

    Related:

    Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: a cross-sectional survey.

    • Do women with breast cancer overestimate their risk for cancer in the unaffected breast?
    • [No authors listed]
    • Ann Intern Med. 2013 Sep 17;159(6):I-30. doi: 10.7326/0003-4819-159-6-201309170-00001.

    Related:

    Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: a cross-sectional survey.

    • Young adult daughters of BRCA1/2 positive mothers: What do they know about hereditary cancer and how much do they worry?
    • Patenaude AF, Tung N, Ryan PD, Ellisen LW, Hewitt L, Schneider KA, Tercyak KP, Aldridge J, Garber JE.
    • Psychooncology. 2013 Sep;22(9):2024-31. doi: 10.1002/pon.3257. Epub 2013 Feb 18.
    • Accuracy of Self-Reported Screening Mammography Use: Examining Recall among Female Relatives from the Ontario Site of the Breast Cancer Family Registry.
    • Walker MJ, Chiarelli AM, Mirea L, Glendon G, Ritvo P, Andrulis IL, Knight JA.
    • ISRN Oncol. 2013 Aug 1;2013:810573. doi: 10.1155/2013/810573. eCollection 2013.
    • Perceived risk and adherence to breast cancer screening guidelines among women with a familial history of breast cancer: a review of the literature.
    • Walker MJ, Chiarelli AM, Knight JA, Mirea L, Glendon G, Ritvo P.
    • Breast. 2013 Aug;22(4):395-404. doi: 10.1016/j.breast.2012.12.005. Epub 2013 Jan 10.
    • Review
    • Comparison of the Screening Practices of Unaffected Noncarriers under 40 and between 40 and 49 in BRCA1/2 Families.
    • Duprez C, Christophe V, Milhabet I, Krzeminski A, Adenis C, Berthet P, Peyrat JP, Vennin P.
    • J Genet Couns. 2013 Aug;22(4):469-81. doi: 10.1007/s10897-012-9569-8. Epub 2013 Jan 25.
    • Genetic Counseling, Cancer Screening, Breast Cancer Characteristics, and General Health among a Diverse Population of BRCA Genetic Testers.
    • Beattie MS, Copeland K, Fehniger J, Cheung E, Joseph G, Lee R, Luce J.
    • J Health Care Poor Underserved. [2013 Aug;]24(3):1150-66. doi: 10.1353/hpu.2013.0151.
    • Cancer risk comparative perception and overscreening behaviours of non-carriers from BRCA1/2 families.
    • Milhabet I, Duprez C, Krzeminski A, Christophe V.
    • Eur J Cancer Care (Engl). 2013 Jul;22(4):540-8. doi: 10.1111/ecc.12060. Epub 2013 Jun 3.
    • Barriers and facilitators to BRCA genetic counseling among at-risk Latinas in New York City.
    • Sussner KM, Jandorf L, Thompson HS, Valdimarsdottir HB.
    • Psychooncology. 2013 Jul;22(7):1594-604. doi: 10.1002/pon.3187. Epub 2012 Sep 16.
    • Association between genomic recurrence risk and well-being among breast cancer patients.
    • Retèl VP, Groothuis-Oudshoorn CG, Aaronson NK, Brewer NT, Rutgers EJ, van Harten WH.
    • BMC Cancer. 2013 Jun 18;13:295. doi: 10.1186/1471-2407-13-295.
    • Intentions for bilateral mastectomy among newly diagnosed breast cancer patients.
    • King L, O'Neill SC, Spellman E, Peshkin BN, Valdimarsdottir H, Willey S, Leventhal KG, Demarco T, Nusbaum R, Feldman E, Jandorf L, Schwartz MD.
    • J Surg Oncol. 2013 Jun;107(7):772-6. doi: 10.1002/jso.23307. Epub 2012 Dec 27.
    • Individual and family characteristics associated with BRCA1/2 genetic testing in high-risk families.
    • Katapodi MC, Northouse LL, Milliron KJ, Liu G, Merajver SD.
    • Psychooncology. 2013 Jun;22(6):1336-43. doi: 10.1002/pon.3139. Epub 2012 Jul 24.
    • Communication and information needs of women diagnosed with ovarian cancer regarding treatment-focused genetic testing.
    • Gleeson M, Meiser B, Barlow-Stewart K, Trainer AH, Tucker K, Watts KJ, Friedlander M, Kasparian N.
    • Oncol Nurs Forum. 2013 May 1;40(3):275-83. doi: 10.1188/13.ONF.40-03AP.
    • Much more than a gene: hereditary breast and ovarian cancer, reproductive choices and family life.
    • Dekeuwer C, Bateman S.
    • Med Health Care Philos. 2013 May;16(2):231-44. doi: 10.1007/s11019-011-9361-9.
    • Reproductive decision-making in young female carriers of a BRCA mutation.
    • Donnelly LS, Watson M, Moynihan C, Bancroft E, Evans DG, Eeles R, Lavery S, Ormondroyd E.
    • Hum Reprod. 2013 Apr;28(4):1006-12. doi: 10.1093/humrep/des441. Epub 2013 Jan 4.
    • Life Events may Contribute to Family Communication About Cancer Risk Following BRCA1/2 Testing.
    • Lapointe J, Côté C, Bouchard K, Godard B, Simard J, Dorval M.
    • J Genet Couns. 2013 Apr;22(2):249-257. Epub 2012 Aug 15.
    • [Multidisciplinary clinical management for prophylactic mastectomy: views of women from one centre in Quebec City].
    • Dorval M, Pelletier S, Bouchard K, Desbiens C, Chiquette J.
    • Bull Cancer. 2013 Mar;100(3):201-11. doi: 10.1684/bdc.2013.1708.
    • [Article in French]
    • Catalysts to withdrawal from familial ovarian cancer screening for surgery and reactions to discontinued screening: a qualitative study.
    • Lifford KJ, Clements A, Fraser L, Lancastle D, Brain K.
    • Fam Cancer. 2013 Mar;12(1):19-26. doi: 10.1007/s10689-012-9567-x.
    • Feasibility evaluation of an online tool to guide decisions for BRCA1/2 mutation carriers.
    • Schackmann EA, Munoz DF, Mills MA, Plevritis SK, Kurian AW.
    • Fam Cancer. 2013 Mar;12(1):65-73. doi: 10.1007/s10689-012-9577-8.
    • Improving mutation notification when new genetic information is identified in research: a trial of two strategies in familial breast cancer.
    • Wakefield CE, Thorne H, Kirk J, Niedermayr E, Doolan EL, Tucker K.
    • Genet Med. 2013 Mar;15(3):187-94. doi: 10.1038/gim.2012.115. Epub 2012 Sep 13.
    • Dealing with the unexpected: consumer responses to direct-access BRCA mutation testing.
    • Francke U, Dijamco C, Kiefer AK, Eriksson N, Moiseff B, Tung JY, Mountain JL.
    • PeerJ. 2013 Feb 12;1:e8. doi: 10.7717/peerj.8. Print 2013.

    Related:

    Comments on NSGC Discussion Forum

    Subject: Current thoughts on 23andme?

    Press: Consumers have few negative reactions to the results of genetic testing for cancer mutations. (EurekAlert!)

    Press: Get ready for the risks of genetic testing. (CNN)

    • A multi-case report of the pathways to and through genetic testing and cancer risk management for BRCA mutation-positive women aged 18-25.
    • Hoskins LM, Werner-Lin A.
    • J Genet Couns. 2013 Feb;22(1):27-38. doi: 10.1007/s10897-012-9521-y. Epub 2012 Aug 3.
    • A follow-up study on men tested for BRCA1/BRCA2 mutations: impacts and coping processes.
    • Shiloh S, Dagan E, Friedman I, Blank N, Friedman E.
    • Psychooncology. 2013 Feb;22(2):417-25. doi: 10.1002/pon.2106. Epub 2011 Dec 2.
    • Risk-reducing salpingo-oophorectomy and ovarian cancer screening in 1077 women after BRCA testing.
    • Mannis GN, Fehniger JE, Creasman JS, Jacoby VL, Beattie MS.
    • JAMA Intern Med. 2013 Jan 28;173(2):96-103. doi: 10.1001/2013.jamainternmed.962.

    Related:

    Comment:

    Role of genetic testing for screening and prevention for ovarian cancer: comment on "Risk-reducing salpingo-oophorectomy and ovarian cancer screening in 1077 women after BRCA testing".

    • Role of genetic testing for screening and prevention for ovarian cancer: comment on "Risk-reducing salpingo-oophorectomy and ovarian cancer screening in 1077 women after BRCA testing".
    • Grann V, Ashby-Thompson M.
    • JAMA Intern Med. 2013 Jan 28;173(2):103-4. doi: 10.1001/jamainternmed.2013.2729.

    Related:

    Risk-reducing salpingo-oophorectomy and ovarian cancer screening in 1077 women after BRCA testing.

    • Breast cancer knowledge and screening behaviour among women with a positive family history: a cross sectional study.
    • Subramanian P, Oranye NO, Masri AM, Taib NA, Ahmad N.
    • Asian Pac J Cancer Prev. 2013;14(11):6783-90.
    • Compliance with screening recommendations according to breast cancer risk levels in Izmir, Turkey.
    • Acikgoz A, Ergor G.
    • Asian Pac J Cancer Prev. 2013;14(3):1737-42.
    • Informed choice about breast cancer prevention: randomized controlled trial of an online decision aid intervention.
    • Korfage IJ, Fuhrel-Forbis A, Ubel PA, Zikmund-Fisher BJ, Greene SM, McClure JB, Smith DM, Alford SH, Fagerlin A.
    • Breast Cancer Res. 2013;15(5):R74.

    Related:

    Comment, Editorial:

    Decision aids for breast cancer chemoprevention.

    • Family history of cancer and its association with breast cancer risk perception and repeat mammography.
    • Haber G, Ahmed NU, Pekovic V.
    • Am J Public Health. 2012 Dec;102(12):2322-9. doi: 10.2105/AJPH.2012.300786. Epub 2012 Oct 18.
    • Anxiety and specific distress in women at intermediate and high risk of breast cancer before and after surveillance by magnetic resonance imaging and mammography versus standard mammography.
    • Brédart A, Kop JL, Fall M, Pelissier S, Simondi C, Dolbeault S, Livartowski A, Tardivon A; Magnetic Resonance Imaging study group (STIC IRM 2005).
    • Psychooncology. 2012 Nov;21(11):1185-94. doi: 10.1002/pon.2025. Epub 2011 Aug 3.
    • Role of Breast Surgery in BRCA Mutation Carriers.
    • Nestle-Krämling C, Kühn T.
    • Breast Care (Basel). 2012 Oct;7(5):378-82. doi: 10.1159/000343717.
    • Outcomes of a systems-level intervention offering breast cancer risk assessments to low-income underserved women.
    • Mays D, Sharff ME, Demarco TA, Williams B, Beck B, Sheppard VB, Peshkin BN, Eng-Wong J, Tercyak KP.
    • Fam Cancer. 2012 Sep;11(3):493-502. doi: 10.1007/s10689-012-9541-7.
    • Hereditary breast and ovarian cancer: research on how women respond to genetic testing.
    • Bingham R.
    • Nurs Womens Health. 2012 Aug-Sep;16(4):319-24. doi: 10.1111/j.1751-486X.2012.01750.x.
    • How should we discuss genetic testing with women newly diagnosed with breast cancer? Design and implementation of a randomized controlled trial of two models of delivering education about treatment-focused genetic testing to younger women newly diagnosed with breast cancer.
    • Watts KJ, Meiser B, Mitchell G, Kirk J, Saunders C, Peate M, Duffy J, Kelly PJ, Gleeson M, Barlow-Stewart K, Rahman B, Friedlander M, Tucker K; TFGT Collaborative Group.
    • BMC Cancer. 2012 Jul 28;12:320. doi: 10.1186/1471-2407-12-320.
    • Beliefs about optimal age and screening frequency predict breast screening adherence in a prospective study of female relatives from the Ontario site of the Breast Cancer Family Registry.
    • Ritvo P, Edwards SA, Glendon G, Mirea L, Knight JA, Andrulis IL, Chiarelli AM.
    • BMC Public Health. 2012 Jul 12;12:518. doi: 10.1186/1471-2458-12-518.
    • Surgical treatment differences among Latina and African American breast cancer survivors.
    • Campesino M, Koithan M, Ruiz E, Glover JU, Juarez G, Choi M, Krouse RS.
    • Oncol Nurs Forum. 2012 Jul;39(4):E324-31. doi: 10.1188/12.ONF.E324-E331.
    • Barriers to genetic testing for breast cancer risk among ethnic minority women: an exploratory study.
    • Glenn BA, Chawla N, Bastani R.
    • Ethn Dis. 2012 Summer;22(3):267-73.
    • Looking different, feeling different: women's reactions to risk-reducing breast and ovarian surgery.
    • Hallowell N, Baylock B, Heiniger L, Butow PN, Patel D, Meiser B, Saunders C; kConFab Psychosocial Group on behalf of the kConFab Investigators, Price MA.
    • Fam Cancer. 2012 Jun;11(2):215-24. doi: 10.1007/s10689-011-9504-4.
    • French women's breast self-examination practices with time after undergoing BRCA1/2 genetic testing.
    • Maheu C, Apostolidis T, Petri-Cal A, Mouret-Fourme E, Gauthier-Villars M, Lasset C, Berthet P, Fricker JP, Caron O, Luporsi E, Gladieff L, Noguès C, Julian-Reynier C.
    • Fam Cancer. 2012 Jun;11(2):269-78. doi: 10.1007/s10689-012-9512-z.
    • BRCA1/2 carriers: their childbearing plans and theoretical intentions about having preimplantation genetic diagnosis and prenatal diagnosis.
    • Julian-Reynier C, Fabre R, Coupier I, Stoppa-Lyonnet D, Lasset C, Caron O, Mouret-Fourme E, Berthet P, Faivre L, Frenay M, Gesta P, Gladieff L, Bouhnik AD, Protière C, Noguès C.
    • Genet Med. 2012 May;14(5):527-34. doi: 10.1038/gim.2011.27. Epub 2012 Jan 12.
    • Breast cancer recurrence risk reduction beliefs in breast cancer survivors: prevalence and relation to behavior.
    • Burris JL, Jacobsen PB, Loftus LS, Andrykowski MA.
    • Psychooncology. 2012 Apr;21(4):427-35. doi: 10.1002/pon.1925. Epub 2011 Feb 10.
    • Disparities in cancer screening in individuals with a family history of breast or colorectal cancer.
    • Ponce NA, Tsui J, Knight SJ, Afable-Munsuz A, Ladabaum U, Hiatt RA, Haas JS.
    • Cancer. 2012 Mar 15;118(6):1656-63. doi: 10.1002/cncr.26480. Epub 2011 Aug 25.

    Related:

    Press: Cancer Screening Lags in Latinos With Family History. (Medscape/Reuters)

    • Self-reported mammography use following BRCA1/2 genetic testing may be overestimated.
    • Larouche G, Bouchard K, Chiquette J, Desbiens C, Simard J, Dorval M.
    • Fam Cancer. 2012 Mar;11(1):27-32. doi: 10.1007/s10689-011-9490-6.
    • Toward a new understanding of risk perception among young female BRCA1/2 "previvors".
    • Hoskins LM, Roy KM, Greene MH.
    • Fam Syst Health. 2012 Mar;30(1):32-46. doi: 10.1037/a0027276.
    • Online tool to guide decisions for BRCA1/2 mutation carriers.
    • Kurian AW, Munoz DF, Rust P, Schackmann EA, Smith M, Clarke L, Mills MA, Plevritis SK.
    • J Clin Oncol. 2012 Feb 10;30(5):497-506. doi: 10.1200/JCO.2011.38.6060. Epub 2012 Jan 9.

    Related:

    Comments from NSGC Discussion Forum Cancer SIG

    Subject: An Online BRCA Positive Decision Guidance Tool.

    Comment:

    Are we ready for online tools in decision making for BRCA1/2 mutation carriers?

    Press: Are We Ready for Online Tools in Decision Making for BRCA1/2 Mutation Carriers? (Journal of Clinical Oncology)

    Press: Online tool helps those with BRCA mutations understand options. (Medical Xpress)

    • Permanence of the information given during oncogenetic counseling to persons at familial risk of breast/ovarian and/or colon cancer.
    • Kwiatkowski F, Dessenne P, Laquet C, Petit MF, Bignon YJ.
    • Eur J Hum Genet. 2012 Feb;20(2):141-7. doi: 10.1038/ejhg.2011.169. Epub 2011 Sep 21.
    • Risk-reducing bilateral salpingo-oophorectomy and sexual health: a qualitative study.
    • Brotto LA, Branco N, Dunkley C, McCullum M, McAlpine JN.
    • J Obstet Gynaecol Can. 2012 Feb;34(2):172-8.
    • Exploring the short-term impact of DNA-testing in breast cancer patients: the counselees' perception matters, but the actual BRCA1/2 result does not.
    • Vos J, Oosterwijk JC, Gomez-Garcia E, Menko FH, Collee MJ, van Asperen CJ, Jansen AM, Stiggelbout AM, Tibben A.
    • Patient Educ Couns. 2012 Feb;86(2):239-51. doi: 10.1016/j.pec.2011.04.017. Epub 2011 Dec 27.
    • Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance.
    • Schwartz MD, Isaacs C, Graves KD, Poggi E, Peshkin BN, Gell C, Finch C, Kelly S, Taylor KL, Perley L.
    • Cancer. 2012 Jan 15;118(2):510-7. doi: 10.1002/cncr.26294. Epub 2011 Jun 29.
    • Attitudes to reproductive genetic testing in women who had a positive BRCA test before having children: a qualitative analysis.
    • Ormondroyd E, Donnelly L, Moynihan C, Savona C, Bancroft E, Evans DG, Eeles R, Lavery S, Watson M.
    • Eur J Hum Genet. 2012 Jan;20(1):4-10. doi: 10.1038/ejhg.2011.146. Epub 2011 Aug 3.
    • Withdrawal from familial ovarian cancer screening for surgery: Findings from a psychological evaluation study (PsyFOCS).
    • Lifford KJ, Fraser L, Rosenthal AN, Rogers MT, Lancastle D, Phelps C, Watson EK, Clements A, Iredale R, Jacobs I, Menon U, Brain KE.
    • Gynecol Oncol. 2012 Jan;124(1):158-163. Epub 2011 Oct 15.
    • What made her give up her breasts: a qualitative study on decisional considerations for contralateral prophylactic mastectomy among breast cancer survivors undergoing BRCA1/2 genetic testing.
    • Kwong A, Chu AT.
    • Asian Pac J Cancer Prev. 2012;13(5):2241-7.
    • Barriers and facilitators for utilization of genetic counseling and risk assessment services in young female breast cancer survivors.
    • Anderson B, McLosky J, Wasilevich E, Lyon-Callo S, Duquette D, Copeland G.
    • J Cancer Epidemiol. 2012;2012:298745. doi: 10.1155/2012/298745. Epub 2012 Oct 22.
    • Knowledge, attitude and practice of prophylactic mastectomy among patients and relations attending a surgical outpatient clinic.
    • Oguntola AS, Olaitan PB, Omotoso O, Oseni GO.
    • Pan Afr Med J. 2012;13:20. Epub 2012 Sep 30.